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Summary 
Pulmonary hypertension (PH) is a rare disease of the pulmonary arteries. It is 
characterised by vascular proliferation and remodelling resulting in a progressive 
increase in pulmonary vascular resistance and right ventricular failure. The 
functional capacity of the right ventricle is the major prognostic determinant in 
PH, and death usually results from right ventricular failure. Although recent 
therapeutic advances have improved the short-to-medium term outlook of PH 
patients, early death due to right ventricular failure remains inevitable in many 
patients. The imperative role of RV performance in the clinical status and long-
term outcome in PH patients is evident. Evaluation of right ventricular function 
is essential in the management of patients with pulmonary hypertension. Current 
methods of assessment of PH patients are suboptimal.  
The right ventricle is difficult to assess due to its position and geometry. Recent 
developments in imaging techniques, such as cardiac magnetic resonance (CMR) 
imaging and echocardiography, have improved our understanding of the 
structure and function of the right ventricle. Assessment of RV function is 
complex and no single measurement is generally accepted in clinical practice. 
The experimental work performed in this thesis aimed to improve our 
understanding of RV function in PH patients and to provide clarity in the role of 
CMR in the non-invasive assessment and monitoring of pulmonary hypertension 
patients.  
A non-invasive measurement of stroke volume would be beneficial to monitor 
disease progression in pulmonary hypertension patients. Chapter 3 demonstrated 
that cardiac magnetic resonance imaging provided non-invasive measurements of 
stroke volume that were as accurate as those obtained by thermodilution 
measured during right heart catheterisation. Inert gas rebreathing using 
photoacoustic analysis also provided accurate non-invasive measurements of 
stroke volume. Chapter 4 compared two patient groups: idiopathic pulmonary 
arterial hypertension (IPAH) and pulmonary hypertension associated with 
connective tissue disease (CTDPAH). We clarified that there was no significant 
differences in RV structure and performance between these two distinct patient 
groups to account for the poorer prognosis in the CTDPAH group.     
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Treatments for PH are always expensive, sometimes invasive and carry 
significant side effects. It is imperative that we are able to assess the patient’s 
response to therapy in a clinically meaningful, accurate and non-invasive 
manner. The importance of escalating therapy if a patient does not respond to 
initial treatment has been emphasised in recently published guidelines. Current 
monitoring techniques have acknowledged limitations and are suboptimal. 
Chapter 5 presents the results obtained from my contribution to the prospective, 
longitudinal multinational EURO-MR study. Longitudinal CMR examination 
identified significant improvements in cardiac function with the introduction of 
disease-targeted therapy. Baseline and 4 months post therapy CMR scans were 
compared. It is anticipated that CMR could be a useful monitoring technique for 
patients with pulmonary hypertension. 
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1 Introduction 
This chapter aims to discuss the background and rationale of the work performed 
for this thesis. An overview of pulmonary hypertension (PH) is undertaken, 
focussing on clinical classification, pathobiology and management. The natural 
history of PH and the pivotal role of the right ventricle are described. The 
principal technique used in this thesis is cardiac magnetic resonance (CMR) 
imaging. This technique is described in detail and a comprehensive review of its 
use in PH is undertaken. Inert gas rebreathing (IGR) is a further technique 
employed in this thesis. The history of IGR is described and its role in the clinical 
setting is discussed. The initial evaluation of a patient with PH is described, 
including the importance of diagnostic investigations in terms of prognosis. This 
is followed by a comprehensive discussion of current methods used in the 
longitudinal assessment of PH and their limitations. Finally, the hypotheses and 
aims of this thesis are outlined.  
 
1.1 Overview of pulmonary hypertension 
Pulmonary hypertension (PH) is a disease of the pulmonary arteries that is 
characterised by vascular proliferation and remodelling (1, 2) resulting in a 
progressive increase in pulmonary vascular resistance (PVR) and right ventricular 
failure. The functional capacity of the right ventricle is the major prognostic 
determinant in PH, and death usually results from RV failure (3-6). PH is a 
haemodynamic and pathophysiological condition defined as an increase in mean 
pulmonary arterial pressure (mPAP) ≥ 25mmHg at rest as assessed by right heart 
catheterisation. A resting mPAP between 8 and 20mmHg should be considered 
normal. Further studies are required to determine the natural history of 
individuals with a resting mPAP between 21 and 24mmHg. 
The most recent clinical classification of PH was proposed, by worldwide 
experts, at the fifth World Symposium on PH held in 2013 in Nice, France (7). PH 
is classified into five diagnostic groups with specific histological, clinical, and 
therapeutic features. Despite possible comparable elevations of pulmonary 
pressure in the different clinical groups, the underlying mechanisms, the 
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diagnostic approaches, and the prognostic and therapeutic implications are 
completely different. Please see table 1.1. 
 
Table 1-1: Clinical classification of pulmonary hypertension (Nice, 2013) 
 
1. Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic 
1.2 Heritable 
1.3 Drugs and toxins induced 
1.4 Associated with (APAH) 
1.4.1 Connective tissue diseases 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’. Pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis 
1’’. Persistent pulmonary hypertension of the newborn  
 
2. Pulmonary hypertension due to left heart disease 
 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
 
4. Chronic thromboembolic pulmonary hypertension 
 
5. PH with unclear and/or multifactorial mechanisms 
 
 
In this thesis, the patients enrolled were diagnosed with either PAH, PH due to 
lung disease and/or hypoxia or CTEPH. I will, therefore, elaborate further on 
each of these conditions. 
 
1.1.1 Pulmonary arterial hypertension (Group 1) 
PAH comprises the idiopathic (IPAH) and familial forms and the forms associated 
with connective tissue diseases, congenital heart defects with systemic-to-
pulmonary shunts, portal hypertension, and human immunodeficiency virus (HIV) 
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infection. They share comparable clinical and haemodynamic pictures and 
virtually identical pathological changes of the lung microcirculation.  
Pathological lesions affect the distal pulmonary arteries (< 500µm of diameter) 
in particular and are characterised by medial hypertrophy, intimal proliferative 
and fibrotic changes, adventitial thickening with moderate perivascular 
inflammatory infiltrates, complex lesions (plexiform, dilated lesions), and 
thrombotic lesions. Pulmonary veins are classically unaffected. The exact 
processes that initiate the pathological changes seen in PAH are still unknown 
although it is recognised that PAH has a multifactorial pathobiology that involves 
various biochemical pathways and cell types. 
Recent registries have described the epidemiology of PAH (8, 9). The lowest 
estimates of the prevalence of PAH and IPAH are 15 cases and 5.9 cases/million 
adult population, respectively. The lowest estimate of PAH incidence is 2.4 
cases/million adult population/year. Recent data from Scotland and other 
countries have confirmed that PAH prevalence is in the range 15–50 subjects per 
million population in Europe (8, 9). In the subgroup of APAH, 15.3% had 
connective tissue diseases (CTDs; mainly systemic sclerosis), 11.3% had CHD, 
10.4% had portal hypertension, 9.5% had anorexigen-associated PAH and 6.2% 
had HIV infection (8, 9). 
 
IPAH 
IPAH is the most prevalent type of PAH. IPAH corresponds to sporadic disease, 
without any family history of PAH or known triggering factor. Mutations in the 
bone morphogenetic protein receptor 2 gene can be detected in 11-40% of 
apparently sporadic cases, thus representing a major genetic predisposing factor 
to PAH (10). 
 
PAH associated with CTD (CTDPAH) 
Connective tissue disease (CTD) is the second most prevalent type of PAH after 
IPAH in registries. The prevalence has been estimated to be 2.3-10 cases per 
million in the general population (8, 9, 11). Compared with IPAH, patients with 
CTDPAH are mainly women (women/men ratio 4:1), are older (mean age at 
diagnosis, 66 years), may present with concomitant disorders (pulmonary 
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fibrosis, left heart disease), and have shorter survival (12). The unadjusted risk 
of death for systemic sclerosis-associated PAH compared with IPAH is 2.9200 and 
the predictors of outcome are the same as for IPAH (right atrial pressure [RAP], 
pulmonary artery pressure [PAP], and cardiac index [CI]). Between 7% and 12% of 
patients with systemic sclerosis (SSc) and around 0.5-14% of patients with 
systemic lupus erythematosus are reported to have PAH, making these the two 
most frequent causes of PAH-CTD (12-14). In these patients, PAH may occur in 
association with interstitial fibrosis or as a result of an isolated pulmonary 
arteriopathy. Pulmonary venous hypertension from left heart disease may also 
be present. Histopathological changes in PAH associated with CTD are generally 
indistinguishable from those of classical IPAH, although there is more frequent 
involvement of the pulmonary veins (15). 
 
1.1.2 PH due to lung disease and/or hypoxia (Group 3) 
Based on published series, the incidence of significant PH in COPD patients with 
at least one previous hospitalization for exacerbation of respiratory failure is 
20%. In advanced COPD, PH is highly prevalent (> 50%) (16, 17), although in 
general it is of only mild severity. In interstitial lung disease, the prevalence of 
PH is between 32 and 39% (18). The combination of lung fibrosis with 
emphysema is associated with a higher prevalence of PH (19). 
The pathophysiological mechanisms involved in this setting are multiple and 
include hypoxic vasoconstriction, mechanical stress of hyperinflated lungs, loss 
of capillaries, inflammation, and toxic effects of cigarette smoke. Pathological 
changes include medial hypertrophy and intimal obstructive proliferation of the 
distal pulmonary arteries. A variable degree of destruction of the whole vascular 
bed in emphysematous or fibrotic areas may also be present. 
 
1.1.3 CTEPH (Group 4) 
No specific genetic mutations have been linked to the development of CTEPH. It 
is suggested that the prevalence of CTEPH is up to 3.8% in survivors of acute 
pulmonary embolism (20). CTEPH can be found in patients without any previous 
clinical episode of acute pulmonary embolism or deep venous thrombosis (up to 
50% in different series) (21). 
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Pathological lesions are characterised by organised thrombi tightly attached to 
the pulmonary arterial medial layer in the elastic pulmonary arteries, replacing 
the normal intima. These may completely occlude the lumen or form different 
grades of stenosis, webs and bands (22). In the non-occluded areas, a pulmonary 
arteriopathy indistinguishable from that of PAH (including plexiform lesions) can 
develop (23). The obstructive lesions observed in the distal pulmonary arteries 
of non-obstructed areas (virtually identical to those observed in PAH) may be 
related to a variety of factors, such as shear stress, pressure, inflammation, and 
the release of cytokines and vasculotrophic mediators. Collateral vessels from 
the systemic circulation (from bronchial, costal, diaphragmatic and coronary 
arteries) can grow to reperfuse at least partially the areas distal to complete 
obstructions. Pulmonary thromboembolism or in situ thrombosis may be initiated 
or aggravated by abnormalities in either the clotting cascade, endothelial cells, 
or platelets, all of which interact in the coagulation process (24). In most cases, 
it remains unclear whether thrombosis and platelet dysfunction are a cause or 
consequence of the disease. Inflammatory infiltrates are commonly detected in 
the pulmonary endarterectomy (PEA) specimens. Thrombophilia studies have 
shown that lupus anticoagulant may be found in approximately 10% of such 
patients, and 20% carry antiphospholipid antibodies, lupus anticoagulant, or 
both. A recent study has demonstrated that the plasma level of factor VIII, a 
protein associated with both primary and recurrent venous thromboembolism, is 
elevated in 39% of patients with CTEPH. No abnormalities of fibrinolysis have 
been identified.  
 
1.1.4 Treatment of PH 
Prior to the availability of treatment, PAH patients had a life expectancy of less 
than 3 years (4, 25). Modern drug therapy leads to a significant improvement in 
patients’ symptomatic status and a slower rate of clinical deterioration. A meta-
analysis performed on 23 RCTs in PAH patients (published prior to October 2008) 
reports a 43% decrease in mortality and a 61% reduction in hospitalisations in 
patients treated with specific drug therapies vs. patients randomised to placebo 
(26). These results, achieved after an average treatment period of 14.3 weeks, 
support the efficacy of the currently approved PAH treatments. Despite this 
finding, PAH remains a chronic disease without a cure. The medical and 
29 
 
interventional treatments for more advanced cases are still invasive and prone 
to significant side effects.  
The guidelines state that the use of one of the three major classes of PH-specific 
therapies, the prostanoids, endothelin antagonists, or PDE-5 inhibitors, is up to 
the discretion of the treating physician. Combination therapy, using two or more 
classes of drugs simultaneously, is one way of escalating treatment, and has 
been used successfully in the treatment of systemic hypertension and heart 
failure (27, 28). It is also an attractive option for the management of PAH 
because three separate signalling pathways known to be involved in the disease 
are targeted by present therapies:  
1) Prostacyclin pathway;  
2) Endothelin pathway;   
3) Nitric oxide (NO) pathway.  
 
Figure 1-1: Signalling pathways involved in the pathogenesis of pulmonary 
hypertension. 
 
 
Figure adapted from the New England Journal of Medicine. 
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1.1.5 Specific drug therapy for PH 
Calcium channel blockers 
Smooth muscle cell hypertrophy, hyperplasia, and vasoconstriction are known to 
contribute to the pathogenesis of IPAH and this has led to the use of traditional 
vasodilators since the mid 1980s, principally involving the use of calcium channel 
blockers (CCBs). It has been increasingly recognised that only a small number of 
patients with IPAH who demonstrate a favourable response to acute vasodilator 
testing at the time of RHC benefit from CCBs (29, 30). 
 
Prostanoids 
Prostacyclin is produced predominantly by endothelial cells and induces potent 
vasodilatation of all vascular beds. This compound is the most potent 
endogenous inhibitor of platelet aggregation and it also appears to have both 
cytoprotective and antiproliferative activities (31). Dysregulation of the 
prostacyclin metabolic pathways has been shown in patients with PAH as 
assessed by reduction of prostacyclin synthase expression in the pulmonary 
arteries and of prostacyclin urinary metabolites (32). The clinical use of 
prostacyclin in patients with PAH has been extended by the synthesis of stable 
analogues that possess different pharmacokinetic properties but share 
qualitatively similar pharmacodynamic effects. 
 
Endothelin receptor antagonists 
Activation of the endothelin system has been demonstrated in both plasma and 
lung tissue of PAH patients (33). Although it is not clear if the increases in 
endothelin-1 plasma levels are a cause or a consequence of PH (34), these data 
support a prominent role for the endothelin system in the pathogenesis of PAH 
(35). Endothelin-1 exerts vasoconstrictor and mitogenic effects by binding to two 
distinct receptor isoforms in the pulmonary vascular smooth muscle cells, 
endothelin-A and endothelin-B receptors. Endothelin-B receptors are also 
present in endothelial cells, and their activation leads to release of vasodilators 
and antiproliferative substances such as NO and prostacyclin that may 
counterbalance the deleterious effects of endothelin-1. Despite potential 
differences in receptor isoform activity, the efficacy in PAH of the dual 
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endothelin-A and endothelin-B receptor antagonist drugs and of the selective 
ERA compounds appears to be comparable. 
 
Phosphodiesterase type-5 inhibitors 
Inhibition of the cGMP-degrading enzyme PDE type-5 results in vasodilatation 
through the NO/cGMP pathway at sites expressing this enzyme. Since the 
pulmonary vasculature contains substantial amounts of PDE type-5 the potential 
clinical benefit of PDE type-5 inhibitors has been investigated in PAH. In 
addition, PDE type-5 inhibitors exert antiproliferative effects (36, 37). 
 
Emerging treatments such as tyrosine kinase inhibitors, soluble guanylate cyclase 
activators (riociguat) and prostacyclin receptor agonists (selexipeg) are currently 
being evaluated in PAH. 
 
1.1.6 Natural history of pulmonary hypertension 
Obliteration of pulmonary capillary beds and vasoconstriction lead to elevated 
pulmonary vascular resistance (PVR) and increased RV afterload. Right 
ventricular adaptation is the main determinant of clinical outcome and survival. 
In early disease, vasodilatation of non-diseased pulmonary capillary beds 
compensates for the loss of functional beds elsewhere, thereby maintaining PVR 
and pulmonary artery pressures. Patients often have few symptoms as stroke 
volume (SV) and cardiac output (CO) at rest and during exercise are preserved. 
The negative impact on cardiopulmonary function becomes clinically apparent 
when around 70% of the pulmonary capillary beds are occluded. Patients 
experience increasing exertional limitation as SV and CO response to exercise 
become progressively restricted. In advanced disease, CO eventually becomes 
compromised at rest resulting in overt RHF, cardiovascular collapse and death 
(Figure 1.2). 
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Figure 1-2: Natural history of pulmonary hypertension. 
 
 
Patients are asymptomatic when both resting and exercise CO are preserved. 
Non-specific symptoms develop on exertion when exercise CO becomes restricted 
without affecting resting CO. Right heart failure ensues when resting CO is also 
compromised. 
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1.2 The Right Ventricle 
Figure 1-3: Anatomy of the heart. 
 
Figure adapted from Heart and Stroke Foundation of Canada. 
 
The functional capacity of the right ventricle (RV) is the major prognostic 
determinant in PH, and death usually results from RV failure (3-6). 
Developments in CMR and echocardiography within the past 2 decades have led 
to new insights into the structure and function of the RV. The important role of 
RV performance in the clinical status and long term outcome of patients with 
PH, congenital heart disease, and LV dysfunction has become increasingly 
evident (38, 39). 
The RV differs substantially from the LV in its morphology, structure, and 
function. These differences are present from the very early embryological origin 
of both ventricles (40, 41). LV myocardial precursor cells originate from the 
primary heart field in the anterior plate mesoderm, whereas RV precursor cells 
originate from the secondary heart field. Their different embryological origins 
probably explain why RV myocytes respond differently from LV myocytes to 
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abnormal haemodynamic loading conditions (42, 43). During fetal life, the RV 
pumps blood to the systemic circulation and placenta and contributes more than 
the LV (~65%) to total cardiac output (CO) (44). After birth, the LV becomes the 
systemic ventricle, whereas the RV remodels to become the subpulmonary 
ventricle, which supports the low-resistance pulmonary circulation. Once this 
adaptation has occurred, the RV loses its capacity to revert to its fetal 
phenotype and is limited in its ability to respond to abnormal haemodynamic 
loading, especially to increased pressure loading (42). 
The RV has complex 3D geometry, with a triangular appearance in the sagittal 
plane and a crescent shape in the coronal plane. The normal RV has an inflow 
component formed by the atrioventricular septum, tricuspid valve and 
subvalvular apparatus, an apical trabecular component and an outflow tract 
which continues into the pulmonary trunk. The RV inflow and outflow regions are 
separated by the crista ventricularis and the RV is “wrapped around” the LV. 
The RV is closely connected to the LV: they share a wall (interventricular 
septum); the RV free wall is attached to the anterior and posterior 
interventricular septum; and they have mutually encircling epicardial fibres and 
share the same intrapericardial space. The RV is characterised by a thin wall (3-
5mm in adults) and normally has one sixth of the muscle mass of the LV. It 
pumps the same stroke volume (SV) as the LV but with approximately 25% of the 
stroke work because of the low resistance of the pulmonary vasculature. In 
health, the pulmonary circulation is a compliant, high flow, low resistance 
system and is nearly maximally vasodilated at rest. Healthy pulmonary arteries 
exhibit very low basal smooth muscle tone and normal PVR is approximately one-
fifteenth of normal systemic vascular resistance. This allows the pulmonary 
circulation to accommodate the entire cardiac output, which flows through the 
lungs at pressures far lower than those seen in the systemic circulation. These 
low pressures prevent fluid from migrating into the interstitial space, optimising 
the conditions for gas exchange and allowing the RV to operate at minimum 
energy cost. 
Nearly all studies of ventricular fibre structure have been performed on the LV. 
Dissection studies have shown that its fibres course in a helical continuum 
between the subendocardium and subepicardium. The LV has a middle layer 
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containing circumferential constrictor fibres that provide the main driving force 
of the LV by reducing ventricular diameter. Since myocardial fibres only shorten 
by 15%, however, an essential contribution to LV ejection is shortening of the 
ventricle through contraction of its oblique fibres. A third component of ejection 
is torsion i.e. rotation of the LV apex relative to the base. The RV also has 
helical fibres and undergoes torsion. However, the RV lacks a middle layer and 
must rely more heavily on longitudinal shortening than does the LV (45) for 
generation of SV. The interventricular septum is generally considered part of the 
LV although the septum contains longitudinal fibres belonging to the RV. There 
are fibres that course between them at both the superficial and deeper layers, 
and the two ventricles interact functionally. 
The RV also differs from the LV in its physiology. RV pressure-volume loops have 
a trapezoidal shape with a less well-defined isovolumic periods compared with 
the typical rectangular LV pressure-volume loops (46-48). RV output is highly 
sensitive to afterload and fairly mild increases in afterload lead to reduced RV 
CO. This sensitivity could explain why systemic arterial hypertension is better 
tolerated than PH. 
 
1.2.1 Assessment of the RV 
The RV is difficult to assess. The RV inflow and outflow tracts are positioned in 
different planes and are difficult to image simultaneously with 2D techniques. 
The normal RV has a thin wall and is, therefore, difficult to visualise and 
differentiate from the surrounding structures. Prominent RV trabeculations 
further complicate border detection, which is required for calculation of RV 
volumes and mass, irrespective of the imaging technique employed. Assessment 
of RV function is complex and no single functional parameter is generally 
accepted in clinical practice. This situation contrasts with assessment of LV 
performance, in which LV ejection fraction (LVEF) is a generally accepted 
parameter to assess systolic function. 
 
1.2.2 RV in pulmonary hypertension 
The functional capacity of the right ventricle (RV) is the major prognostic 
determinant in PH, and death usually results from RV failure (3-6). It is unknown 
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why some patients with markedly elevated pulmonary artery pressures maintain 
well-preserved cardiac function for several years, while others with equal or less 
severe PH suffer rapidly progressive right heart failure. Although pulmonary 
pressure rise is the distinctive characteristic of this disease, the level of 
pulmonary artery pressure itself has only modest prognostic significance in 
patients with PAH.  One factor that has hindered the understanding of RV 
performance in patients with PH has been the lack of techniques that give a 
reliable picture of right ventricular morphological and functional change in the 
face of increasing outflow obstruction. However, in patients with PAH, RV 
dysfunction has not received the same scientific interest as the mechanisms of 
PAH. 
Significant morphological and functional adaptive changes of the RV develop in 
patients affected by PH. The first adaptation that occurs is myocardial 
hypertrophy, followed by progressive contractile impairment. Possible 
mechanisms involved in the progression of RV myocardial contractile dysfunction 
include:  
i) ischaemia,  
ii) changes in gene expression of the sarcomere proteins, 
iii) activation of myocardial renin–angiotensin system.  
However, afterload mismatch remains the main determinant of RV dysfunction in 
patients with PH. RV dilatation occurs in order to compensate a reduced 
fractional shortening by an increase in preload, so that stroke volume is 
maintained. As contractile dysfunction progresses, RV failure occurs and it is 
characterized by high RV filling pressures, diastolic dysfunction, and reduced 
cardiac output (CO). The decrease in CO is also due to the functional tricuspid 
regurgitation caused by tricuspid annular dilatation and impaired leaflet 
coaptation. Augmented RV volume is the result of chamber remodelling, owing 
to the increase in cardiac myocyte length as a consequence of newly synthesized 
sarcomeres assembled in series. With hypertrophy and dilatation, the RV 
progressively becomes more spherical, its cross-sectional area enlarges, and the 
interventricular septum flattens, causing also LV diastolic dysfunction. Diastolic 
dysfunction is the most frequent type of LV impairment in patients with PAH.  
Usually, patients with PAH show a delayed relaxation pattern of LV filling and a 
small end-diastolic LV volume. The reduced LV end-diastolic volume contributes 
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to the decrease in stroke volume. Reduction of LV ejection fraction may occur in 
patients with PAH but this is a rather uncommon finding. 
 
1.3 Cardiac Magnetic Resonance (CMR) Imaging 
1.3.1 Introduction 
CMR imaging is well established in clinical practice for the diagnosis and 
management of a wide spectrum of cardiovascular disease. Its advancing role is 
related to technical improvements, which allow increasingly rapid and robust 
data acquisition. Use of CMR represents the specialised application of magnetic 
resonance (MR) to the cardiovascular system, employing specialised receiver 
coils, pulse sequences, and gating methods. Images may be performed with ECG 
gating/triggering and with respiratory suppression (breath holding or navigator 
gating), thereby reducing image artefacts. 
CMR is fundamentally safe. No short or long-term ill effects have been reported 
at current field strengths (less than 3 Tesla). MR does not interfere with the 
electron shells involved in chemical binding (e.g. DNA) that can be altered by 
ionizing radiation. The phenomenon of MR is restricted to atomic nuclei with 
unpaired spin e.g. hydrogen, carbon, oxygen, sodium, potassium, and fluorine. 
The majority of clinical CMR imaging involves the hydrogen nucleus, which is 
abundant in water, fat, and muscle. 
 
1.3.2 Basic Physics of CMR 
MRI is based on nuclear magnetic resonance, the phenomenon of the resonance 
of atomic nuclei in response to radiofrequency (RF) waves. The hydrogen (H+) 
atom is the simplest and most abundant element in the body and consists of one 
proton nucleus orbited by one electron. The H+ nucleus can therefore also be 
termed a proton, and current clinical MRI techniques are based on receiving and 
processing RF signals from protons. Protons have a magnetic axis which is 
normally randomly orientated. When a magnetic field is applied, the protons 
align in synchrony and spin around an axis in line with the main magnetic field. 
This spinning is termed precession. The rate at which protons precess is 
measured by the precession frequency, which changes linearly with increasing 
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magnetic field strengths. When protons precess in synchrony they are said to be 
in-phase. There is loss of synchrony with time, and this is also termed out-of-
phase. At equilibrium within a magnetic field, overall proton alignment is in the 
direction of the main magnetic field and they have net longitudinal 
magnetisation. This equilibrium can be disturbed by transmission of RF energy at 
the precession frequency of the proton which is 63 megaHertz (MHz) for water 
protons at 1.5 Tesla (T) which is the strength of most commercially used 
magnets. 
The degree of proton excitation is proportional to the amplitude and duration of 
the RF pulse. After excitation, proton relaxation occurs as the energy is 
dissipated and this process is defined by two parameters known as T1 and T2. T1 
relaxation times measure the time after excitation to recover the longitudinal 
magnetisation found in the equilibrium state. Transverse magnetisation decays 
at a rate measured by T2, which is faster than the rate of T1 recovery. T1 and 
T2 relaxation vary according to the environment of the H+ atom within tissues 
and imaging sequences can be designed with different preference (or weighting) 
to one of these relaxation parameters for tissue characterisation, known as T1-
weighted (T1W) and T2-weighted (T2W) acquisitions. The values for T2 are 
always below that of T1, and T1 represents the upper limit of T2. T1 and T2 
values tend to parallel each other when proton motion is relatively random, e.g. 
in adipose tissue (which has a short T1 and T2) and in free water (which has a 
long T1 and T2). Tissues with a more organised structure contain abundant 
bound water. In this case proton motion is not random, there is increased 
transverse decay from the exchange of energy between protons, and T2 values 
become shorter than those of T1. 
Localisation of anatomical position within a selected imaging slice or volume is 
done with the application of frequency- and phase-encoding gradients. The 
corresponding direction of application of these gradients is known as the 
frequency encode or phase encode direction. With modifications of the phase 
encoding gradients flowing blood can be differentiated from stationary anatomy 
via alterations in the phase of the MR signal. The velocity of material is 
proportional to the phase change or phase shift caused by its movement during 
gradient application. 
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Transmission and reception of RF energy is via special aerials known as coils with 
subsequent conversion of these raw data into images using ultrafast computers 
and a process known as Fourier transformation. 
 
1.3.3 Main sequences in CMR 
There are two fundamental types of sequence commonly used in CMR: gradient 
echo (GE) and spin echo (SE). As a general rule, with GE sequences both blood 
and fat appear white and so this technique is also known as white blood imaging. 
By contrast, in SE sequences blood is usually black but fat is white, giving rise to 
the term black-blood imaging. SE sequences are more useful for anatomical 
imaging as opposed to the functional imaging performed with GE sequences. 
Variations in GE sequences are fast low-angle shot (FLASH), fast imaging with 
steady-state free precession (SSFP), and velocity mapping. GE imaging also forms 
the basis of the inversion recovery technique. 
Cine imaging using SSFP (or cines) are obtained by rapid repetition of a variant 
of the basic GE sequence to obtain a series of cardiac images at progressively 
advancing points of the cardiac cycle which when put together form a cine loop. 
The weighting of SSFP sequences depends on the ratio of T2/T1, therefore most 
fluids and fat have a high signal and appear white. However, muscle and many 
other solid tissues have along value for T1 and a short value for T2. This means 
that their signal intensity is reduced to shades of grey.  
Velocity mapping (or flow velocity mapping) techniques can determine the 
average velocity within a single imaging voxel, typically 1 x 1 x 10mm3. The 
operator selects the required plane and sets a maximal encoding velocity (Venc). 
The Venc represents the practical upper limit of velocities that can be depicted 
unambiguously and should ideally be set to a numerical value just greater than 
the true velocity. Problems occur if it is set much higher or lower than this value 
– with the former leading to less sensitivity and the latter causing 
misrepresentation via the phenomenon of aliasing. Velocity mapping sequences 
are also used to calculate overall flow in a major vessel throughout the cardiac 
cycle.        
 
40 
 
1.3.4 Components of a modern CMR scanner 
The scanner itself is comprised of a superconducting magnet (made of Niobium, 
low resistance wire) bathed within supercooled liquid Helium (circulating at 
around -250ºC). The smaller gradient magnet coils are housed on the inner 
circumference of the main magnet and the whole apparatus is enclosed within a 
copper lined room designed to deflect commercial radio waves that might 
interfere with its operation. Copper lined channels in one wall of this box allow 
transmission of tubing from infusion pumps in the control room and the delivery 
of drugs or oxygen to the patient during scanning. The floor beneath the MR 
scanner must be reinforced to accommodate the weight of the main 
electromagnet. 
The MR signal is received by a phased array chest coil. This is a dedicated 
receiver coil that lies on top of the chest. It contains several component coils, 
the arrangement of which is designed to maximise MR signal strength but 
minimise interference from tissue movement and system noise (i.e. optimise the 
signal to noise ratio). ECG-gating is used to synchronise imaging cycles with the 
motion of the heart. The R wave of a 3-lead ECG, recorded continuously, is used 
to trigger the excitatory RF pulse. Gradient echo sequences, which have a short 
TR, can be used to generate video-quality cine loops. This capability has 
revolutionised cardiac imaging as end-diastolic and end-systolic phases can be 
defined on the resulting cine images and end-diastolic and end-systolic volumes 
can be accurately measured. Individual lines of K-space (representing individual 
phase encoding steps) are filled during consecutive heart beats; therefore each 
cine loop takes at least 5 cardiac cycles to complete, depending on the sequence 
being used. To minimise motion artefact on the resulting images, patients are 
asked to hold their breath in expiration during most gradient echo sequences. In 
longer pulse sequences this is not possible and the patient must be allowed to 
breath freely, but they are asked to do so as smoothly as possible. 
Once the predetermined K-space volume has been filled, the digital data is fed 
into a ‘Reconstructor’ computer which performs Fourier Transform Image 
Reconstruction and generates pixelated grey-scale data that is presented to the 
user on a flat screen monitor as a completed MR image. During any MR 
examination the user can alter the operation of the gradient coils and select a 
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variety of pulse sequences using a modified keyboard and mouse. Individual 
parameters within these sequences e.g. TR, TE, flip angle, can be modified as 
the operator desires. Images can be saved to an internal database and to 
external compact disc drives. The same PC workstation can be used for image 
analysis using the necessary software.  
    
1.3.5 Limitations of CMR 
CMR is expensive, not widely available and requires significant operator 
expertise. It can be a difficult examination for PH patients to complete due to 
time duration and breath holding requirements. Claustrophobia is a significant 
problem. This can be overcome in the majority of patients by using mild 
sedation, although this is often inappropriate in PH patients. Ferromagnetic 
objects must not enter the MR scanner area because they will become 
projectiles. This is an extremely important safety issue. Common practice is to 
specifically check and verify that each medical device present in patients is MR 
compatible. The radiofrequency field, which is used for excitation, can induce 
heating of tissue and implanted devices. It is possible to stimulate sensitive 
tissues such as peripheral nerves owing to the rapidly changing gradient 
magnetic fields used to generate images. Myocardial stimulation has not been 
described with current hardware. 
 
1.3.6 Ventricular Morphology and Function by CMR 
CMRI is regarded as the “gold standard” for quantifying ventricular volume, 
mass, structure and function. Impressive results for accuracy have been 
demonstrated by several investigators in various disease states (49-53). The 
interstudy reproducibility of CMR-derived parameters of ventricular function and 
mass is good for both the left and right ventricle and is superior to two-
dimensional and M mode echocardiography (54-56). The results from a study 
performed by Grothues et al demonstrate that the interstudy reproducibility of 
the RV is lower than for the LV, although CMR is still a reliable method and can 
be considered the gold standard for serial assessment of RV volumes, function 
and mass (57).   
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MRI produces tomographic still images that can accurately and reproducibly 
assess left ventricular and right ventricular chamber sizes, wall thickness and 
mass. The multifaceted nature of MRI enables it to be used not only for 
morphological assessment, but also for functional assessment. Conventional 
gradient-recalled echo or steady-state-free-precession pulse (SSFP) sequences 
can be used to construct a cine image, which is a movie of 15-20 frames in which 
the full cardiac cycle can be seen; each movie frame represents approximately 
30-40ms of the cycle. Recent technological advances enable the implementation 
of SSFP sequences which provide a substantially higher signal-to-noise ratio than 
can be obtained by conventional gradient-echo techniques. The contrast 
between myocardium and cavity blood (58) make planimetry of the interface 
accurate and easily reproducible for assessment of left and right ventricular 
function. The SSFP technique is the preferred cardiac CMR pulse sequence for 
acquisition of volumetric data sets of the left and right ventricle. Cine mode MRI 
allows regional and global systolic function to be evaluated because wall motion 
abnormalities can be identified. Ventricular volumes, ejection fraction, and 
myocardial mass are usually obtained from a stack of contiguous “bright blood” 
cine CMR 5-10mm slices covering the LV and RV acquired in short axis or 
transverse orientation. Endocardial and epicardial contours are drawn during 
post processing on end-diastolic and end-systolic frames, and LV and RV volumes 
are calculated as the sum of individual slice volumes. Ventricular mass is the 
product of myocardial volume and muscle specific density (1.05g/cm3). A 
previous criticism of this technique has been the time required to analyse the 
cine data to generate accurate volume and mass data. New PC-based software 
solutions with intensity based thresholding for semiautomated myocardial-blood 
border definition has enabled analysis to become less time consuming. 
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Figure 1-4: Planimetry of the right ventricle. 
 
 
Epicardial and endocardial borders of the right ventricular myocardium are 
manually traced at end-diastole on this short axis CMR image. This scan is taken 
from a patient with idiopathic pulmonary hypertension. Right ventricular dilatation, 
hypertrophy and increased trabeculation are evident. (RV = right ventricle; LV = 
left ventricle). 
 
1.3.7 Flow Analysis 
Phase contrast velocity mapping is an MR sequence used to measure velocity and 
flow in blood vessels, or within the heart, in which each pixel in the image 
displays the signal phase, which is encoded. Volumetric flow (ml/sec) is obtained 
in each time frame by multiplying the spatial mean velocity (cm/sec) of blood 
flow with the cross sectional area of the vessel (cm2). Integrating the volumetric 
flow curve over systole gives the stroke volume (SV). This imaging technique has 
been available for over 20 years (59). Velocity encoded imaging has been shown 
to be a reliable method to measure blood flow in different vessels of the body. 
Analogous to Doppler echocardiography, this technique allows the calculation of 
stroke volume, cardiac output, ejection fraction, valvular regurgitant fractions, 
and quantification of cardiac shunts, while mitral and tricuspid transvalvular 
flow profiles allow the assessment of ventricular diastolic filling patterns (E and 
A waves). Cardiac output and the pulmonary-to-systemic flow ratio (Qp:Qs) 
measured with the use of this technique have been shown to be accurate (60, 
61). SV calculated from flow measurements in the pulmonary artery corresponds 
well with volumetric measurements of the RV in healthy subjects. Phase contrast 
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MR flow is less accurate in patients with either cardiac arrhythmia during 
acquisition or turbulent blood flow; the presence of these is a general limitation 
of this technique. Of note, even when appropriate methods of acquisition have 
been used, there can be inaccuracies of flow measurement on some CMR systems 
caused by background phase errors due to eddy currents or uncorrected 
concomitant gradients.  
 
1.3.8 Contrast Enhanced CMR imaging 
Gadolinium is a contrast agent utilised in MR scanning. It has seven unpaired 
electrons in its outer shell, and it hastens T1 relaxation, thereby increasing 
signal in the area of interest. Gadolinium alone is cytotoxic, but not if chelated 
with diethylenetriamine pentaacetic acid (DTPA). It has similar pharmacokinetic 
properties to iodinated X-ray contrast but with minimal nephrotoxicity and 
anaphylaxis risk. Attention has been drawn, however, to recent reports 
identifying a possible link between exposure to gadolinium-containing agents 
used in patients with end-stage renal disease and a rare, potentially life 
threatening condition referred to as nephrogenic systemic fibrosis (NSF). 
Regulatory authorities advise caution in the administration of gadolinium-
containing agents in renally impaired patients.   
In addition to evaluating the first-pass transit of gadolinium contrast, images can 
be obtained 10-15 minutes later, in a pseudoequilibrium phase. Gadolinium is 
avidly retained in abnormal myocardial regions resulting in a shortened T1 and 
increased signal intensity. The bright areas on the resulting images are described 
as areas of delayed contrast enhancement (DCE). DCE is not biologically specific 
and has been described in a variety of illnesses. Myocardial infarction, fibrosis 
and inflammation have all been shown to result in DCE using gadolinium as an 
intravenous contrast agent (62-66). 
 
1.3.9 MR Pulmonary Circulation 
Several methods have been proposed for MRI imaging of the pulmonary 
vasculature, both with and without the use of gadolinium. 3D gadolinium-
enhanced magnetic resonance angiography is now the most commonly applied. 
Contrast-enhanced MR angiography utilises 3D ultrafast imaging sequences (T1 
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weighted) after intravenous injection of gadolinium and uses the first pass of 
this contrast agent (67). Limitations of MR angiography include a lower spatial 
resolution and longer breath hold when compared to CT.  
Preliminary protocols are being developed to image lung perfusion into the 
diseased lung. These will allow for quantitative analysis of lung perfusion. This 
technique may allow for perfusion/functional assessment pre and post disease 
targeted therapy. 
 
1.4 CMR Assessment of Pulmonary Hypertension  
It is recognised that the response of the RV in PH is the most important 
determinant of patient outcome. A range of haemodynamic, structural and 
functional measures associated with the RV have prognostic importance in PH 
and, therefore, have potential value as measurements for the evaluation and 
follow up of patients. If these measures are to be used clinically, we require 
simple, reproducible, accurate, easy to use, and non-invasive methods to assess 
them. CMRI is regarded as the “gold standard” method for assessment of the RV. 
CMR is only reliable when adequately standardised. Measurement accuracy 
depends on optimisation of image acquisition and consistency in postprocessing. 
Imaging acquisition can be influenced by inconsistent breath-holding and 
different scanning parameters. Postprocessing requires extensive manual 
contouring, which is operator dependent. Measurement variability is related to 
difficulties in defining the tricuspid and pulmonary valve planes and in 
identifying the endocardial border owing to the extensive trabeculations that 
characterise the right ventricle. Manual analysis offers better control over 
delineation than semi-automated analysis, reflected in improved interobserver 
reproducibility (68). However it is time consuming and requires end-systole to be 
predefined. This can be difficult in PH due to abnormal interventricular septal 
motion. 
 
1.4.1 Ventricular Volumes 
Right ventricular end-diastolic (RVEDV) and end-systolic volumes (RVESV) are 
significantly elevated in PH patients when compared to control subjects (49, 69-
71). RV ejection fraction (EF) is impaired in PH compared to healthy subjects 
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(69, 70, 72). RVEF, calculated by measuring end-diastolic and end-systolic RV 
volume, is a prognostic indicator in PAH (73). RV stroke volume (SV) (69) and 
RVCO are significantly reduced in patients with PH compared to healthy control 
subjects (72). A CMR study of 64 patients with IPAH confirmed that a large RV 
volume and a low SV measured at baseline were strong independent predictors 
of mortality and treatment failure (73). 
LVEDV, LVSV and LV peak filling rate were significantly smaller in patients with 
PH compared to healthy controls (69). A reduced LVEDV at baseline predicts a 
poor outcome (73). A CMR study by Noordegraaf et al compared patients with PH 
secondary to emphysema and healthy controls. A significantly reduced LV 
ejection fraction was demonstrated in the emphysematous patients although 
especially in those without RV hypertrophy (72). Decreased LV volumes can be 
explained by the increased PVR, which limits RV SV and therefore the volume 
available for LV filling. LV septal bowing further reduces the LV volume in early 
diastole, thus limiting the LV filling process during the most important phase of 
rapid filling. Gan and colleagues investigated the contribution of direct right to 
left ventricular interaction to LV filling and SV in PAH patients and controls using 
CMR (74). They confirmed a close relationship between LVEDV and SV and 
concluded that ventricular interaction mediated by the IVS impairs LV filling, 
contributing to a decreased SV.  
 
1.4.2 Ventricular Mass 
CMR has confirmed a significantly higher RV mass in PH patients compared with 
healthy volunteers. Right ventricular hypertrophy is a consequence of the 
increased pulmonary afterload (51). The left ventricular mass does not differ 
significantly from normal values in PH patients (51). A study by Saba et al 
including 26 patients who underwent CMR and echocardiography examination 
shortly after right heart catheterisation showed that a ventricular mass index > 
0.6 (obtained by dividing RVM by LVM) had a sensitivity of 84% and specificity of 
71% for detecting pulmonary hypertension of various aetiologies (75). The VMI 
was more accurate than echocardiography in diagnosing PH and demonstrated 
excellent correlation (r=0.81) with the mPAP determined during right heart 
catheterisation (75). This correlation was superior to that obtained from RVM 
alone. A recent, larger study by Roeleveld et al, however, showed a much 
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weaker correlation between the VMI and mPAP (r=0.56) although the VMI was 
found to be the best among five different CMR-based methods for the estimation 
of mPAP (76). 
 
1.4.3 Interventricular Septal Configuration 
Distortion of the normal shape of the interventricular septum (IVS) has been 
reported in situations of RV pressure and/or volume overload (77). Patients with 
PH show characteristic changes in the movement and shape of the IVS as a result 
of increased RV pressure. Cine CMRI demonstrates how the IVS flattens and bows 
during diastole and systole. This can be expressed quantitatively as curvature, 
and the degree of curvature has been shown to be related to systolic PAP (78). 
Severe left ventricular septal bowing (LVSB) is often considered to be associated 
with an unfavourable prognosis in PH (4). 
 
Figure 1-5: Cardiac magnetic resonance short axis image from a patient with 
pulmonary hypertension. 
 
 
A short axis cine image at mid-ventricular level in early diastole. The CMR image 
was acquired from a patient with severe IPAH. The RV is grossly dilated and 
hypertrophied. The distorted IVS is bowed towards the LV (D-shaped) due to RV 
pressure overload.     
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1.4.4 RV Diastolic Function 
Diastolic function has been shown to be abnormal in diseases affecting the LV 
and is often an early sign of ventricular dysfunction. It is targeted 
therapeutically. In PAH, a prolonged post-systolic isovolumetric time interval, 
between PV closure and TV opening is seen (79-82). Several reports have shown 
that this post-systolic isovolumetric period is related to disease severity (83) and 
was previously interpreted as a reflection of RV diastolic dysfunction (81, 84-87). 
Gan et al showed that this, determined by CMRI, can be a marker for RV 
dysfunction, correlating positively with ventricular mass and PVR (80). More 
recently the use of MRI-tagging techniques has shown that the underlying 
mechanism of increased post-systolic time is increased RV contraction rather 
than impaired relaxation time (88, 89). One consequence of this prolonged RV 
contraction time is leftward septal bowing impairing early LV diastolic filling 
(74). This, together with a low SV, might explain why LV end-diastolic volume 
(LVEDV) is such a good prognostic parameter in PAH; impaired LVEDV is an 
independent predictor of mortality, while a further decrease in LVEDV is among 
the strongest predictors of mortality in PAH. Other significant predictors include 
a decrease in SV and progression of RV dilatation (73, 90).  
To simplify RV assessment, surrogate measurements are being developed. 
Recently, geometric shortening measured in the longitudinal or, more 
significantly, transversal plane using CMRI has been shown to have a stronger 
relation to RVEF than tricuspid annular plane systolic excursion (TAPSE) (91). A 
more recent publication by Mauritz and colleagues showed that geometric 
changes in the transversal plane are particularly important for monitoring the RV 
in end-stage disease (92).   
 
1.4.5 Right Ventricular Contractility 
Recent advances in MR scanner hardware and software have enabled CMR 
guidance of endovascular catheters under real time imaging (magnetic 
resonance fluoroscopy). This CMR approach is a promising tool for assessing RV 
contractility in the clinical setting (93). Interventional CMR allows RV pressure-
volume loops to be created from which 3 key measures are extracted:1) Systolic 
function (Emax; end-systolic pressure divided by ESV) 2) Afterload (Ea; end-
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systolic pressure divided by SV) and 3) Ventricular-arterial coupling (Emax/Ea). 
In patients with PAH, Kuehne and colleagues (93) found that while systolic 
function was increased, the increase in arterial elastance was relatively greater 
leading to ventricular-arterial decoupling. These findings have been echoed 
more recently in a larger cohort of patients with PH (albeit using different 
definitions of Emax and Ea) (94). CMR-guided RHC has been successful in 
assessing the changes in PVR after nitric oxide inhalation in patients with IPAH 
(95). Reduction or elimination of x-ray radiation, added anatomic and functional 
information available with MR, and the relative ease and accuracy of phase 
contrast MR flow quantification may make this technique an attractive method 
for invasive measurement of PVR. This is a single centre experience and major 
limitations are cost and availability of MR compatible equipment. This procedure 
is not suitable for serial follow up due to its invasive nature. 
 
1.4.6 Contrast Enhanced Perfusion CMR  
An interesting pattern of hyperenhancement within the RV is described with 
delayed contrast CMR in patients with PH. This delayed contrast enhancement 
pattern has a mid-wall distribution involving the RV septal insertion points and 
the IVS (96). A higher degree of enhancement was correlated with worse RV 
function and haemodynamics. When contrast enhancement was present in the 
IVS it was associated with septal bowing on cine-CMR. This data was confirmed 
by McCann and colleagues (66). This has led to speculation that it may reflect 
pathological fibrosis (96) and hence a source of ventricular arrhythmias (66). 
Proving its histological basis is difficult. Its position is inaccessible to in-vivo 
biopsy. Pathological correlation in a patient who had died 6 weeks after CMR 
(97) showed myocardial disarray and plexiform fibrosis at the insertion regions 
where LGE occurred. These histological features are normally found in the 
insertion regions since they represent crossing points for left and right 
ventricular fibres with collagen in between (98). Hence LGE may reflect pooling 
of gadolinium with an area of normal myocardium whose architecture has been 
accentuated by hypertrophy and mechanical stress. 
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Figure 1-6: Delayed contrast enhanced cardiac magnetic resonance images 
of a patient with pulmonary hypertension. 
 
 
A contrast enhanced short axis cardiac MR cine image was acquired at a basal 
ventricular level. The delayed contrast enhancement pattern has a mid wall 
distribution involving the right ventricular insertion point (RVIP) and the IVS.  
 
1.4.7 Stress CMR  
Stress testing, by exercise or drug infusion, can be used to determine cardiac 
reserve. Physical exercise within the confines of the magnet is technically 
difficult and leads to image degradation. Holverda and colleagues, however, 
demonstrated that IPAH patients were unable to significantly increase SV from 
rest to exercise, using an MR compatible ergometer (99). Pharmacological CMR 
stress can be used in patients with congenital heart disease to detect early RV 
dysfunction. The physiological effects of exercise are imitated by a continuous 
infusion of a short acting agent such as dobutamine (a relatively selective beta-
1-adrenoceptor agonist) (100). Dobutamine has a positive inotropic effect on RV 
contractility, which can be determined using MRI. During CMR, perfusion with 
adenosine stress in PH patients, biventricular vasoreactivity has been found to 
be diminished. The degree to which this occurs in both ventricles could be 
predicted from mPAP (101). 
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1.4.8 CMR flow measurements 
Velocity encoded imaging is another CMR approach for the assessment of PH. In 
the setting of PH, the most important applications of flow analysis include 
measurement of cardiac output (CO) / stroke volume (SV) and pulmonary to 
systemic flow measurements in the estimation of right-to-left and left-to-right 
shunts. It has been suggested that measurement of SV/CO in PH patients should 
be made by aortic flow analysis during CMR imaging (102). The aorta is smaller, 
has more coherent flow patterns and less translational movement than the main 
pulmonary artery. RV SV can be calculated as the difference of end-diastolic and 
end-systolic RV volumes, or by the measurement of volumetric flow in the main 
pulmonary artery employing phase contrast velocity mapping. SV, calculated 
from flow measurements in the pulmonary artery, and from volumetric 
measurements of the RV correspond well in healthy controls, and show little 
divergence in patients with mild TR. However, with considerable tricuspid 
regurgitation (TR) (e.g. PH patients), the volumetric SV overestimates the actual 
SV (69) because it is impossible to differentiate between the volume that moves 
back through the tricuspid valve and forward though the pulmonary valve.  
The analysis of these images enables us to describe changes or irregularities of 
pulmonary blood flow in PH. Previous studies using this technique have found 
highly inhomogeneous velocity profiles, a large volume of retrograde flow, and 
decreased distensibility of the main pulmonary artery in patients with PH (103, 
104). From the quantitative analysis of the pulmonary flow profile, non-invasive 
indexes (e.g. acceleration time [defined as time from onset of flow to the peak 
velocity] and acceleration volume) have been derived for the assessment of 
pulmonary vascular resistance (105). Peak blood flow velocity in the main 
pulmonary artery (MPA) is lower in patients with PH and shows inverse 
correlation with mean PAP and PVR. When examined in patients with CTEPH, 
values after pulmonary endarterectomy were significantly higher than before 
surgical intervention, but did not reach normal range (106). A significant 
reduction of peak velocity in both right and left pulmonary arteries was observed 
in patients with PH secondary to cystic fibrosis (107). As the study revealed no 
change in the flow of the main pulmonary artery, it was concluded, that early 
and subtle changes of pulmonary haemodynamics are first noticeable in the 
periphery of the pulmonary arterial system. CMR could, therefore, be the 
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method of choice for detection of early haemodynamic change before RV 
function is altered. 
CMR derived flow in the mPA has also been used to gauge haemodynamics e.g. 
pulmonary pressures were shown to be inversely correlated with average blood 
velocity in the mPA (108). In addition, total pulmonary resistance has been 
estimated by determining the percentage of regurgitant flow  and cross sectional 
area of the MPA (104), or calculating the ratio of the maximal change in flow 
rate during ejection to the acceleration volume (105). Finally, the use of four 
dimensional flow (109) has built on early work in two dimensional flow (110), to 
show that in patients with PH, a vortex can be detected in the primary flow 
direction whose duration correlates well with mPAP.  
 
1.4.9 Distensibility of Pulmonary Artery 
Pulmonary artery distensibility measured by CMR was found to be significantly 
lower (8%) in PH patients than it was in normal subjects (23%) (103). A pilot 
study performed by Jardim and colleagues (111) indicated that the non-invasive 
assessment of pulmonary artery distensibility by MR reflected the acute response 
pattern in IPAH patients. Pulmonary artery distensibility was significantly higher 
in responders to an acute vasodilator test during invasive haemodynamic 
evaluation. Gan and colleagues (112) have recently demonstrated that proximal 
pulmonary artery stiffness (in terms of area distensibility and noninvasively 
assessed relative area change [RAC] by CMR) predicted mortality in patients with 
PH. It has been shown that a fractional change in the cross-sectional area of the 
mPA of less than 40% has a high sensitivity for detecting elevated mPAP (113). 
Additionally, compliance has been calculated by combining velocity-encoded 
data and cross-sectional area change of the mPA and deriving pulse pressure 
through an iterative process (114). From this, pulse wave velocity (PWV – a 
measure of vessel stiffness) was derived which had a reliability percentage of 
87% for framing the actual mPAP. PWV can be calculated directly using the 
transit time technique by determining flow wave arrival time at two points in 
the proximal PAs using a high-temporal resolution flow mapping sequence and 
dividing the difference between them (115). This calculation does not depend on 
a prior knowledge of PA pressure and raises the possibility of entirely non-
invasive assessment of PA stiffness. 
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1.4.10 CMR Pulmonary Angiography 
The typical findings of CTEPH (intraluminal webs and bands, vessel cut-offs, and 
organised thrombus) are well demonstrated by pulmonary MRA and can be seen 
in vessels to segmental level. Beyond the segmental level, the higher spatial 
resolution of conventional angiography makes it superior. Surgical intervention is 
largely limited to proximal and segmental vessels, and in a study by Kreitner and 
colleagues (106), ceMRA correctly predicted surgical success in 33 out of 34 
patients. The study demonstrated that 3D contrast enhanced MRA performed 
equally as well as X-ray pulmonary angiography for the visualisation of segmental 
pulmonary vessels, was slightly worse for subsegmental vessels but was superior 
for the depiction of the central origin of thromboembolic material. Pulmonary 
MRA may be combined in the same examination with a variety of cine techniques 
to gauge cardiac function and flow. Contrast enhanced MRA should identify 
patients with CTEPH that delineate typical findings and are potential candidates 
for surgery. 
 
1.4.11 CMR Pulmonary Perfusion Imaging 
Ohno and colleagues have demonstrated that 3D dynamic contrast-enhanced MRI 
has the potential for assessment of disease severity in PH patients (116). This 
technique showed significant differences in pulmonary blood flow and mean 
transit time between healthy and PH subjects.   
 
1.4.12 Pulmonary Artery Pressure Estimation by CMR  
Repeated measurements of pulmonary artery pressure (PAP) are sometimes used 
to assess disease progression in PH. Echocardiography (117) is safe and widely 
available, but has limitations as previously discussed. MRI has been proposed as 
an accurate alternative for echocardiography in estimating PAP. Investigators 
have attempted to use CMR as a non-invasive means of estimating mean PAP but 
none have reported any advantages over echocardiography. Several estimators 
based on different MRI techniques have been described in recent years including 
acceleration time (AT: the time of onset of forward flow to the moment of 
maximum flow velocity in the MPA), AT/ejection time (ET) ratio, pulse wave 
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velocity, cross-sectional area of MPA and ventricular mass index. RV end-
diastolic wall thickness has been shown to correlate well with mean PAP in IPAH 
and some cases of secondary PH (118, 119). A linear relationship between RVM 
and mean PAP has been described for IPAH (51). The ratio of the MPA diameter 
over descending aortic diameter has also been shown to correlate with mean 
PAP in PH. A computed method for the non-invasive MR assessment of PH has 
been elaborated (120, 121), where a combination of physical parameters 
including mPA blood flow velocity at peak systole, maximal systolic mPA cross 
sectional area and biophysical parameters including patient height, weight and 
heart rate were used to estimate pulmonary artery pressure The ventricular 
mass index was found to be the best among five different CMR-based methods 
for the estimation of PAP and similar to echocardiography (r=0.55 using the 
modified Bernoulli equation and peak tricuspid regurgitation velocity), but not 
accurate enough to replace RHC in clinical practice (76). Based on recent 
results, the degree of septal displacement may be a more promising measure 
(78). 
 
1.4.13 NMR Spectroscopy 
Despite its potential, nuclear magnetic resonance (NMR) spectroscopy remains 
relatively unexplored in PH. An isolated case report using 31P-NMR spectroscopy 
offers a unique insight into the failing RV by showing how RV energetics are 
disturbed in PAH but improve with bosentan treatment (122). 
 
1.4.14 Summary of CMR 
CMR imaging has a number of advantages over other techniques (123, 124). It is 
non-invasive, employs nontoxic contrast agents and does not use ionizing 
radiation. CMR imaging provides high resolution, 3-dimensional images that avoid 
the need for geometric assumptions that are required for some calculations in 
echocardiography. Images can be obtained from every plane, allowing accurate 
volume measurement. Cardiac gating can permit the acquisition of scans in a 
single brief breath hold, which limits respiratory motion artifacts. CMR imaging 
can show soft tissue and is able to identify early changes in cardiac structure 
and function. But CMR imaging is less suitable for dynamic measurements than 
echo because temporal resolution is more limited. It is less widely available, 
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incompatibility with ferrous objects and long scan times limit its usefulness in 
some patients. Despite these limitations, given the relevance of the RV in PAH, 
CMR imaging is likely to increase in importance as the optimal method for 
assessment of structural and functional parameters in the evaluation of patients 
where PAH is established.   
 
1.5 Inert gas rebreathing 
The functional consequence of a raised pulmonary vascular resistance is a 
decrease in exercise capacity and a low cardiac output. In patients with PH, the 
CO is directly related to the clinical severity of the disease and is one of the 
most important prognostic factors. The evaluation of treatment efficacy in PH 
would benefit from non-invasive tools to monitor haemodynamic changes.  
Inert gas rebreathing is a physiological technique, which measures pulmonary 
blood flow (PBF), which is equivalent to CO in the absence of intracardiac and 
intrapulmonary shunts (125). Inert gas rebreathing is an old technique which was 
introduced by August Krogh in 1912 and has been widely validated (126-129). 
Acetylene rebreathing method using a mass spectrometer has been shown to 
provide an accurate estimate of CO compared with TD and the Fick method in 
PH patients. 
The IGR method measures PBF during rebreathing of an oxygen enriched mixture 
of blood soluble and blood insoluble gases. As inert gases are non-physiological, 
their serum concentration in systemic venous blood can be assumed to be zero. 
As the subject re-breathes through a respiratory apparatus from a bag prefilled 
with the gas mixture for about 30 seconds, the blood soluble gas dissolves 
rapidly in the pulmonary capillary blood, and its rate of disappearance from the 
alveoli is proportional to the effective PBF. The blood-insoluble gas is not taken 
up in the pulmonary capillary blood, and remains in the alveoli to correct for 
changes in total alveolar volume during the rebreathing manoeuvre. Cardiac 
output is equivalent to PBF in the absence of significant intrapulmonary or 
intracardiac shunts. 
Inert gas rebreathing, with continuous analysis of ventilatory gas concentrations, 
is an easy, safe and well-established method for non-invasive measurements of 
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effective PBF or CO. However, IGR measurements have traditionally required the 
use of mass spectrometers, which are bulky, difficult to operate and need 
frequent calibration and maintenance. These factors have significantly limited 
the clinical application of measurements of PBF/CO by the inert gas rebreathing 
technique. 
More recently, a metabolic system (Innocor, Innovision, Odense, Denmark), using 
rebreathing of nitrous oxide (N2O) and sulphur hexafluoride (SF6), has been 
introduced. This device (Innocor®), which is employed in this thesis, uses rapid 
photoacoustic analysis of gas concentrations. It was validated against the direct 
Fick and thermodilution methods in a cohort of patients with stable heart failure 
(130) and in patients pre and post cardiac surgery (131). Compared with 
conventional mass spectrometers, this analyser is more portable and easier to 
maintain, which markedly facilitates clinical use. Please refer to the materials 
and methods section of this thesis for physiological principles and operational 
detail. 
 
1.6 Evaluation of Pulmonary Hypertension 
The evaluation process of a patient with suspected PH requires a series of 
investigations intended to:  
i. confirm the diagnosis  
ii. clarify the clinical group of PH and the specific aetiology within the 
PAH group 
iii. evaluate the functional and haemodynamic impairment 
iv. consider the prognosis 
 
An accurate diagnostic assessment is imperative for the appropriate 
management of the patient with a new diagnosis of PH. 
 
1. Clinical evaluation 
Precise history taking and physical examination are essential. Although the 
symptoms PH are nonspecific, the New York Heart Association (NYHA) functional 
classification for heart failure has been adapted for PH as the WHO functional 
class. It is a four point scale to rate the impact of breathlessness and fatigue 
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according to daily activity. Despite large interobserver variation in the 
measurement, WHO functional class remains a powerful predictor of survival. In 
untreated patients with IPAH or heritable PAH, historical data showed a median 
survival of 6 months for WHO-FC IV, 2.5 years for WHO-FC III, and 6 years for 
WHO-FC I and II (4). It can be confounded by comorbidities e.g. obesity, and by 
coexisting/underlying diseases e.g. patients with systemic sclerosis associated 
PAH may have their symptoms and exercise capacity limited by musculoskeletal 
factors (132).  Extremes of age (<14 years or >65 years), falling exercise 
capacity, syncope, haemoptysis, and signs of RV failure also carry a poor 
prognosis in IPAH.  
 
2. Electrocardiogram (ECG) 
The ECG may provide suggestive or supportive evidence of PH by demonstrating 
RV hypertrophy and strain, and right atrial dilatation.  
 
3. Chest radiograph (CXR) 
In 90% of patients with IPAH the chest radiograph is abnormal at the time of 
diagnosis (25). Findings include central pulmonary arterial dilatation, which 
contrasts with ‘pruning’ (loss) of the peripheral blood vessels. Right atrium and 
RV enlargement may be seen in more advanced cases although the degree of PH 
does not correlate with the extent of radiographic abnormalities. The CXR allows 
associated moderate-to-severe lung diseases or pulmonary venous hypertension 
due to left heart disease to be reasonably excluded.  
 
4. Blood tests and immunology 
Routine biochemistry, haematology, and thyroid function tests are required. 
Serological testing is important to detect underlying CTD, HIV, and hepatitis. 
Thrombophilia screening should be performed in CTEPH.  
 
5. Biomarkers 
• Serum uric acid is a marker of impaired oxidative metabolism of 
ischaemic peripheral tissue and high levels are found to relate to poor 
survival in patients with IPAH (133).  
• Brain natriuretic peptide (BNP) induces vasodilatation and natriuresis and 
is released from the myocardium in response to wall stress. The final step 
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of BNP synthesis consists of a high molecular weight precursor, proBNP 
cleaved into biologically inactive N-terminal segment (NT-proBNP) and the 
proper low molecular weight BNP. NT-proBNP has a longer half-life and a 
better stability both in circulating blood and after sampling. RV failure is 
the main cause of death in PAH, and BNP/NT-proBNP levels reflect the 
severity of RV dysfunction. Nagaya et al. (134) showed that the baseline 
median value of BNP (150 pg/mL) distinguished patients with a good or 
bad prognosis. In a trial involving 68 patients with PAH associated with 
scleroderma, NT-proBNP below a median of 553 pg/mL was related to 
better 6-month and 1-year survival (135). Using receiver operating 
characteristic (ROC) analysis, an NT-proBNP cut-off point at 1400 pg/mL 
was predictive of a 3-year outcome in 55 patients with severe precapillary 
PH (136). Serum NT-proBNP below 1400 pg/mL seemed particularly useful 
for identification of patients with good prognosis, who would not need 
escalation of treatment in the immediate future, and this has been 
independently confirmed (137). Larger outcome trials are still required to 
verify the suggested cut-off levels for NT-proBNP.  
• Elevated plasma levels of cardiac troponin T and troponin I are 
established specific markers of myocardial damage and are prognostic 
indicators in acute coronary syndromes and acute pulmonary embolism. 
Elevated cardiac troponin T was an independent predictor of fatal 
outcome during 2-year follow-up in a single trial on 51 patients with PAH 
and five with CTEPH (138).  
 
6. Pulmonary function tests (PFTs) and arterial blood gases (ABGs) 
PFTs and ABGs will identify the contribution of underlying airway or parenchymal 
lung disease. Patients with PAH usually have decreased lung diffusion capacity 
for carbon monoxide (DLCO) and mild to moderate reduction of lung volumes. 
Arterial oxygen tension is normal or only slightly lower than normal at rest and 
arterial carbon dioxide tension is decreased because of alveolar 
hyperventilation.  
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7. Exercise testing  
For objective assessment of exercise capacity, the 6-minute walk test (6MWT) 
and cardiopulmonary exercise (CPET) testing are commonly used in patients with 
PAH.  
 
• The 6MWT is a submaximal exercise test, which can be performed by 
patients who are incapable of tolerating maximal exercise testing. The 
6MWT is technically simple, inexpensive, reproducible, and well 
standardized (139). Distance walked, dyspnoea on exertion (Borg scale) 
and finger O2 saturation are recorded. The 6MWT correlates fairly well 
with peak aerobic capacity (140) and has prognostic significance in PAH 
(141).  
 
• CPET measures metabolic gas exchange at rest and during exercise. It 
quantitates aerobic capacity and ventilatory inefficiency in order to 
determine the severity of PAH (142) and might provide a more sensitive 
exercise assessment than 6MWT early in the course of the disease (143). 
In PAH, O2 uptake at the anaerobic threshold and peak exercise are 
reduced in relation to disease severity, as are peak work rate, peak heart 
rate, O2 pulse, and ventilatory efficiency (144). Following multivariate 
analysis of clinical, haemodynamic, and exercise parameters peak O2 
uptake (<10.4 ml O2/kg/min) and peak systolic arterial pressure during 
exercise (<120 mmHg) independently predicted a worse prognosis in IPAH 
patients (145).  
 
8. Echocardiography 
Transthoracic echocardiography (TTE) provides several measurements which 
correlate with right heart haemodynamics including pulmonary artery pressure 
(PAP). The estimation of PAP is based on the peak velocity of the tricuspid 
regurgitation (TR) jet. Other TTE measurements suggestive of PH include 
increased velocity of pulmonary valve regurgitation and a short acceleration 
time of RV ejection into the PA. Increased dimensions of right heart chambers, 
abnormal shape and function of the interventricular septum, increased RV wall 
thickness, and dilated main PA are suggestive of PH, but tend to occur later in 
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the course of the disease. Echocardiography can be helpful in detecting the 
cause of suspected or confirmed PH e.g. identification of congenital heart 
disease (CHD).  
Echocardiography generates many indices, and those with the best prognostic 
value identified by multivariate analysis are pericardial effusion (6, 90), indexed 
right atrium area, LV eccentricity index (90) and the RV Doppler index (83, 146). 
Estimated systolic PAP derived from TR jet velocity is not prognostic (90). 
Normal RV function is highly dependent on longitudinal shortening and this can 
be assessed by placing an M-mode cursor on the tricuspid valve annulus in the 2D 
four-chamber view to measure the annular displacement in the longitudinal 
direction. A normal tricuspid annular plane systolic excursion (TAPSE) should be 
higher than 1.5cm in adults. The TAPSE has been reported to be of prognostic 
value in patients with PH (147).  
Although there is substantial interest in exercise stress echocardiography, 
particularly in early disease, this study is difficult to perform and interpret. 
Similarly, although 3-D echo might improve our understanding of the 
pathophysiology of RV failure in PAH, it has been minimally evaluated in PAH.  
 
9. Ventilation/perfusion (V/Q) scan 
The V/Q scan should be performed in patients with suspected PH to look for 
potentially treatable CTEPH. This is the screening method of choice for CTEPH 
because of its higher sensitivity than CT (148). A normal or low probability V/Q 
scan effectively excludes CTEPH with a sensitivity of 90–100% and a specificity of 
94–100%. While in PAH the V/Q scan may be normal, it may also show small 
peripheral unmatched and non-segmental defects in perfusion. Contrast-
enhanced CT may be used as a complementary investigation but does not 
replace the V/Q scan or traditional pulmonary angiogram.  
 
10. High-resolution computed tomography (HRCT) and CT pulmonary 
angiography (CTPA) 
HRCT provides detailed views of the lung parenchyma and facilitates the 
diagnosis of interstitial lung disease and emphysema. HRCT may be very helpful 
where there is a clinical suspicion of PVOD or PCH. CTPA is helpful in 
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determining whether there is evidence of surgically accessible CTEPH. It can 
delineate the typical angiographic findings in CTEPH such as complete 
obstruction, bands and webs, and intimal irregularities as accurately and reliably 
as digital subtraction angiography (149, 150).  
 
11. Cardiac magnetic resonance (CMR) imaging 
CMR is increasingly used in patients with PH for the evaluation of pathological 
and functional changes in the heart and pulmonary circulation. It provides a 
direct evaluation of right ventricular size, mass, morphology and function (151). 
Normal ranges of cardiac measurements have been established (51, 104). CMR 
findings in PH include RV dilatation, tricuspid regurgitation, RV hypertrophy, 
interventricular septal flattening or paradoxical motion, and change in chamber 
morphology from a normal crescent shape to a more concentric form. Non-
invasive assessments of blood flow, including stroke volume and cardiac output, 
and distensibility in the pulmonary arteries can be made (152-154). There is 
good correlation between RHC and MR suggesting that MR data could be used as 
a surrogate of right heart haemodynamics (153). CMR has also been used to 
determine which patients with IPAH might benefit from long term CCBs by 
assessing mPA distensibility (155). Baseline CMR measurements in PAH associated 
with a poor prognosis include a decreased stroke volume, an increased RV end-
diastolic volume, and a decreased LV end-diastolic volume (73). More recently, 
RVEF has been confirmed to be a prognostic marker in PAH (156). CMR 
parameters of PA stiffness are also relevant to prognosis (112).  
 
12. Abdominal ultrasound scan 
Liver cirrhosis and/or portal hypertension can be reliably excluded by the use of 
abdominal ultrasound.  
 
13. Right heart catheterisation, vasoreactivity and pulmonary angiography 
RHC is required to confirm the diagnosis of PH, to assess the severity of the 
haemodynamic impairment, and to test the vasoreactivity of the pulmonary 
circulation. When performed at experienced centres, RHC procedures have low 
morbidity (1.1%) and mortality (0.055%) rates (21). The following measurements 
must be recorded during RHC: PAP (systolic, diastolic, and mean), right atrial 
pressure, PWP, and RV pressure. CO must be measured in triplicate preferably 
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by thermodilution or by the Fick method. Superior vena cava, PA, and systemic 
arterial blood oxygen saturations should also be determined. Adequate recording 
of PWP is required for the differential diagnosis of PH due to left heart disease. 
Left heart catheterisation may be required for direct assessment of LV end-
diastolic pressure. Coronary angiography may be required in the case of the 
presence of risk factors for coronary artery diseases and angina or in case of 
listing for double lung transplantation or pulmonary thromboendarterectomy 
(PEA) in patients with CTEPH.  
In PAH, vasoreactivity testing should be performed at the time of diagnostic RHC 
to identify patients who may benefit from long-term therapy with calcium 
channel blockers (CCBs) (29, 30). Currently the agent most used in acute testing 
is nitric oxide (NO). A positive acute response (positive acute responder) is 
defined as a reduction of mean PAP ≥ 10 mmHg to reach an absolute value of 
mean PAP ≤ 40 mmHg with an increased or unchanged CO (29). Only 
approximately 10% of patients with IPAH will meet these criteria.  
Traditional pulmonary angiography is still required in many centres for the work-
up of CTEPH to identify patients who may benefit from PEA (22). Angiography 
can be performed safely by experienced staff in patients with severe PH using 
modern contrast media and selective injections. Angiography may also be useful 
in the evaluation of possible vasculitis or pulmonary arteriovenous 
malformations. 
Resting haemodynamics measured at RHC predict prognosis (4). These include PA 
O2 saturation, RAP, CO, PVR, and a marked vasoreactivity response. PAP is also 
prognostic but less reliable as it may fall towards the end stage of the disease as 
the RV fails. Some studies suggest that reduced arterial O2 saturation, low 
systolic blood pressure, and increased heart rate carry a worse prognosis (145).  
 
The clinical assessment of the patient has a pivotal role in the choice of initial 
treatment, the evaluation of the response to therapy, and the possible 
escalation of therapy.  
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1.7 Follow up assessment of PH patients 
Treatments for PH are always expensive, sometimes invasive and carry 
significant side effects. In order to convince patients, treating physicians, 
funding agencies and regulatory bodies of the value of treatments it is, 
therefore, extremely important to be able to assess patients response to therapy 
with investigations of appropriate quality. It is essential that we can assess the 
progress of patients in a non-invasive manner. The importance of having 
clinically meaningful methods to assess the patient’s response to treatment must 
be reinforced.  
 
It has been suggested that characteristics for an ideal assessment tool / marker 
in PH might include (157).  
i. it should be heart or lung specific 
ii. it should be abnormal in PH 
iii. sample collection should be simple 
iv. the marker should be easy to measure 
v. values should be reproducible 
vi. values should follow the course of the disease (i.e. increasing if 
patients deteriorate and falling if patients improve) 
vii. abnormal values should be indicative of a poor survival. 
 
The current aim is for an early diagnosis of PAH followed by treatment with first-
line monotherapy (26, 158).  The importance of escalating therapy if a patient 
does not respond to initial treatment has been emphasised in the recently 
published clinical guidelines. Regular evaluation of patients enables early 
identification of an inadequate response to treatment and should focus on 
measurements with established prognostic significance. Both clinical and 
haemodynamic assessments provide prognostic information which guides clinical 
management. Prognosis is significantly affected by the aetiology of PH (159). 
According to the guidelines, published jointly by the ESC and ERS, the clinical 
condition of a patient can be defined as stable and satisfactory, stable but not 
satisfactory, or unstable and deteriorating. The goal of therapy is to bring the 
patient into the stable and satisfactory group (160). Please refer to table 1.2. 
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Table 1-2: Definition of patient status as guided by the European Society of 
Cardiology / European Respiratory Society guidelines. 
 
Definition of patient status (ESC/ERS Guidelines) 
Stable and 
satisfactory 
Patients meet the criteria listed in the “green zone” of 
the table 1.3. The most important features are absence 
of clinical signs of RV failure, stable WHO functional 
class I or II, absence of syncope, a 6MWT distance > 400 
to 500m depending on the individual patient, a peak 
oxygen uptake of > 15mL/min/kg, normal or near 
normal BNP/NT-pro-BNP levels, no pericardial effusion, 
TAPSE > 2.0cm, and RAP < 8mmHg and a CI > 
2.5L/min/m2. 
Stable but not 
satisfactory 
Patients are not deteriorating but have not achieved 
the status that the patient and treating physician 
would consider desirable. Some of the limits described 
above for a stable and satisfactory condition and 
included in the green zone in table 1.3 are not 
fulfilled. Re-evaluation and consideration for additional 
or different treatment is required. 
Unstable and 
deteriorating 
Some or all of the criteria listed in the “red zone” of 
table 1.3. Patients present with RV failure, progression 
of symptoms and signs, worsening of functional class, a 
6MWT distance < 300m to 400m, a peak oxygen uptake 
< 12mL/min/kg, rising BNP/NT-pro-BNP plasma levels, 
evidence of a pericardial effusion, TAPSE < 1.5cm, a 
RAP > 15mmHg and rising, and a CI < 2.0L/min/m2. 
Clinical warning signs are increasing oedema and 
escalation of diuretic therapy, new onset, or increasing 
frequency of angina. The presence of syncope requires 
immediate attention as it is a common manifestation of 
a low cardiac output. 
 
Table adapted from ESC/ERS guidelines. 
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Table 1-3: Current measurements with established importance for assessing 
disease severity, stability and prognosis in pulmonary arterial hypertension. 
 
 
This table lists measurements of prognostic importance that are widely used as 
follow-up tools. Patients with better or worse prognosis are separated by an 
intermediate group for which prognostication is more difficult. Table adapted from 
McLaughlin et al (161).  
 
Physicians currently rely on the WHO functional class, exercise testing (6MWT 
and CPET), biomarkers (Brain Natriuretic Peptide [BNP] levels), 
echocardiography and RHC to follow up patients with PH. These investigations 
have acknowledged limitations. The question of which end points are most 
relevant in the assessment of PH has been the topic of intense discussion at End 
Point Meetings. Many clinicians feel that the current end points used in clinical 
trials of PAH are not as relevant as they might be. This frustration has been 
articulated recently (162). What is clear, however, is that since the trials of 
currently licensed therapies mostly used combination of 6MWD, functional class, 
and haemodynamics, all new studies will likely require significant improvement 
in one or more of these variables before they will be approved. Any new end 
point would probably need to be tested alongside traditional end points and 
shown to be demonstrably better if it is to be considered a primary or first-level 
secondary end point in the future. The impact of a treatment on disease 
progression associated with PAH was be measured by time to clinical worsening 
(TTCW). This endpoint is viewed as clinically relevant by clinicians and 
regulatory agencies. This end point has been used in several clinical trials as a 
secondary, or a primary end point, in the recent past.  
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1.7.1 WHO Functional Class 
The WHO functional class has been an important end point in clinical trials of 
PH, although the assignment of patients to categories is subject to the bias of 
investigators, which limits its usefulness as an end point. 
 
1.7.2 Quality of life (QoL) 
It has been suggested that QoL is an important method to measure the efficacy 
of drug therapy. Unfortunately, it has always been very difficult to objectify QoL 
measurements, and until recently, there had been no specific health-related 
QoL measures in PAH. Advantages of QoL include that it is easy, cheap and quick 
and it measures things of particular value to patients. Disadvantages of QoL as 
an assessment include until recently, tests were not specific to PAH. A specific 
test is now available – Cambridge Pulmonary Hypertension Outcome Review 
(CAMPHOR) (163) but not yet has proven efficacy, and must be adapted for 
different countries and languages. 
 
1.7.3 Exercise Testing 
Exercise capacity is one of the most important prognostic indicators in PAH (141, 
164, 165). Several exercise protocols have been used in PAH including 6MWT, 
formal exercise testing (treadmill, cycle ergometry) and CPET. Of these, the 
6MWT has been accepted by regulatory agencies and is the most commonly used 
primary end point in randomised controlled trials (166, 167). The 6MWT must be 
performed correctly using the appropriate guidelines (ATS Statement) (139). 
With respect to treatment effects, absolute values >380 m following 3 months of 
i.v. epoprostenol correlated with improved survival in IPAH patients, while the 
increase from baseline did not (164). 
Flaws have been highlighted in its performance. There are concerns (168) that 
the 6MWD is influenced by (but not corrected for) a number of factors other 
than PH including age, gender, height, weight, musculoskeletal conditioning and 
patient motivation. Furthermore, it has been shown that the 6MWD can improve 
considerably with rehabilitation measures alone (169). The test is not 
sufficiently validated in PAH subgroups (139). Within-subject variability has been 
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seen in the 6MWT, with repeat testing on the same day resulting in a 66-ft 
improvement in a study of patients with COPD (170), an 18m improvement on 2 
successive days in post-MI patients (171), and a 4.2% change in patients with ILD 
after 1 week (172). In addition, the 6MWT may be less discerning in patients who 
are less ill (173). Drug effects on the 6MWT tend to be slow to manifest and 
modest (10-15%) and may not provide an accurate reflection on how the patient 
might feel. 
Several questions, therefore, remain regarding the 6MWT. 
1. What is a clinically relevant improvement in 6MWT? 
2. How should variables that are known to affect the 6MWT, such as age 
and height, be factored into this endpoint/assessment? 
3. Is the 6MWT still a sensitive exercise test as we study patients earlier in 
the course of the disease? 
Despite detailed recommendations (174, 175), a generally accepted 
standardisation of cardiopulmonary exercise testing with respect to data 
acquisition and analysis in PAH is lacking. The CPET is expensive and has proven 
technically difficult to perform and interpret in the setting of a multicentre RCT. 
While the results of both the 6MWT and CPET do correlate in PAH, CPET exercise 
testing failed to confirm improvements observed with 6MWT in RCTs (166, 167). 
Although lack of standardisation and insufficient expertise in performing 
cardiopulmonary exercise testing were identified as the main reasons explaining 
this discrepancy (144, 176), the 6MWT remains until now the only Food and Drug 
Administration- and European Agency for the Evaluation of Medicinal Products-
accepted exercise endpoint for studies evaluating treatment effects in PAH. 
 
1.7.4 Echocardiography 
Echocardiography is the most well established and accessible imaging technique 
for screening and diagnosis of PH (177). As an imaging modality, it has the 
advantage of being widely available, inexpensive and safe. Echocardiography is 
routinely used for assessing RV size and function and severity of PH. In one RCT 
(32), advanced PAH therapy improved many echo variables, including LV area, 
systolic eccentricity index, RV/LV diastolic area ratios, pericardial effusion 
score, RV ejection time, Doppler RV index, LVSV and CO, and parameters of LV 
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filling. Thus, this technique is sufficiently sensitive to clinical changes to be used 
as a reinforcing end point. Standardising of echo measurements (some of which 
are highly technical) would be necessary to consider this as an end point in 
clinical trials. Two indexes that might be considered are the Tei Index and TAPSE 
(147, 178). 
Doppler echocardiography is suitable for serial assessments although has some 
limitations. This investigation relies upon geometric assumptions which can be 
difficult to adopt for the complex shaped RV. Limiting factors include operator 
dependence and influence by prevailing conditions such as heart rate and body 
habitus. Most studies report a high correlation (0.57-0.93) between 
echocardiography and right heart catheterisation (RHC) measurements of PASP 
(179) although Arcasoy and colleagues concluded that estimation of PASP by 
echocardiography is frequently inaccurate in patients with advanced lung 
disease (180). 
 
1.7.5 Biomarkers 
Biochemical markers are a non-invasive tool for assessment and monitoring of RV 
dysfunction in patients with PH. RV failure is the main cause of death in PAH, 
and BNP/NT-proBNP levels reflect the severity of RV dysfunction. Nagaya et al. 
(134) showed that the baseline median value of BNP (150 pg/mL) distinguished 
patients with a good or bad prognosis. In 49 out of 60 patients, BNP 
measurement was repeated after 3 months of targeted therapy and the 
supramedian level (>180 pg/mL) was related to worse long-term outcome. 
Plasma BNP significantly decreased in survivors but increased in non-survivors 
despite treatment. Larger outcome trials are still required to verify the 
suggested cut-off levels for NT-proBNP. Increases in NT-proBNP plasma levels on 
follow-up have been associated with worse prognosis (135). Several recent trials 
assessing new drugs in PAH or CTEPH reported a significant decrease in NT-
proBNP in the actively treated vs. placebo patients. 
Serial measurement of plasma NT-proBNP has great attractions as an end point. 
Its presence in the blood is related to RV dysfunction, the test is non-invasive, it 
is simple to measure and relatively inexpensive. Some remarkable relationships 
between plasma BNP/NT-proBNP and various elements of RV dysfunction have 
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been shown (96, 181, 182). It would appear that BNP/NT-proBNP measurement is 
a dynamic measurement reflecting the current state of the RV. An increase in 
NT-proBNP over time reflects RV dilatation concomitant to hypertrophy and 
deterioration of systolic function (182). We await the results of large scale 
studies to determine the role of BNP in the assessment and management of 
patients with PH. 
Elevated plasma levels of cardiac troponin T and troponin I are established 
specific markers of myocardial damage and are prognostic indicators in acute 
coronary syndromes and acute pulmonary embolism. Elevated cardiac troponin T 
was an independent predictor of fatal outcome during 2-year follow-up in a 
single trial on 51 patients with PAH and five with CTEPH (138). In some patients 
cardiac troponin T disappeared from plasma either temporarily or permanently 
after introduction of treatment. The value of monitoring of the cardiac troponin 
T level in patients with PH still requires confirmation in future studies. Other 
biomarkers are currently under investigation (183, 184). 
Several circulating biomarkers convey prognostic information in patients with 
PAH, but their value in everyday clinical practice is still not established. 
BNP/NT-proBNP plasma levels should be recommended for initial risk 
stratification and may be considered for monitoring the effects of treatment, in 
view of their prognostic implications. Low and stable or decreasing BNP/NT-
proBNP may be a useful marker of successful disease control in PAH. 
 
1.7.6 Haemodynamics 
The normalisation of measures of cardiovascular haemodynamics would be an 
ideal end point. However, resting haemodynamics improve only marginally in 
most patients, even when the clinical response appears to be excellent (185), 
and do not reflect changes that may occur with exercise. Clinical improvement, 
therefore, is only partly related to a modification of resting haemodynamics in 
most patients. The magnitude of the mPAP correlates poorly with symptoms and 
outcome as it is determined not only by the degree of PVR increase but also by 
the performance of the RV. Thus, the PAP alone should not be used for 
therapeutic decision making. In patients with PAH, CO is directly related to the 
clinical severity of the disease and is an important prognostic factor (1, 4). It has 
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been suggested that monitoring SV could be a meaningful outcome measure in 
PAH patients. Van de Veerdonk and colleagues recently demonstrated that PVR 
decreased after 12 months of medical therapy in 68% of patients (156). 
Although, 25% of those patients with a decreased PVR showed deterioration in 
RV function (as determined by CMR) and had a poor prognosis.    
There are disadvantages to this procedure, but most important are the 
significant risks to the patient. A recent study by Hoeper and colleagues assessed 
the risks associated with RHC (7218 procedures) in patients with PH (21). It was 
concluded that when performed in experienced centres, RHC in this patient 
group was associated with low morbidity and mortality rates (76 serious adverse 
events). 4 fatal events were recorded in association with any of the catheter 
procedures, resulting in an overall procedure-related mortality of 0.055% (95% 
confidence interval 0.01% to 0.099%). RHC, therefore, is an invasive procedure 
that is not ideal for serial evaluation due to the associated risks. Apart from the 
risks, hospital admission is usual procedure which may be inconvenient for 
patients. Some units, however, use RHC to determine success or response to 
treatment. 
 
1.7.7 Cardiac Magnetic Resonance Imaging 
CMR is well suited to longitudinal follow up as it is non-invasive and non-ionising.  
CMR findings in PH include RV dilatation, tricuspid regurgitation, RV 
hypertrophy, interventricular septal flattening or paradoxical motion, and 
change in chamber morphology from a normal crescent shape to a more 
concentric form. Prognosis of patients with PH remains poor despite the 
improvements in PVR or 6MWD seen during therapy. It has been suggested that 
RV function may be continuing to deteriorate despite the encouraging 
haemodynamic or functional signs e.g. van de Veerdonk and colleagues 
demonstrated that 25% of patients with reduced PVR following 12 months of 
therapy had deteriorating RV function (assessed by RVEF) during this period and 
that these patients had a poor outcome (156). It is imperative, therefore, that 
we can monitor RV function accurately.    
  
CMR imaging fulfils the stated characteristics of an ideal marker. Modern CMR 
protocols provides abundant information regarding the ventricular myocardium 
71 
 
and pulmonary vasculature. RV volumes, muscle mass and functional parameters 
including stroke volume, ejection fraction and cardiac output differ significantly 
in PH compared to healthy subjects. CMR imaging is easily performed by trained 
MR technicians/physicians although is technically demanding. The majority of 
patients tolerate this non-invasive investigation well. Manual planimetry of the 
myocardium and flow analysis is simple to perform and reproducible although 
time consuming at present. Sequential MRI is the optimal tool to monitor 
therapeutic effects on vascular remodelling and right heart performance. CMR 
derived RV functional parameters correlate well with established haemodynamic 
parameters of prognostic significance. Although RHC remains the definitive 
assessment of pulmonary hypertension at present, the non-invasive evaluation of 
cardiac morphology and function and of the pulmonary circulation is a new and 
promising application for CMR imaging. 
 
Figure 1-7: Pre (A) and post (B) treatment cardiac magnetic resonance 
images. 
 
Figure A     Figure B     
   
A fourteen year old male presented with dyspnoea and exertional syncope. 
Idiopathic pulmonary arterial hypertension was diagnosed. Figure A is the baseline 
short axis mid ventricular CMR image demonstrating a grossly dilated right 
ventricle with pronounced bowing of the interventricular septum compromising the 
left ventricle. Oral bosentan and anticoagulation therapy were commenced. There 
was considerable functional improvement. Figure B is the interval short axis mid 
ventricular CMR image at 6 months. A dramatic improvement in cardiac 
morphology is demonstrated.  
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CMR as an End Point  
CMR is gaining a dominant role as the reference method for clinical trials 
assessing longitudinal changes in LV function after therapeutic interventions 
(186-188). The accuracy and reproducibility of CMR in assessing cardiac 
morphological and functional parameters leads to low interstudy variability, 
which translates into a significant reduction in sample sizes required to test the 
efficacy of therapeutic interventions (57, 68). It is expected that the number of 
clinical trials using CMR parameters as study end points will increase 
considerably in the future. Patient outcome is the relevant clinical issue and 
effort should be directed toward testing whether changes in cardiac variables as 
measured by CMR indeed translate into differences in patient outcome. 
Several studies have reported the positive effects that medical (70, 189-191) and 
surgical (188, 192-195) therapies have on RV structure and function. Changes in 
RV mass, function and pulmonary artery blood flow have been demonstrated by 
CMR following lung transplantation in several studies (188, 192, 196). The 
functional and morphologic effects of pulmonary endarterectomy in patients 
with CTEPH was assessed by Kreitner et al using a combination of three-
dimensional (3D) gadolinium-contrast enhanced MR angiography, cine-CMR and 
velocity encoded CMR (106). In 2003, Michelakis and colleagues (189) performed 
a small non-randomised, pilot study of 5 patients with PH to investigate the 
effect of sildenafil 50mg tid. RVM was utilised as an endpoint. Sildenafil 
significantly reduced RVM and increased the RVSV as measured by CMR. The 
pathological septal shift towards the LV was reversed by long-term sildenafil 
therapy. In a prospective study of PH patients with prostacyclin therapy, the 
significant increase in RVSV (PA flow analysis) corresponded well with functional 
improvement (WHO functional class, 6MWT) (70). In a comparison study between 
sildenafil and bosentan, RV mass (measured by CMR) did not change after 3 
months of bosentan treatment, whereas sildenafil reduced RV mass (191). It was 
demonstrated by CMR that the addition of sildenafil reversed RV dilatation and 
hypertrophy in patients receiving treatment (190). More recently, 16 patients 
with PAH were assessed by CMR at baseline and after 12 months treatment with 
bosentan (197). After treatment cardiac index, PVR and 6MWT distance 
increased. There was a trend towards improvement in RV SV (p=0.08) although 
there was no change in RV ejection fraction or RVEDV as determined by CMR. To 
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date, two trials (191, 198) have used CMR-derived RVM as an end-point. This 
particular surrogate remains unvalidated and may not be the best end point 
since it is not known whether a reduction in RVM is beneficial or harmful to 
patients. 
Deterioration of RV function at follow up examinations indicates an unfavourable 
prognosis because functional impairment of the RV is the major factor in disease 
progression and decline in life expectancy (164). Medical therapies or surgical 
interventions may stop, or even reverse this process, and the improvement of RV 
function could be detected by CMR. 
Baseline CMR measurements in PAH associated with a poor prognosis include a 
decreased stroke volume, an increased RV end-diastolic volume, and a 
decreased LV end-diastolic volume (73). Van Wolferen et al performed a 
longitudinal CMR study which confirmed RV dilatation and a decrease in SV and 
LV diastolic volume are strong predictors of treatment failure and death at 
follow up (73). A recent cardiac magnetic resonance (CMR) study (73) confirmed 
that a low baseline stroke volume index (SVI) was predictive of a poor survival 
whereas cardiac index (CI) was not. A further reduction in SV at 1 year follow up 
predicted treatment failure and a poor long term outcome. SV directly reflects 
RV function in response to its load, without the correlation of compensatory 
increased HR as is the case for CO. SV, therefore, is an important haemodynamic 
parameter to monitor during treatment. A recent CMRI based study confirmed 
that a 10ml change in SV during follow up should be considered as clinically 
relevant. This value can be used to interpret changes in SV during clinical follow 
up in PH (199). The first outcome study to be reported with CMR (73) 
demonstrated the importance of indexed biventricular dimensions; a relationship 
that had not been hitherto revealed by echo studies. Indexed RVEDV was 
prognostic both at baseline and at 1 year as were indexed SV and LVEDV. These 
data have recently been extended to include RVEF (200).  
 
CMR imaging enables a unique combination of morphological and functional 
assessment of the right ventricle and pulmonary circulation. CMR has emerged 
over recent years as the gold standard for a detailed study of the RV and has 
become an established modality for the physiological assessment of PH patients 
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in cross-sectional studies, longitudinal follow up studies and clinical trials of 
therapy. We anticipate that MR imaging will increasingly be utilised as the 
primary modality for combined anatomic and functional assessments that enable 
more complete and efficient evaluation of patients with PH.  
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1.8 Hypotheses and Aims 
Pulmonary hypertension is a rare disease that is characterised by increased 
pulmonary vascular resistance leading to chronic right ventricular pressure 
overload. On the strength of available evidence, the adaptation of the right 
ventricle is the major prognostic influence in pulmonary hypertension. The right 
ventricle is difficult to assess. As discussed in the introduction, the currents 
methods of assessment are suboptimal. Modern drug therapy leads to a 
significant improvement in patients’ symptomatic status and a slower rate of 
clinical deterioration. With the advent of multiple new disease-targeted 
therapies for pulmonary hypertension, it is increasingly important that we can 
assess the progress of patients in a non-invasive manner.  
 
CMR will be used as the primary imaging modality in this thesis, as it represents 
the current gold standard method to measure ventricular volumes, mass and 
function. This study intends to provide a comprehensive evaluation of the use of 
CMR imaging in patients with PH.  
 
The hypotheses and aims of the study are as follows: 
 
Chapter 3 
Non-invasive assessment of patients with PH is imperative. Measurement of 
stroke volume (SV) non-invasively is a promising method to monitor disease 
progression in PH. We aim to determine the accuracy of SV measurement by CMR 
imaging and by inert gas rebreathing using photoacoustic analysis compared with 
thermodilution technique (current gold standard) during right heart 
catheterisation in patients with suspected PH.  
 
Chapter 4 
The prognosis of IPAH associated with connective tissue disease is much worse 
than IPAH. RV function is the main prognostic determinant of patients with PH.  
Can CMR identify any differences in RV adaptation between these two groups? 
We hypothesise that RV adaptation (as assessed by CMR) to high pulmonary 
artery pressures may differ between the IPAH and CTDPH patient groups. 
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Chapter 5 
Cardiac magnetic resonance imaging is proposed as a method to noninvasively 
assess the right ventricle in patients with PH. The clinical utility of CMR imaging 
in patients with PH requires confirmation. By evaluating CMR along with 
established methods of assessment, we hope the use of CMR will be clarified. 
Ultimately this study endeavours to determine if CMR imaging has a role in the 
continuing assessment of patients with PH. Can cardiac magnetic resonance 
imaging be used as a non-invasive, accurate, patient friendly method to follow 
up patients with pulmonary hypertension? This thesis was the starting point for 
the EURO-MR study. This was a prospective, longitudinal study conducted in four 
European centres.  
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Chapter 2 
 
Materials and Methods  
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2 Materials and Methods  
 
2.1 Introduction 
The principle technique used for this thesis was cardiac magnetic resonance 
(CMR) imaging. This technique was supplemented by assessment of WHO 
functional class, six minute walk test, right heart catheterisation and inert gas 
rebreathing. In this chapter, the background, methods, apparatus and protocols 
used for these techniques will be outlined. 
 
The Scottish Pulmonary Vascular Unit  
The Scottish Pulmonary Vascular Unit (SPVU) provides a tertiary service for the 
population in Scotland. An epidemiology study performed in 2007 estimated the 
incidence of PAH in Scotland to be 7.6 cases per million per annum and the 
prevalence 26 cases per million (9).  
 
Patient Recruitment 
Newly referred treatment-naïve patients undergo a comprehensive diagnostic 
evaluation at the SPVU. The patients involved in the studies for this thesis were 
recruited during the course of their routine diagnostic assessment for suspected 
PH at the Western Infirmary / Golden Jubilee National Hospital, Glasgow, UK. All 
patients had undergone an initial assessment at an outpatient pulmonary 
vascular clinic; those in whom a diagnosis of PH was suspected were offered a 
one-week elective admission for further investigation. All subjects were asked to 
participate in the studies on the Monday of their admission. The patients, who 
agreed, gave informed written consent to a study protocol that had been 
approved by the ethics committee of West Glasgow University NHS Trust. The 
studies included in this thesis did not interfere with in-patient management in 
any way. 
 
Definition of pulmonary hypertension 
The diagnosis of PH is based on RHC in accordance with contemporary guidelines 
(7). PH was defined as an increase in mean pulmonary arterial pressure (mPAP) ≥ 
25mmHg at rest, with a PCWP ≤ 15mmHg and PVR > 3 Wood units. The term 
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“PAH” is used specifically for WHO group I disease whereas “PH” is used as a 
general term to describe any group. Positive acute vasodilator response is 
defined as a drop in mPAP to < 40mmHg and by > 10mmHg with maintained or 
increased CO.    
 
Table 2-1: Baseline diagnostic investigations at the Scottish Pulmonary 
Vascular Unit. 
 
SPVU: Baseline diagnostic investigations 
• Full clinical history 
• Full physical examination – including height and weight 
• WHO functional class status 
• Routine blood sampling / ABGs 
• NT-proBNP 
• ECG 
• CXR 
• Transthoracic echocardiogram 
• 6MWT 
• CPET 
• Inert gas rebreathing (subgroup of patients) 
• V/Q scan 
• HRCT / CTPA 
• Cardiac magnetic resonance imaging 
• Right heart catheterisation ± pulmonary angiography ± vasodilator studies 
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Figure 2-1: Flow chart of patient journey at the Scottish Pulmonary Vascular 
Unit. 
 
 
 
SPVU; Scottish Pulmonary Vascular Unit. PH; pulmonary hypertension. IP; 
inpatient. CMR; cardiac magnetic resonance imaging. 
 
This thesis includes three separate studies as identified in the subsequent 
chapters. Baseline investigations were performed for all patients during their 
diagnostic evaluation at the SPVU. All patients underwent CMR imaging. A 
subgroup of 33 patients underwent inert gas rebreathing. Cross-sectional data 
obtained at baseline assessment was utilised in two of the studies (chapters 3 
and 4) in this thesis. Chapter 5 details the longitudinal project performed. This 
study was performed as part of the multinational Framework 6 project EURO-MR. 
  
Admission	  of	  pa,ent	  
with	  suspected	  PH	  
Baseline	  Inves,ga,ons	  
(SPVU	  IP)	  
Eligible	  for	  CMR	  	  	  	  	  	  	  
No	  contraindica,ons	  
Consent	  form	  signed	  
Diagnosis	  of	  PH	  
conﬁrmed	  
Pa,ent	  enrolled	  into	  	  
CMR	  study	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Table 2-2: Inclusion and exclusion criteria for entry into cardiac magnetic 
resonance studies at Scottish Pulmonary Vascular Unit. 
 
Criteria for enrolment into cardiac magnetic resonance studies 
Inclusion criteria: 
1. Diagnosis of pulmonary hypertension confirmed 
2. Ability to give informed consent 
3. Patient ≥ 18 years 
Exclusion criteria: 
1. Severe or significant co-morbidity 
2. MRI-incompatible (ferrous) prosthesis 
3. Inability to complete CMR scanning e.g. orthopnoea 
4. Claustrophobia causing inability to tolerate CMR 
5. Pregnancy 
 
 
Figure 2.2 presents the consent form utilised for the studies in this thesis.  
Please refer to Figure 2.3 for the patient information sheet.   
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Figure 2-2: Consent form for CMR clinical research project. 
 
 
 
  
WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
 
 
Title of Project:  The Assessment of Pulmonary Hypertension using Cardiac MRI 
 
 
 
 
 
 
 
 
 
 
 
 
By signing this form you give consent to your participation in the project whose title is at the top of the 
page. You should have been given a complete explanation of the project to your satisfaction and have been 
given the opportunity to ask questions. You should also have been given a copy of the patient information 
sheet approved by the West Ethics Committee to read and to keep. Even though you have agreed to take 
part in the research procedures you may withdraw this consent at any time without the need to explain why 
and without any prejudice to your care. 
 
 
 
 
 
 
 
 
Consent: 
 
………………………………………………………………………………(PRINT) 
 
 
of …………………………………………………………………................ 
 
 
give my consent to the research procedures above, the nature, purpose and possible 
consequences of which have been described to me 
 
 
by …………………………………………………………………………… 
 
 
Patient’s signature ………………………………………..Date……………. 
 
 
Doctor’s signature …………………………………………………………...  
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Figure 2-3: Patient information sheet. 
 
 
Brief Title of Project 
 
The Assessment of Pulmonary Hypertension using Cardiac MRI 
 
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible risks in 
terms which the patient or volunteer can understand). 
 
Background 
 
Pulmonary Hypertension is a rare and potentially serious condition. It is often difficult to 
diagnose and to treat. The major problem in Pulmonary Hypertension is high blood pressure in 
the lungs; this often leads to excessive stress being exerted on the right hand side of the heart. 
Sometimes, as a result of this, the right side of the heart becomes unable to pump blood into the 
lungs, as it should. This obviously can make the patient feel very unwell. 
 
We usually make the diagnosis after a number of tests have been carried out; the most 
important of these currently is a Right Heart Catheter. This involves passing a plastic catheter 
into the heart through a vein in the neck or groin. Through this catheter we can measure the 
blood pressure in the lungs and assess how well the heart is pumping. We can also assess how 
likely the patient is to respond to treatment. 
 
This test is very useful and generally safe, but some patients find it unpleasant and there are 
some risks involved. We therefore do not tend to repeat it to see how well or badly a patient is 
doing unless it is absolutely necessary. Instead, we use a test that measures how far a patient 
can walk in six minutes. We then compare this measurement to the last one to say whether they 
are better or worse. This test is useful but can sometimes be misleading. 
 
The Study 
 
We are conducting a study looking at new ways to diagnose and monitor patients with Pulmonary 
Hypertension. We would like to invite you to take part. The study involves the use of a relatively 
new scanning technique called MRI (Magnetic Resonance Imaging). 
 
MRI allows us to get a lot of useful information about Pulmonary Hypertension. It does not use 
any X-rays or radiation, but instead uses magnets to acquire detailed images of pulmonary blood 
vessels and the heart. It is therefore very safe. We can get a lot of the same information using 
MRI that we get at right heart catheterisation. Gadolinium is a clear fluid like water. It is used in 
MRI scanning as it accumulates for a short time in abnormal tissue and lights up that area so that 
the scanner can detect this part of the body. It is therefore useful in telling us which part of the 
blood vessels and heart are affected. After a short while Gadolinium fades away and is removed 
from your body (within a few hours). 
 
Compared with right heart catheterisation, MRI is safer, and patients tend to fine it less 
unpleasant. This means not only could MRI be used in the diagnosis of Pulmonary Hypertension, 
we would be happier to repeat it in the future. This may allow us to better identify changes in 
the illness over time and so allow better tailoring of your treatment. 
 
In addition to the MRI we would like to measure certain proteins in your bloodstream that may go 
up and down depending on how well you are. 
 
What the study involves 
 
During your 5-day stay at the Western Infirmary you will have a number of tests, including blood 
samples and x-rays. On the Thursday you will have your right heart catheterisation. We would 
propose doing an MRI scan at some time during this week. The scan would take around 11/2
 hours 
and would not prolong your stay in hospital. We will take some extra blood samples in addition 
(around one tablespoon in total). These samples will be taken off at the same time as your 
routine bloods and will not involve any extra needles. We normally see patients about 3 months 
after their discharge in clinic and repeat the six-minute walking test. You will follow this normal 
routine. As part of the study you will also have further MRI scans 4 months and 12 months 
later, to assess your progress. If required, we will be able to organise for a taxi to pick you up 
and take you home free of charge.   
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What does the MRI involve? 
 
On arrival at the Clinical Research Initiative (CRI) a radiographer will go through a safety 
checklist and make sure that all magnetic objects (e.g. jewellery and bankcards) have been 
removed. Following this you will be asked to sign the consent form. Once you have changed into 
a hospital gown you will then be asked to lie flat on the bed that will move into the scanner. The 
scanner is basically tunnel shaped, like a large “polo” mint. You are slid into the centre of the 
“polo” on an electric bed and the scans are acquired. Some patients find it a little enclosing, but 
you can come out at any time.  
 
Before you go into the scanner a small plastic cannula (similar to that used when putting up a 
drip) will be inserted into a vein in your arm. This allows us to give you a harmless dye called 
Gadolinium. A doctor will insert the cannula. During the scan we will inject some Gadolinium dye 
into the cannula in your arm, this will help light up your blood vessels and heart muscles on the 
pictures. A doctor will be in the control room throughout this procedure. 
 
When you are in the scanner you will need to wear a pair of headphones, allowing you to listen 
to music of your choice (you are welcome to bring your own CD) and to allow us to communicate 
with you throughout the scan. The headphones are also necessary because of the loud knocking 
noise that occurs when the pictures are being taken. You will be given an emergency buzzer and 
you can very quickly be taken out the scanner should you feel it uncomfortable or if it is felt 
necessary. During the scan you will be asked to hold your breath at times to improve the quality 
of the pictures. 
 
What are the risks? 
 
◦ The MRI scanner is very safe as long as you have no metal implants in your body. 
 
◦ The dye used is called Gadolinium. It is generally harmless and will be washed out of your 
system by your kidneys. Rarely, it can cause headaches.  
 
NB • You should not take part in this study if you are pregnant. 
 
• If you wish to take part in this study, your General Practitioner will be advised of your 
participation and the clinical management that you will undergo. 
 
• If you do not wish to participate in this study, or wish to withdraw at any time your 
care will not, in any way, be affected. 
 
 
If you have any questions regarding the study please contact DR LINDSEY MCLURE at 0141 211 
1812. 
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2.2 Cardiac Magnetic Resonance Imaging 
2.2.1 CMR protocol 
All scans were performed on a 1.5 Tesla Siemens Sonata whole body MR scanner 
(Siemens Medical Solutions, Erlangen, Germany). The CMR scans completed for 
the purpose of these studies were performed by myself (after completion of the 
Magnetic Resonance Imaging Basic Competencies course run by the Institute of 
Physics and Engineering in Medicine) or by Ms Tracey Steedman, Cardiac MR 
Radiographer, Western Infirmary. I was present throughout all the scans to 
provide constant medical cover. The importance of keeping as motionless as 
possible, and maintaining adequate breath-holds, was reinforced verbally prior 
to commencement of the scan. End-expiration is optimal for consistent breath 
holding and was preferred. 
 
2.2.2 Preparation of patient for CMR scan. 
The following steps were performed in all cases:  
• Prior to entering the controlled zone, an MRI safety checklist was 
performed and signed by both patient and qualified MRI personnel. 
• Before entry into the MR scanning room the patient was asked to 
complete and sign a safety questionnaire. If the patient reported any 
previous injuries involving metal fragments, especially any to the eyes, 
appropriate plain radiographs were requested to ensure that no fragments 
remained.  
• Patient demographic details entered on scanner database. 
• Patient placed on MR table. 
• Siemens active Brooker electrodes placed on patient’s anterior chest wall, 
and position varied to obtain an optimal R wave 
• The phased-array chest coil (Siemens CP body array flex) was applied and 
aligned 
• Patient, wearing ear protectors or headphones, enters scanner. 
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2.2.3 Cardiovascular Magnetic Resonance Imaging 
The patient was asked to lie supine on the examination table, which had been 
remotely removed from inside the bore of the magnet, to a more accessible 
position (see Figure 2.4). Adhesive monitoring pads for the 3-lead ECG were 
connected, and the phase array chest coil was placed on the patient’s chest and 
secured in position with a loose fitting Velcro strap. The patient was then 
supplied with an emergency buzzer and protective ear defenders. Immediately 
before movement of the patient inside bore of the magnet, the centre of the 
chest coil, approximating the position of the heart, was defined by a laser 
pointer attached at the 12 o’clock position of the magnet’s inner circumference. 
This point of reference was used to move the patient to a precise point within 
the bore of the magnet which ensured their heart was at the centre of the main 
magnetic field. Once the patient was inside the bore of the magnet, the door of 
the scanning room was sealed and staff performing the scan moved to the 
control room. Proper functioning of the microphones and headphones that allow 
direct communication between patient and operator was verified before image 
acquisition was initiated. 
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Figure 2-4: Cardiac magnetic resonance imaging at the Scottish Pulmonary 
Vascular Unit. 
 
 
Tracey Steedman (Cardiac MR Radiographer) positioning a patient before a scan 
using the Siemens Sonata 1.5 Tesla system at the Western Infirmary, Glasgow. 
The examination table is extended and the phased-array chest coil has been 
secured over the patient’s chest using velcro straps. 
 
2.2.4 CMR image acquisition and analysis 
RV/LV structure and function 
All CMR scans commenced with a multi-slice breath hold localiser. Each of the 
localisers described in this section used the same protocol: 
Protocol: Multislice single-shot breath-hold true fast imaging with steady state 
precession (trueFISP) localiser with transverse, sagittal and coronal slices. 
Settings: field of view = 360mm, field of view phase = 81.3%, slice thickness = 
6mm, repetition time (TR) = 3.41ms, echo time (TE) = 1.71ms, flip angle = 60%, 
averages = 1, phase resolution = 80%, phase oversampling = 0%. 
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Figure 2-5: Typical orthogonal scout images used to localise the heart within 
the thoracic cavity. 
 
 
Coronal Scout Image 
 
 
 
Transverse Scout Image 
 
 
 
Sagittal Scout Image 
Typical orthogonal scout images used to localise the heart within the thoracic 
cavity during CMR imaging of a patient with pulmonary hypertension. Note the low 
definition images of these preliminary Fast imaging with steady state precession 
(TrueFISP) scout images. 
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From these images, the best axial image depicting the LV and septum was 
selected. If no suitable image was produced by the initial localiser, a second 
axial localiser was performed using the coronal images until the closest match to 
Figure 2.6 (A) was obtained. This was used to plan 3 vertical long axis (VLA) 
parallel localisers along the long axis of the LV from the mid-point of the mitral 
valve to the apex. 
From the resulting VLA scan, 3 horizontal long axis (HLA) localisers were then 
planned, using the mid-point of the mitral valve and the LV apex to prescribe 
the orientation (Figure 2.6 (B)). This resulted in 3 HLA slices (Figure 2.6 (C)). 
Using the atrioventricular groove as a landmark, 3 short axis (SA) localiser slices 
were planned, with the most basal slice positioned in the atria to depict the left 
ventricular outflow (Figure 2.6 (C)). From the resulting SA images, 3 long axis 
views can be prescribed – the 4-chamber, the 2-chamber and the left ventricular 
outflow tract (LVOT) (Figure 2.6 (D)). 
 
Cinematographic (cine) imaging: 
Having thus acquired 3 orthogonal long axis views, cine studies were acquired in 
each of these 3 orientations, as follows: 
Protocol: trueFISP breath-hold cine. Settings: field of view = 360mm, field of 
view phase 81.3%, slice thickness = 8mm, TR = 47.4ms, TE = 1.58ms, flip angle = 
60°, averages = 1, measurements = 1, phase resolution = 65%, phase 
oversampling = 20%, segments = 15. 
These images were used for visual analysis of structure and long axis function. 
 
Short axis cine stack: 
Quantitative volumetric assessment of ventricular function requires that the 
LV/RV be divided into a stack of SA slices from base to apex. Measurements from 
each slice are then summed to provide overall ventricular mass and volumes. 
The SA stack was prescribed from 4-chamber HLA cine already acquired. Using 
the end-diastolic image from this view, the cursor was positioned in an 
orientation across the mitral valve plane through the atrioventricular groove (as 
a marker of the most basal SA slice) as in Figure 2.6 (E). The most basal slice 
that results is depicted in Figure 2.6 (F). The slice position was then 
incremented by 10mm moving towards the apex of the LV/RV and repeated until 
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the LV/RV were completely covered; interslice gaps of 2mm were used. A 
representation of the final SA cine stack is shown in Figure 2.6 (G). The same 
protocol was used for all SA cine slices: 
Protocol: trueFISP breath-hold cine. Settings: field of view = 340mm, field of 
view phase = 81.3%, slice thickness = 8mm, interslice gap = 2mm, TR = 47.4ms, 
TE = 1.58ms, flip angle = 60°, averages =1, measurements = 1, phase resolution 
= 65%, phase oversampling = 20%, segments =15. 
 
Figure 2-6: Planning of cine cardiac magnetic resonance image acquisition. 
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Planning of cine CMR image acquisition. From coronal, transverse and sagittal 
scout images, the best image depicting the LV and septum is selected (A) and 
utilised to produce a vertical long axis (VLA) localiser (B). Prescribing an 
orientation through the apex and mid-point of the mitral valve (B – orientation line) 
creates a horizontal long axis (HLA) localiser (C). Using the atrioventricular 
grooves as landmarks (C), a perpendicular plane to this HLA localiser is 
prescribed (D), based on which three orthogonal long axis planes can be planned 
(2-chamber, 4-chamber and LV outflow tract views). Cine images are acquired for 
each of these three long-axis orientations. Finally a short axis cine stack is 
planned on the 4-chamber HLA cine image (E). A short axis image is acquired of 
the base of the LV (F), from which slice position is advanced at 10mm intervals 
from base to apex, creating a short-axis cine stack (G).   
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Flow Analysis 
Right ventricular stroke volume (SV) was measured using MR phase-contrast flow 
quantification in an image plane positioned perpendicular to the main pulmonary 
artery, at least 1cm distal to the pulmonary valve. Left ventricular SV (aortic 
flow) was also measured, approximately 2 - 4cm above the aortic valve and 
distal to the coronary arterial ostia. A velocity encoded k-space segmented 
gradient-echo sequence was used (imaging parameters: echo time / repetition 
time / flip angle / slice thickness / temporal resolution / image matrix / field of 
view / in-plane resolution / velocity encoding range = 3.1ms / 16ms / 15° / 
6mm / limited by TR / 256 / 380mm / 1.9x1.5mm / 150cm per second) to 
generate 45 matched pairs of anatomical and velocity images. Retrospective 
ECG-gating was used to ensure coverage of the complete cardiac cycle. Patients 
were instructed to breath freely throughout this section of the protocol and the 
average time of acquisition was 2-3 minutes depending on the patient’s heart 
rate.  
 
2.2.5 Analysis of CMR images 
CMR analysis methodology 
All CMR images were analysed by a single operator (L.M.) on a satellite 
workstation attached to the main MR scanner using the Argus analysis software 
(Siemens, Erlangen, Germany). At the time of analysis, I was blinded to the 
haemodynamic results of any given patient. Although the name of the patient 
was visible in the corner of each MR image, each analysis was performed some 
time after their invasive assessment and I was unaware of their haemodynamic 
results at the time of MR analysis. 
The images for each patient were loaded into the Argus program from each 
compact disc (CD). Argus automatically identified the images within each SA cine 
loop that had the largest and the smallest blood volumes and defined these as 
end-diastole and end systole, respectively. The number of slices required to 
cover the RV/LV in end-diastole and end-systole varied from scan to scan 
dependent on the long axis diameter of the RV/LV.   An example of a complete 
image series with these images defined is provided (Figure 2.7). The end-
diastolic image was usually the first image acquired after R-wave deflection. 
93 
 
Using a trackball cursor the endocardial and epicardial borders of the end-
diastolic and end-systolic images at each slice position within the SA stack were 
then defined by manual planimetry. These methods are standard in clinical MR 
practice and have been published before. Particular points of note regarding the 
planimetry used herein include the deliberate inclusion of trabeculations ad 
papillary muscles in all analyses. This has been shown by previous authors to be 
a more accurate, but more time consuming method (201). By multiplying the 
individual slice areas by slice thickness (8mm) plus the inter-slice gap (2mm) and 
applying Simpson’s Rule, the Argus software automatically calculated RVEDV, 
RVESV, LVEDV and LVESV. Right and left ventricular stroke volumes (RVSV and 
LVSV) were determined as RVEDV – RVESV and LVEDV –LVESV. Ejection fraction 
was determined as a percentage (%) as (RV or LV SV/EDV) x 100) using this 
planimetry derived SV measurement. 
Velocity encoded flow mapping was used to determine precise, forward stroke 
volumes for each ventricle. The measurements of SV yielded by this technique 
were used to calculate RV and LV EF. The flow mapping technique circumvents 
the predictable measurement error in planimetry derived SV resulting from 
tricuspid valve regurgitation. However, both methods are established and 
commonly used tools for the assessment of SV and EF in clinical practice. Please 
refer to Figure 2.8. 
RV and LV mass (RVM and LVM) were determined as the product of the 
difference between the end-diastolic and end-systolic volume for each ventricle 
and the quoted density of cardiac muscle (1.05g/cm3). RVM was determined as 
RV free wall mass, with the interventricular septum (IVS) considered part of the 
LV. These methods are again, common in clinical CMR practice and have been 
published before (151, 201). Ventricular mass index (VMI) was determined as 
RVM/LVM as previously shown (75). Throughout this thesis, all ventricular 
volumes are corrected for body surface area (BSA) and are reported as indexed 
measurements. 
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Table 2-3: Measurements obtained from cardiac magnetic resonance 
imaging for this thesis. 
 
Measurements from CMR imaging 
• RV/LV end diastolic volume index (RV/LVEDVI) 
• RV/LV end systolic volume index (RV/LVESVI) 
• RV/LV ejection fraction (RV/LVEF) 
• RV/LV mass index (RV/LVMI)  
• Ventricular mass index (VMI) 
• Pulmonary artery flow analysis (SVI) 
• Aortic flow analysis (SVI) 
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Figure 2-7: Planimetry analysis of the right ventricle. 
 
 
 
An example of planimetry analysis of right ventricular volumes and mass using the 
Argus analysis software. Each row of short axis images represents a loop of cine 
images acquired during one cardiac cycle at consecutive slice positions, beginning 
at the base of the heart, moving apically to cover both ventricles. The first images 
within each row (or slice position) were acquired immediately after R-wave 
deflection. They are therefore defined by the Argus software as the end-diastolic 
images (indicated by the yellow ED at the top of the left-hand column) and have 
the greatest total ventricular blood volume. The end-systolic images were defined 
automatically by the Argus software as the column of images with the smallest 
total ventricular blood volume and verified visually. A trackball mouse and cursor 
was used to define the endocardial (in red) and epicardial (in green) surfaces of 
the RV at end-diastole and the endocardial surface only at end-systole (in red). 
This allowed computation of RV end-diastolic and endsystolic volumes and RV 
mass. 
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Figure 2-8: Velocity encoded flow maps of the pulmonary artery to determine 
stroke volume. 
 
 
Velocity encoded flow maps were used to determine RVSV and LVSV at rest; two 
flow maps were therefore analysed for each patient, each containing 90 images. 
The resting main pulmonary artery flow map from a patient with PH is shown 
below. The anatomical image is shown on the left with the corresponding velocity-
encoded image, from the same time point in the cardiac cycle on the right. A 
region of interest (ROI) was drawn around the interior surface of the target vessel 
on the first anatomical image. This ROI was propagated throughout the 45 
anatomical images using a semi-automatic function within the Argus software. The 
propagated ROIs were then checked visually and modified using the nudge 
function within Argus to approximate the interior surface of the target vessel 
throughout the set. These modifications were then copied onto the corresponding 
45 velocity images. The final contours that resulted are shown overleaf in red. A 
second, reference ROI (shown in purple) was then drawn on the first anatomical 
image and copied directly onto all of the other images. This was defined within the 
soft tissue of the chest wall as close as possible to the target vessel and was used 
to correct for background movement of the thoracic contents through the imaging 
plane during cardiac motion and normal respiration. 
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2.2.6 Intra-observer variability of CMR analysis in this thesis 
 
Ten CMR examinations were randomly selected during this thesis to determine 
intra-observer variability. I reanalysed the CMR scans and was blinded to the 
initial results. End-diastolic and end-systolic volumes, stroke volume and mass 
were not indexed for body surface area during this analysis. Variability analyses 
were compared using Bland-Altman analysis and t tests. Please refer to Table 2.4 
and Table 2.5. 
 
These results demonstrate that variability was low in my CMR analysis. Intra-
observer variability was higher in the right ventricular analysis compared with 
left ventricular measurements. This reflects the more challenging planimetry of 
the right ventricle compared to the left ventricle.  
 
Table 2-4: Intra-observer variability data of CMR analysis. 
 
CMR Measurement Mean difference ± SD 
±±±SD 
Paired t-test Correlation 
coefficient 
Left heart    
LVEDV (ml) 0.33 ± 3.38 0.88 0.96 
LVESV (ml) -0.36 ± 1.78 0.53 0.97 
LVM (g) -2.27 ± 3.02 0.04 0.99 
LVSV (Ao Flow) (ml) -0.74 ± 2.83 0.43 0.99 
Right heart    
RVEDV (ml) -3.05 ± 7.45 0.23 0.99 
RVESV (ml) -5.9 ± 4.66 0.03 0.99 
RVM (g) 5.14 ± 6.61 0.03 0.99 
RVSV (PA flow) (ml) -2.139 ± 3.39 0.07 0.99 
 
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic 
volume; LVM: left ventricular mass; LVSV (Ao flow): left ventricular stroke volume 
(aortic flow); RVEDV: right ventricular end-diastolic volume; RVESV: right 
ventricular end-systolic volume; RVM: right ventricular mass; RVSV (PA flow): 
right ventricular stroke volume (pulmonary artery flow).   
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Table 2-5: Summary of Bland-Altman analyses performed. 
 
CMR Measurement Bias SD 95% Limits of Agreement 
   From To 
LVEDV (ml) 0.26 5.57 -10.67 11.19 
LVESV (ml) -0.36 1.78 -3.86 3.14 
LVM (g) -2.27 3.019 -8.19 3.65 
LVSV (Ao) (ml) -0.82 2.992 -6.09 5.04 
RVEDV (ml) -3.05 7.44 -17.63 11.53 
RVESV (ml) -5.90 4.66 -15.04 3.24 
RVM (g) 5.14 6.61 -7.81 18.09 
RVSV (PA) (ml) -2.14 3.39 -8.79 4.509 
  
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic 
volume; LVM: left ventricular mass; LVSV (Ao flow): left ventricular stroke volume 
(aortic flow); RVEDV: right ventricular end-diastolic volume; RVESV: right 
ventricular end-systolic volume; RVM: right ventricular mass; RVSV (PA flow): 
right ventricular stroke volume (pulmonary artery flow).   
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2.3 WHO Functional Class (WHO FC) 
Despite large inter-observer variation in the measurement, WHO FC remains a 
powerful predictor of survival. All patients had their WHO FC confirmed at 
baseline and at each follow up visit. 
 
Table 2-6: World Health Organisation functional classification in pulmonary 
hypertension. 
 
WHO FC Description 
Class I Patients with PH but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue 
dyspnoea or fatigue, chest pain, or near syncope. 
Class II Patients with PH resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity 
causes undue dyspnoea or fatigue, chest pain, or near syncope. 
Class III Patients with PH resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary 
activity causes undue dyspnoea or fatigue, chest pain, or near 
syncope. 
Class IV Patients with PH with inability to carry out any physical activity 
without symptoms. These patients manifest signs of right heart 
failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
 
 
2.4 Six-minute walk test 
2.4.1 Test protocol  
The 6MWT was performed by a respiratory physiologist according to the 
American Thoracic Society guidelines (139). Testing was performed in a location 
where a rapid appropriate response to an emergency was possible and 
resuscitation equipment was available. The 6MWT was performed indoors, along 
a long, flat, straight, enclosed corridor with a hard surface that was seldom 
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travelled. The walking course was 20m in length. The turnaround points were 
marked with small, orange cones. A starting line, which marked the beginning 
and end of each 40m lap was marked on the floor. Measurements recorded 
included the 6MWT distance walked, dyspnoea on exertion (Borg scale) and 
finger O2 saturation.  
The performance of the six minute walk test was audited internally during these 
studies.   
 
2.5 Right heart catheterisation 
RHC was performed according to international recommendations (26). This 
investigation was required to confirm the diagnosis of PH, to assess the severity 
of the haemodynamic impairment, and to test the vasoreactivity of the 
pulmonary circulation. RHC was performed by SPVU physicians, in the 
catheterisation laboratory at the Western Infirmary (August 2005 – September 
2007) and subsequently at the Golden Jubilee National Hospital (September 2007 
- August 2008). Please see Figure 2.9.  
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Figure 2-9: Right heart catheterisation at the Scottish Pulmonary Vascular 
Unit. 
 
 
A photograph of Dr Colin Church and Specialist Nurse Jim Mearns performing a 
right heart catheterisation on a patient under investigation for pulmonary 
hypertension. 
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Figure 2-10: Swan-Ganz Pulmonary Artery Catheter. 
 
 
A photograph of a 7F triple-channel, balloon-tipped, flow directed 
thermodilution Swan Ganz catheter (Baxter Healthcare, Irvine, California, USA). 
 
An 8F introducer sheath was inserted into the right internal jugular vein under 
ultrasound guidance prior to transfer to the catheterisation laboratory. If this 
was technically impossible, an 8F introducer sheath was inserted into the right 
femoral vein. Anxious patients were occasionally prescribed a short acting 
benzodiazepine, but in general no premedication was used.  
A 7F triple-channel, balloon-tipped, flow directed thermodilution Swan Ganz 
catheter (see figure 2.10) (Baxter Healthcare, Irvine, California, USA) was 
advanced through an 8F introducer sheath inserted into the right internal jugular 
vein or the right femoral vein. All measurements were recorded with the patient 
in a supine position, at rest, breathing room air or supplemental oxygen if 
required. Measurements included mean right atrial pressure (RAP), right 
ventricular pressure and systolic and diastolic pulmonary artery pressures (PAP). 
Mean PAP was determined as the area under the PAP trace. Pulmonary capillary 
wedge pressure (PCWP) was recorded with the catheter in the wedge position 
and the balloon inflated. Mixed venous blood is sampled from the main 
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pulmonary artery to measure SvO2. CO was measured by the thermodilution 
technique (202) following injection of 10ml of ice-cold, 0.9% saline through the 
proximal (right atrial) lumen of the catheter; the drop in temperature was 
measured at the distal thermistor. The final value is calculated by averaging 
three measurements with ≤ 10% variation. Cardiac output measurement allowed 
determination of pulmonary vascular resistance (PVR) by the following equation: 
 PVR =    (mPAP− PCWP)CO  
 
Cardiac index was determined as CO / body surface area.  
An acute vasodilator study was performed using inhaled nitric oxide (40 parts per 
million) for 5 minutes to identify calcium channel blocker (CCB) responders. If, 
after review of the V/Q scan and CTPA prior to RHC, suspicion remained 
regarding the presence of thromboembolic disease, selective pulmonary 
angiography was also performed. 
 
Table 2-7: Haemodynamic measurements performed during right heart 
catheterisation. 
 
Routine measurements obtained during RHC 
• RAP 
• RVP 
• Systolic, diastolic and mean PAP 
• PCWP 
• CO by thermodilution (CI as determined by BSA) 
• PVR 
• Mixed venous blood oxygen saturation 
• ± Pulmonary angiography 
• ± Vasodilator studies (inhaled nitric oxide) with repeat haemodynamic 
measurements  
 
RAP; right atrial pressure. RVP; right ventricular pressure. PAP; pulmonary artery 
pressure. PCWP; pulmonary capillary wedge pressure. CO; cardiac output. CI; 
cardiac index. BSA; body surface area. PVR; pulmonary vascular resistance.  
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2.6 Inert gas rebreathing 
2.6.1 Principles and operational detail 
The rebreathing system (Innocor®) consists of a three-way respiratory valve with 
a mouthpiece and a rebreathing bag connected to an infrared photoacoustic gas 
analyser (AMIS 2001; Innovision A/S) (125). Pulmonary blood flow (PBF) was 
measured by rebreathing a gas mixture of 0.1% sulphur hexafluoride (SF6) and 
0.5% nitrous oxide (N2O) through a mouthpiece with the nose occluded. Breath-
by-breath respired gases were continuously sampled as patients breathed into 
the respiratory valve via a mouthpiece with the nose clipped. Gas concentrations 
were analysed using infrared photoacoustic gas analysers.  
The rebreathing software calculated the pulmonary blood flow (PBF) from the 
rate of uptake of N2O into the blood (slope of the regression line through the 
logarithmically transformed expiratory [i.e. alveolar] N2O concentrations plotted 
against time) after correction for system volume changes using the SF6 (blood 
insoluble gas) concentrations. PBF is equivalent to CO in the absence of 
significant intracardiac or intrapulmonary shunt. Right ventricular SV was 
derived by dividing PBF by heart rate. Repeatability of SV measurements by IGR 
(Innocor) was assessed by comparing the results from two IGR efforts.  
Prior to each IGR measurement, a 3L Douglas bag was pre-filled with an oxygen 
enriched mixture containing two inert gases, N2O and SF6. This was obtained by 
mixing a bolus from a gas bottle containing 94% oxygen, 5% N2O and 1% SF6 with 
ambient air. The measurements were taken with the patient in the supine 
position. Patients were coached on how to perform the rebreathing manoeuvre 
and had 2-3 practices prior to testing. Duplicate measurements were made after 
10 minutes of rest in the supine position. There was an interval of 5 minutes 
between duplicate measurements to ensure complete wash out of inert gases 
from the lungs.  
Reproducibility of IGR measurements was tested on a subgroup of patients. 
IGR measurements were initiated by the operator (L.M.) at the end of 
expiration. At this point, the respiratory valve was activated so that the patient 
rebreathed into the rebreathing bag in a closed circuit. The patient was 
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instructed to empty the bag during each inspiration and breathe at a rate of at 
least 20 breaths/min. N2O, being highly blood-soluble and diffusion- 
independent, disappeared from the alveoli into the pulmonary capillary blood at 
a rate proportional to PBF. SF6, being insoluble in blood, remained in the alveoli 
and served to determine the final lung volume from which N2O was removed. 
The total lung volume was calculated using the following formula: 
 
VL   =    [SF6]0  [SF6]eq      .VRB 
 
VL   = total systemic volume (STDP)  
VRB   = rebreathing bag volume  
[SF6]0  = initial SF6 concentration in the rebreathing bag  
[SF6]eq = SF6 concentration after good mixing (back extrapolated to time 
zero) 
 
After a few breaths, SF6 was mixed in the lungs and its concentration stabilised. 
The difference between maximum and minimum SF6 concentrations within a 
breath was continuously analysed. Calculation of PBF would start when this 
difference fell below a predefined level indicating good gas mixing (set at 15% of 
the average of maximum and minimum SF6 concentrations) (Figure 2.11). It 
would usually be achieved after three breaths and calculation of PBF would take 
place over the subsequent three breaths. The rebreathing time should not 
exceed 30 seconds as re-circulation of N2O may occur.  
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Figure 2-11: Sulphur hexafluoride concentration during rebreathing. 
 
    
 
 
 
During the rebreathing period, the lung volume varied slightly due to changes in 
the rate of carbon dioxide output relative to oxygen uptake. At the start, due to 
slight hyperventilation, more carbon dioxide entered the alveoli whereas oxygen 
uptake remained constant. The lung volume increased. As the alveolar carbon 
dioxide concentration increased, the diffusion gradient decreased. The rate of 
carbon dioxide output slowed and the lung volume shrunk. Alveolar N2O 
concentration was normalised for changes in lung volume using SF6 
concentration before the start of each PBF calculation. As the rate of N2O 
concentration decrease was proportional to PBF and N2O concentration itself, 
N2O concentration was a mono-exponentially decreasing function of time giving 
rise to a linear semi-logarithmic plot of normalised N2O against time (Figure 
2.12). 
Good gas mixing achieved and PBF 
calculation starts. 3 breaths are 
included in the calculation indicated 
by the blue bars. 
[SF6]0 
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Figure 2-12: A semi-logarithmic plot of normalised nitrous oxide against 
time. 
  
 
Regression line through the end-expiratory points of 3 breaths after good gas 
mixing. The slope of the line (β) is calculated directly from the plot. 
 
PBF was calculated using the following formula: 
 PBF =   −  β  .VL  .C1  .C2αb  
β  = slope of regression line  
VL  = total systemic volume (STDP) 
C1  = 760 mmHg/(ambient pressure in mmHg – 47 mmHg) 
C2  = constant to account for absorption of N2O into lung tissue 
= Bunsen solubility coefficient of N2O in tissue (0.407 STPD) x lung tissue 
volume (default 0.6 L) 
αb  = Bunsen solubility coefficient of N2O in blood (0.412 STPD) 
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Pulmonary blood flow (PBF) is equivalent to cardiac output (CO) in the absence 
of intracardiac or intrapulmonary shunt. SV was derived from PBF and HR. 
 SV =   PBFHR  
 
 
2.7 Statistical methods. 
The statistical methodology pertaining to each study in this thesis is described 
separately, within the relevant chapters. 
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Chapter 3 
 
Non-invasive stroke volume measurement by 
cardiac magnetic resonance imaging and inert 
gas rebreathing in pulmonary hypertension. 
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3 Non-invasive stroke volume measurement by 
cardiac magnetic resonance imaging and inert 
gas rebreathing in pulmonary hypertension. 
 
3.1 Introduction 
Pulmonary arterial hypertension (PAH) is a rare disease that is characterised by 
increased pulmonary vascular resistance leading to chronic right ventricular 
pressure overload. Without treatment patients have a poor prognosis and die of 
right heart failure.  Although recent therapeutic advances have improved the 
short-to-medium term outlook of pulmonary hypertension patients, early death 
due to progressive right ventricular failure remains inevitable in many patients 
(164, 203). 
The functional consequence of a raised pulmonary vascular resistance is a 
decrease in exercise capacity and a low cardiac output. In patients with PAH, 
the cardiac output (CO) is directly related to the clinical severity of the disease 
and is an important prognostic factor (1, 4). Stroke volume (SV) is highly variable 
in normal subjects and is increased during exercise. Patients with idiopathic PAH 
are unable to augment their SV in response to exercise due to an exercise 
induced increase in pulmonary arterial pressure resulting in further impairment 
of RV function and underfilling of the left vetricle (99). It has been suggested 
that monitoring SV rather than CO would be a more meaningful outcome 
measure in PAH patients. Physiologically, a reduction in resting SV can be 
compensated by an increase in resting heart rate (HR) leading to no or a small 
net change in CO. A recent cardiac magnetic resonance (CMR) study (73) 
confirmed that a low baseline stroke volume index (SVI) was predictive of a poor 
survival whereas cardiac index (CI) was not. In addition, a further reduction in 
SV at 1 year follow up predicted treatment failure and a poor long term 
outcome.  A noninvasive, accurate measure of SV, therefore, could be beneficial 
to monitor disease progression in patients with PAH.  
Several invasive and noninvasive techniques have been evaluated for the 
measurement of CO and SV in humans. The “gold standard” is the direct Fick 
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method, in which the CO is calculated as the quotient of oxygen uptake (VO2) and 
the difference of the arterial and mixed venous oxygen content measured during 
right heart catheterisation (RHC). This method is rarely used in clinical practice, 
however, primarily because the bedside measurement of oxygen uptake is 
cumbersome and has been largely replaced by the thermodilution (TD) technique. 
TD is also performed during RHC and has been demonstrated to have reasonable 
accuracy in PAH (204). Noninvasive methods of monitoring SV and CO include 
cardiac magnetic resonance imaging (CMR) and inert gas rebreathing (IGR). CMR 
imaging is recognised as an accurate and reproducible means of measuring 
pulmonary arterial flow in patients with PAH (104, 105) despite their 
inhomogeneous velocity profile. However, a recent study by Mauritz and 
colleagues has suggested that CMR measurement of LV volumes and aortic flow are 
to be preferred for the measurement of SV in PAH patients (102). IGR, using the 
acetylene rebreathing technique, has been validated for measuring CO in PAH 
patients (204). A new rebreathing technique using rapid photoacoustic analysis of 
nitrous oxide has been introduced and validated in left heart failure. This 
technique has not yet been validated in patients with PAH. 
The aim of this study was to determine the accuracy of SV measurement by CMR 
imaging and by IGR using photoacoustic analysis compared with the thermodilution 
technique measured during RHC in patients with suspected pulmonary 
hypertension. 
 
 
3.2 Methods and Materials 
3.2.1 Patients and Protocol 
This was a cross-sectional study of thirty-three consecutive patients attending 
for assessment at the Scottish Pulmonary Vascular Unit (Glasgow, UK), with a 
provisional diagnosis of pulmonary hypertension determined by 
echocardiography. Patients had CO measured by (i) thermodilution technique 
during RHC, (ii) CMR imaging (pulmonary artery flow measurements), (iii) CMR 
imaging (aortic flow measurements) and (iv) IGR. These four techniques were 
performed within 48 hours of each other. The patients were supine during each 
technique and the measurements were performed after 5 minutes of rest. The 
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study protocol was approved by the Glasgow West Research Ethics Review 
Committee. All subjects gave informed written consent.  
 
3.2.2 Right heart catheterisation and thermodilution 
measurements 
A 7F gauge, balloon-tipped, flow directed Swan-Ganz catheter was advanced 
through an 8F introducer sheath inserted into the right internal jugular vein or 
the right femoral vein. CO was measured by the thermodilution technique (202) 
following injection of 10ml of ice-cold, 0.9% saline through the proximal (right 
atrial) lumen of the catheter. The drop in temperature was measured at the 
distal thermistor. The final value used was the average of three measurements 
agreeing within 10%.        
 
3.2.3 CMR image acquisition and analysis 
CMR imaging was performed on a 1.5T Sonata MRI scanner (Siemens Medical 
Solutions, Erlangen, Germany) with simultaneous ECG recording using a protocol 
that has been described in detail in the materials and methods section of this 
thesis. Right ventricular SV was measured using MR phase-contrast flow 
quantification in an image plane positioned perpendicular to the main pulmonary 
artery, at least 1cm distal to the pulmonary valve. Left ventricular SV (aortic 
flow) was also measured, approximately 2 - 4cm above the aortic valve and 
distal to the coronary arterial ostia. A velocity encoded k-space segmented 
gradient-echo sequence was used (imaging parameters: echo time / repetition 
time / flip angle / slice thickness / temporal resolution / image matrix / field of 
view / in-plane resolution / velocity encoding range = 3.1ms / 16ms / 15° / 
6mm / limited by TR / 256 / 380mm / 1.9x1.5mm / 150cm per second) to 
generate 45 matched pairs of anatomical and velocity images. Retrospective 
ECG-gating was used to ensure coverage of the complete cardiac cycle. Patients 
were instructed to breath freely throughout this section of the protocol and the 
average time of acquisition was 2-3 minutes depending on the patient’s heart 
rate.  
All MR images were analysed by a single operator (L.M.) using the Argus analysis 
software (Siemens, Erlangen, Germany). Individual scans were coded by number 
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and analysed in batches by L.M. who was blinded to the haemodynamic and inert 
gas rebreathing results of any given subject at the time of analysis.  
 
3.2.4 Inert Gas Rebreathing 
The rebreathing system (Innocor®, Innovision A/S, Denmark) consisted of a three-
way respiratory valve with a mouthpiece and a rebreathing bag connected to an 
infrared photoacoustic gas analyser (AMIS 2001; Innovision A/S) (125). Pulmonary 
blood flow (PBF) was measured by rebreathing a gas mixture of 0.1% sulphur 
hexafluoride (SF6) and 0.5% nitrous oxide (N2O) through a mouthpiece with nose 
occluded. Gas was sampled continuously from the mouthpiece for analysis by the 
infrared photoacoustic gas analyser. The rebreathing software calculated the 
PBF from the rate of uptake of N2O into the blood (slope of the regression line 
through the logarithmically transformed end-expiratory [i.e. alveolar] N2O 
concentrations plotted against time) after correction for system volume changes 
using the SF6 (blood insoluble gas) concentrations.  CO was assumed to be 
equivalent to PBF and right ventricular SV was derived by dividing PBF by heart 
rate. Repeatability of SV measurements by IGR was assessed by comparing the 
results from two IGR efforts. 
 
3.2.5 Statistical Analysis 
Data are given as mean ± SD unless otherwise specified.  Correlation coefficients 
were calculated using the Pearson method.  The agreement between the three 
techniques was analysed in a pairwise manner using the method described by 
Bland and Altman (205).  All calculations were performed using GraphPad Prism 
(Version 4.00, GraphPad Software Inc, La Jolla, USA). 
 
3.3 Results 
Patient characteristics and haemodynamic variables are shown in Table 3.1. The 
results of the diagnostic evaluation are shown in Table 3.2. The presence of 
pulmonary hypertension was confirmed in 29 patients and 15 were diagnosed as 
having PAH. Four patients had no evidence of a raised mean pulmonary artery 
pressure (mPAP) as determined by RHC.  Twelve patients had significant lung 
pathology (3 patients with chronic obstructive pulmonary disease [COPD] 
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[normal mPAP], 3 with pulmonary hypertension secondary to COPD and 
interstitial lung disease [ILD], 3 with PAH associated with connective tissue 
disease [CTD] and ILD, 1 with PAH secondary to sarcoidosis and 2 patients with 
pleural effusions secondary to left heart disease).  Thirty-two patients provided 
satisfactory IGR measurements. This technique was unsuccessful in one patient 
with interstitial lung disease (sarcoidosis) due to severe destructive lung disease. 
Thirty patients completed CMR imaging and 30 patients underwent diagnostic 
RHC.  
 
Table 3-1: Baseline characteristics of the subjects in the study. 
 
Parameter Value (mean ± SD) 
Number of patients 33 
Age  55 ± 17 years 
Sex (male:female) 17:16 
Echo PASP 69 ± 25 mmHg 
mPAP 39 ± 12 mmHg 
CI 2.34 ± 0.52 L/min/m2 
PVRI 4.50 ± 3.49 WU/m2 
6MWD 327 ± 113 m 
FEV1 2.11 ± 0.88 L/min 
FVC 3.09 ± 1.33 L/min 
 
Data are expressed as mean ± standard deviation. 33 patients were enrolled into 
this study. PASP; pulmonary artery systolic pressure. mPAP; mean pulmonary 
artery pressure. CI; cardiac index. PVRI; pulmonary vascular resistance index.  
6MWD; six minute walk distance. FEV1; forced expiratory volume in 1 second. 
FVC; forced vital capacity.  
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Table 3-2: Results of diagnostic evaluation. 
 
Diagnosis Number 
No pulmonary hypertension 4 
Pulmonary arterial hypertension 
- Idiopathic (IPAH) 
- Familial (FPAH) 
- Connective tissue disease 
- HIV infection 
 
9 
1 
4 
1 
Pulmonary hypertension associated with left heart disease 4 
Pulmonary hypertension associated with lung disease/hypoxia 
- Chronic obstructive pulmonary disease 
- Interstitial lung disease 
 
2 
1 
Chronic thromboembolic pulmonary hypertension 
- Obstruction of proximal pulmonary arteries 
- Obstruction of distal pulmonary arteries 
 
2 
4 
Miscellaneous 
- Sarcoidosis 
 
1 
 
 
The average (± SD) SV values from the three techniques were as follows: CMR SV 
aortic flow 55.26 (± 23.67)ml, CMR SV pulmonary artery flow 61.77 (± 25.14) ml, 
TD SV 61.87 (± 22.90) ml and IGR SV 57.02 (± 25.01) ml. The reproducibility of 
the IGR SV measurements had a coefficient of variation of 6.9%. The correlation 
plots and Bland-Altman analyses for the 3 comparisons are shown in Figures 3.1, 
3.2 and 3.3 and summarised in Table 3.3. 
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Figure 3-1: Correlation plot and Bland-Altman analysis comparing stroke 
volume measured by thermodilution and CMR (aortic flow). 
 
A: Correlation plot comparing SV measured by thermodilution and CMR aortic flow 
methods. n = 21, r = 0.9322, p < 0.0001.  
B: Bland-Altman plot: Agreement between paired measurements of stroke volume 
measured by thermodilution and aortic flow by CMR.  
SV: stroke volume. TD: thermodilution. Ao: aortic. CMR: cardiac magnetic 
resonance. n = number of patients. r = correlation coefficient. 
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Figure 3-2: Correlation plot and Bland-Altman analysis comparing stroke 
volume measured by thermodilution and CMR (pulmonary artery flow). 
 
 
A: Correlation plot comparing stroke volume measured by thermodilution and 
cardiac magnetic resonance pulmonary artery flow. n = 27, r = 0.9048, p < 0.0001.  
B: Bland-Altman plot; Agreement between paired measurements of stroke volume 
measured by thermodilution and cardiac magnetic resonance pulmonary artery 
flow methods.  
n; number of patients. r; correlation coefficient. SV; stroke volume. TD; 
thermodilution. CMR; cardiac magnetic resonance. PA; pulmonary artery.  
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Figure 3-3: Correlation plot and Bland-Altman analysis comparing stroke 
volume measured by thermodilution and inert gas rebreathing. 
 
 
A: Correlation plot comparing stroke volume measured by thermodilution and inert 
gas rebreathing method. n = 29, r = 0.8735, p < 0.0001.  
B: Bland-Altman plot; Agreement between paired measurements of stroke volume 
measured by thermodilution and inert gas rebreathing.  
SV; stroke volume. TD; thermodilution. IGR; inert gas rebreathing. n; number of 
patients. r; correlation coefficient.  
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Table 3-3: Summary of Bland-Altman analyses performed. 
 
Methods Number Correlation 
coefficient 
Bias (ml) 95% Limits of 
Agreement (ml) 
    From To 
TD SV vs 
CMR Ao SV 
21 0.9322 -5.405 -22.37 11.56 
TD SV vs 
CMR PA SV 
27 0.9048 0.1215 -20.13 20.37 
TD SV vs 
IGR SV 
29 0.8735 6.251 -16.01 28.51 
 
TD; thermodilution. SV; stroke volume. CMR; cardiac magnetic resonance. Ao; 
aortic. PA; pulmonary artery. IGR; inert gas rebreathing. vs; versus. 
  
 
The IGR technique is reported to be less accurate in the presence of 
parenchymal lung abnormalities (206). In our cohort, 12 patients had significant 
lung disease, as determined by high resolution computed tomography imaging 
and pulmonary function testing. The Bland-Altman analysis was repeated on both 
this subset and the whole cohort with this subset excluded and the results are 
shown in Table 3.4. As expected, the limits of agreement widen in the group 
with lung disease although the bias remains small.  
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Table 3-4: Results of Bland-Altman analyses performed in the presence and 
absence of lung disease. 
 
Methods Bias (ml) 95% Limits of Agreement (ml) 
  From To 
No lung disease 
IGR vs TD 
 
-6.23 
 
-25.47 
 
13.02 
Lung disease 
IGR vs TD 
 
2.47 
 
-27.88 
 
32.81 
 
IGR: inert gas rebreathing. TD; thermodilution. 
 
3.4 Discussion 
The aim of this study was to evaluate the performance of CMR imaging and inert 
gas rebreathing using a device based on photoacoustic analysis for the 
measurement of CO in patients with PAH. With the advent of multiple new 
disease targeted therapies for PAH it is increasingly important that we can assess 
the progress of patients in a non-invasive manner.  
To evaluate these techniques, the results were compared with those from the 
widely accepted reference standard, thermodilution measured during right heart 
catheterisation. Bland-Altman analysis confirmed acceptable levels of 
agreement between the four techniques. Measurement of SV by aortic flow 
analysis during CMR imaging provided the most accurate results when compared 
to our reference standard. IGR was the least accurate of the techniques 
employed with increased 95% limits of agreement. The level of agreement, 
however, remained acceptable for this technique. The presence of parenchymal 
lung disease is a source of error in the IGR measurement of PBF and, as 
expected, caused a marginal impairment in the accuracy of the IGR results. It 
was still possible, however, to obtain reasonable results in this subgroup of 
patients. This study highlighted the ease with which IGR can be performed. The 
method was acceptable to all patients, even breathless patients with significant 
lung disease and the technique failed in only one subject who had severe 
121 
 
destructive lung disease (sarcoidosis). Reproducibility of the IGR technique was 
equivalent to that of the six minute walk test (8%) (139). 
There have been many techniques, both invasive and noninvasive, proposed for 
the measurement of CO and these have had mixed success. These include the 
Fick (direct and indirect) method, indicator dilution techniques (including 
thermodilution), CMR imaging, IGR, echocardiography, electrical bioimpedance 
and pulse contour analysis. Since the introduction of the Swan-Ganz catheter in 
1971 (202), the thermodilution technique (207) has been used extensively to 
measure CO in the clinical setting. It provides reliable results in healthy 
volunteers and in patients with cardiovascular disease (208) although there are 
concerns about its accuracy in patients with low CO or severe tricuspid 
regurgitation (209-213) which are both commonly present in patients with severe 
PAH. Hoeper et al (204) explored this question in detail and concluded that 
thermodilution provided a reliable assessment of CO in patients with pulmonary 
hypertension. One hundred and five CO measurements by the Fick method and 
thermodilution were compared in 35 patients with PAH. The mean difference ± 
95% limit of agreement between thermodilution and the Fick method was + 0.01 
± 1.1L/min. As a consequence, the clinical evaluation of new methods is often 
done by comparison with the thermodilution method.  
This study used CMR imaging to measure SV (214, 215). CMR imaging is 
recognised as an accurate and reproducible means of measuring pulmonary 
arterial flow in patients with PAH (104, 105) despite the inhomogeneous velocity 
profile. A recent study by Mauritz and colleagues has suggested that CMR 
measurement of LV volumes and aortic flow are to be preferred for the 
measurement of SV in PAH patients (102). Mauritz et al compared SV 
measurement by CMR and right heart catheterisation (Fick method). In a subset 
of 9 patients, the correlation of SV with CMR aortic flow (r=0.95) was stronger 
than with CMR pulmonary flow (r=0.76). In contrast, Bland-Altman analysis of our 
results confirmed that CMR aortic and pulmonary artery flow analysis provided 
very similar limits of agreement and minimal bias suggesting they could both be 
utilised for the measurement of SV in PAH patients.   
IGR was introduced by August Krogh in 1912 and has been widely validated (126-
129). This technique for CO measurement has been validated in PAH patients 
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using the acetylene rebreathing technique (204). It measures pulmonary blood 
flow (PBF), which is equivalent to cardiac output (CO) in the absence of 
intracardiac and intrapulmonary shunts (125). However, IGR measurements have 
traditionally required the use of mass spectrometers which are bulky, difficult to 
operate and require frequent calibration and maintenance. The new device 
employed in this study uses rapid photoacoustic analysis of gas concentrations. 
This device was recently validated against the direct Fick and thermodilution 
methods in a cohort of patients with stable heart failure (130) and in patients 
pre- and post-cardiac surgery (131). It has been successfully performed in 
patients with left heart failure during exercise combined with metabolic stress 
testing (216). So far only 3 patients with PAH have been evaluated using the 
Innocor device prior to this study (125). This device is of interest because of its 
ease of use and flexibility, as it can be used in both resting and exercise 
settings. 
IGR becomes less accurate in conditions that affect the intra-alveolar 
distribution of gas such as in the presence of severe interstitial or obstructive 
lung disease (206). Kallay et al (217), using a mass spectrometer observed good 
agreement between PBF determined by rebreathing and CO determined by 
indicator dilution techniques in a group of patients with various cardiopulmonary 
diseases with preserved pulmonary function. However, the agreement was 
weakened when patients exhibited either restrictive or combined restrictive and 
obstructive pulmonary disease.  Twelve patients in our study had significant lung 
disease. Analysis of the IGR technique in this patient subgroup demonstrated a 
reduction in accuracy with increased 95% limits of agreements. However, the 
level of agreement remained acceptable and IGR may still prove to be useful in 
this patient group.  
 
The evaluation of treatment efficacy of pulmonary vascular disease would 
benefit from noninvasive tools to monitor haemodynamic changes. Although CMR 
is noninvasive, it is an expensive, inflexible and technically demanding 
alternative to measure SV. IGR measured by the Innocor® device could easily be 
performed in the outpatient setting as it is quick and readily tolerated and could 
have several applications such as:- 
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• serial, longitudinal measurements in PAH patients on medication to 
demonstrate treatment efficacy 
• estimation of exercise stroke volume as this may be more sensitive to 
changes in the underlying pathology of the disorder than resting 
measurements 
 
Our study was limited by the small number of patients recruited. Also, the four 
techniques were not completed by all patients making the population for 
analysis within each group different (eleven patients could not complete CMR 
imaging, IGR was unsuccessful in one patient and three patients did not proceed 
to RHC). The techniques to measure PBF in this study were not contemporaneous 
but performed within 48 hours of each other. Further investigation, however, 
indicated there was no significant variation in heart rate between each of the 
measurements. A potential source of error in the determination of CO by 
rebreathing is the presence of shunted blood through areas without gas 
exchange. In this study, we assumed PBF was equivalent to CO and did not 
investigate further for the presence of shunted blood flow.    
This study has demonstrated that both cardiac magnetic resonance imaging and 
inert gas rebreathing using photoacoustic analysis can provide non-invasive 
measurements of stroke volume that are as accurate as those obtained by 
thermodilution in patients with suspected PAH. The presence of lung disease 
caused a marginal impairment in the accuracy of the IGR method.  
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Chapter 4 
 
Comparison of right ventricular function, 
assessed by cardiac magnetic resonance 
imaging, in patients with idiopathic 
pulmonary arterial hypertension versus 
connective tissue disease associated 
pulmonary arterial hypertension: A cross-
sectional study.  
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4 Comparison of right ventricular function, 
assessed by cardiac magnetic resonance 
imaging, in patients with idiopathic pulmonary 
arterial hypertension versus connective tissue 
disease associated pulmonary arterial 
hypertension: A cross-sectional study. 
 
4.1 Introduction 
Pulmonary arterial hypertension (PAH) is a progressive disease with a poor 
prognosis, although there have been recent improvements in survival with the 
introduction of disease targeted therapy. Idiopathic PAH (IPAH) is the most 
common cause of pulmonary arterial hypertension. An important clinical 
subgroup is PAH associated with connective tissue disease (CTDPAH), which is 
the second most prevalent type of PAH in the registries (8, 9). Systemic sclerosis 
(SSc) represents the main CTD associated with PAH (SSc-PAH). SSc-PAH is 
particularly aggressive and accounts for 30% of deaths among SSc patients (218). 
There is a relative paucity of literature regarding the outcome of CTDPAH in 
conditions other that SSc.  The prognosis for patients with SSc-PAH remains poor 
and worse compared to other PAH subgroups. The 1 year mortality in IPAH is 
approximately 15% (219) versus 30% in PAH associated with scleroderma (220). A 
more recent prospective study has reported an improvement in survival in SSc-
PAH patients at 1 year in the modern treatment era, although the outlook at 3 
years remained very poor (221).  
CTDPAH has a less favourable response to modern therapy and worse survival for 
reasons that remain unclear. Factors such as age and other comorbidities (e.g. 
cardiac and lung parenchymal involvement) do not fully account for this 
difference in outcomes (222). Baseline resting haemodynamic measurements 
offer valuable information in terms of severity and prognosis of PAH. Increased 
right atrial pressure (RAP), decreased cardiac index (CI), and increased mean 
pulmonary artery pressure (mPAP) are predictors of a poor prognosis in IPAH (4).  
Although these data have been validated in IPAH, they remain of unclear 
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usefulness in SSc-PAH. Recent studies have highlighted the lack of correlation 
between baseline haemodynamic data and clinical evolution in patients with 
SSc-PAH. These patients appear to have less severe alterations in 
haemodynamics compared with IPAH (8, 222, 223). In a retrospective analysis 
comparing baseline haemodynamic data in patients with IPAH and SSc-PAH, 
patients with SSc-PAH had a significantly lower mPAP and pulmonary vascular 
resistance (PVR), and equally depressed CI compared to patients with IPAH; 
However, follow up indicated they were 4 times more likely to die compared 
with patients with IPAH despite comparable therapy (222). These paradoxical 
findings suggest that the RV may have a reduced ability to adapt to increased 
PVR in SSc-PAH. RV adaptation and ventricular remodeling in PAH is a complex 
process that depends on multiple factors including the severity of pulmonary 
vascular disease, neurohormonal activation, myocardial perfusion, and 
myocardial metabolism (38, 42, 93, 224-231). Other factors that could influence 
RV adaptation include the rate and time of onset of PAH, its underlying 
aetiology, and genetic  factors 
 
Studies comparing haemodynamic measurements and survival of patients with 
IPAH and SSc-PAH suggest that increased myocardial dysfunction from failure to 
adapt to increased pulmonary vascular load might contribute to the poorer 
prognosis in SSc-PAH. Overbeek et al investigated the differences in RV pump 
function (using the pump function graph which relates mean RV pressure to SV 
index) between IPAH and SSc-PAH patient groups (232). They concluded that RV 
contractility was lower in SSc-PAH than in IPAH. More recently, Tedford and 
colleagues, using pulmonary resistance compliance relations and invasive PV 
loop analysis, concluded that intrinsic systolic RV dysfunction accounted for the 
poorer prognosis in the SSc-PAH patient cohort compared with IPAH (233). 
Patients with SSc-PAH have relatively depressed RV function, despite similarly 
augmented pulmonary afterload compared with IPAH. 
  
The purpose of this study was to examine the haemodynamic and CMR findings, 
in the well-characterised populations of IPAH and CTDPAH, and to evaluate 
whether differences exist in cardiac structure and function that might affect 
survival. The reason for poorer survival in CTDPAH patient group remains poorly 
understood. We hypothesise that there will be a difference in right heart 
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adaptation, as determined by CMR, for a given mPAP that could account for the 
poorer prognosis in the CTDPAH group.  
 
 
4.2 Methods 
4.2.1 Study population 
This was a cross-sectional study of fifty patients attending for assessment at the 
Scottish Pulmonary Vascular Unit (SPVU). The inclusion criteria were patients 
with a diagnosis of idiopathic pulmonary arterial hypertension (IPAH) or 
connective tissue disease related pulmonary arterial hypertension (CTDPAH). 
The study subjects were either incident patients attending the SPVU for initial 
diagnostic assessment or prevalent patients in whom disease targeted therapy 
was being modified. The diagnosis of PAH was based on RHC in accordance with 
contemporary guidelines (7). This study was approved by the West Glasgow 
Research Ethics Committee and written informed consent was obtained from all 
study participants. 
 
4.2.2 Study design 
All patients underwent CMR imaging followed by RHC within a 48 hour period. 
Conventional outcome measures including WHO functional class and 6 minute 
walk distance were also recorded.  
 
4.2.3 Cardiac magnetic resonance (CMR) image acquisition and 
analysis 
CMR imaging was performed on a 1.5 Tesla MRI scanner (Sonata Magnetom, 
Siemans, Germany). CMR was performed using a protocol described in detail in 
the materials and methods chapter of this thesis. All CMR images were analysed 
by a single operator (L.M.) using the Argus analysis software (Siemans, Erlangen, 
Germany). Individual scans were coded by number and analysed in batches by 
L.M. who was blinded to the haemodynamic and six minute walk distance results 
of any given subject at the time of analysis. Table 4.1 documents the 
measurements obtained from the CMR assessment.   
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Table 4-1: Measurements obtained in this study from cardiac magnetic 
resonance imaging. 
 
Measurements obtained from CMR Imaging 
Right ventricular end diastolic volume (RVEDV)  
Right ventricular end systolic volume (RVESV) 
Left ventricular end diastolic volume (LVEDV)  
Left ventricular end systolic volume (LVESV) 
Right ventricular mass (RVM) 
Left ventricular mass (LVM) 
Pulmonary artery flow analysis – stroke volume (PASV) 
Aorta flow analysis – stroke volume (AoSV) 
 
4.2.4 Right heart catheterisation  
RHC was performed according to international recommendations (160). A 7F 
gauge, balloon tipped, flow directed, triple channel thermodilution Swan-Ganz 
catheter (Baxter Healthcare, Irvine, California, USA) was advanced through an 
8F introducer sheath inserted into the right internal jugular vein or the right 
femoral vein. All measurements were recorded with the patient in a supine 
position, at rest, breathing room air or supplemental oxygen if required. Please 
refer to materials and methods section of this thesis for further information on 
RHC methodology. 
 
4.2.5 Six-minute walk test 
The 6MWT was performed on a 20-metre corridor, but otherwise according to 
the American Thoracic Society guidelines (234). 
  
4.2.6 Statistical analysis 
Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois, USA) and Graphpad Prism Version 6 (Graphpad Software, California, 
USA). Data are given as mean ± standard deviation (SD) unless otherwise stated. 
Correlation coefficients were calculated using the Pearson method. 
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4.3 Results 
4.3.1 Patient characteristics 
Fifty patients with PAH  (30 IPAH and 20 CTDPAH) were recruited for this study. 
All patients underwent CMR imaging and RHC. 4 patients were unable to 
complete the full CMR protocol. 3 patients (WHO functional class IV) were 
unable to perform a 6 minute walk test. Table 4.2 presents the demographic 
data, WHO functional class, 6 minute walk distance and haemodynamic data for 
both groups of patients. There was no significant difference in age or BSA 
between the IPAH and CTDPAH patient groups. There was a higher proportion of 
female patients in the CTDPAH group. The functional status of both patient 
groups was similar. The majority of patients were in WHO functional class III. 
There was no significant difference in the 6 minute walk distance achieved 
between the 2 groups (252.7 ± 117.7 versus 262.4 ± 133.7, p=0.79). 
Haemodynamic measurements confirmed that all patients in this study had 
significant pulmonary hypertension. 50 patients had an elevated mPAP and PVR 
during RHC. The diagnosis of IPAH or CTDPAH was ascertained at the SPVU 
multidisciplinary meeting. There was no significant difference in mPAP (46.67 ± 
10.72 versus 43.10 ± 15.13, p=0.33), cardiac index (2.14 ± 0.48 versus 2.27 ± 
0.55, p=0.39) or PVRI (6.50 ± 3.46 versus 4.19, p=0.84) between these distinct 
patient groups. 
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Table 4-2: Baseline characteristics for patients enrolled in this study. 
 
Characteristic IPAH (n=30) CTDPAH (n=20) p value 
Number of patients 30 20  
Age (years) 53.93 ± 17.69 57.88 ± 14.19 0.4079 
Female:Male 21:9 18:2  
BSA 1.753 ± 0.2629 1.660 ± 0.2324 0.2044 
mPAP (mmHg) 46.67 ± 10.72 43.10 ± 15.13 0.3337 
CI (L/min/m2) 2.12 ± 0.42 2.26 ± 0.55 0.2949 
PVRI (WU/m2) 6.62 ± 3.44 6.74 ± 4.59 0.9183 
6 MWD (m) 252.7 ± 117.7 262.4 ± 133.7 0.7948 
 
Baseline characteristics for the 50 patients enrolled in this study are documented. 
Data are expressed as mean ± standard deviation. BSA: body surface area; 
mPAP: mean pulmonary artery pressure: CI: cardiac index; PVRI: pulmonary 
vascular resistance index; 6MWD; six minute walk distance.  
 
4.3.2 CMR measurements  
Table 4.3 documents CMR measurements obtained from all patients in the study. 
4 patients were unable to complete the full CMR protocol. 50 patients 
completed the mass and volumetric assessment. 49 patients completed 
pulmonary artery flow analysis and only 46 patients managed to complete aortic 
flow analysis. There was a significant difference in ventricular mass index (VMI). 
The CTDPAH group had a significantly lower VMI than the IPAH group (0.85 ± 0.23 
versus 1.12 ± 0.44, p=0.01). Left ventricular ejection fraction (LVEF) was 
significantly higher in the CTDPAH group (62.08 ± 11.57 versus 50.91 ± 17.15, 
p=0.02). There were no further significant differences in CMR measurements 
between the 2 groups. 
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Table 4-3: Baseline cardiac magnetic resonance measurements for enrolled 
patients. 
 
CMR 
Measurement 
IPAH  
n = 30 
CTDPAH  
n = 20 
p value 
RVEDVI 85.59 ± 26.16 77.58 ± 20.32 0.2536 
RVESVI 57.95 ± 26.27 47.75 ± 24.58 0.1743 
RVMI 55.77 ± 26.47 47.45 ± 16.70 0.2186 
LVEDVI 46.68 ± 12.56 48.56 ± 15.72 0.6412 
LVESVI 18.53 ± 6.876 17.19 ± 9.388 0.5627 
LVMI 49.63 ± 10.09 55.76 ± 12.91 0.0661 
VMI 1.124 ± 0.4418 0.849 ± 0.2278  0.0137 * 
RVSVI (PA) 31.38 ± 11.78 29.64 ± 11.67 0.6084 
LVSVI (Aorta) 25.11 ± 11.03 30.02 ± 7.366 0.1184 
RVEF 38.52 ± 15.04 43.08 ± 23.66 0.4077 
LVEF 50.91 ± 17.15 62.08 ± 11.57 0.0243 * 
 
Ventricular dimensions and function measured by CMR imaging in 50 patients with 
pulmonary hypertension (30 IPAH and 20 CTDPAH). Data are expressed as mean 
± standard deviation. IPAH; idiopathic pulmonary arterial hypertension. CTDPAH; 
pulmonary arterial hypertension associated with connective tissue disease. CMR; 
cardiac magnetic resonance. PA; pulmonary artery.  
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Figure 4-1: Bar graphs depicting ventricular dimensions and function 
measured by CMR in IPAH and CTDPAH patient groups 
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Legend for Figure 4.1 
IPAH: idiopathic pulmonary arterial hypertension. CTDPAH: pulmonary arterial 
hypertension associated with connective tissue disease.  
A: Bar graph demonstrating LVEDVI (left ventricular end diastolic volume index) 
measurements in IPAH and CTDPAH groups.  
B: Bar graph demonstrating LVESVI (left ventricular end systolic volume index) 
measurements in IPAH and CTDPAH groups.  
C: Bar graph demonstrating RVEDVI (right ventricular end diastolic volume index) 
measurements in IPAH and CTDPAH groups.  
D: Bar graph demonstrating RVESVI (right ventricular end systolic volume index) 
measurements in IPAH and CTDPAH groups.  
E: Bar graph demonstrating LVMI (left ventricular end mass index) measurements 
in IPAH and CTDPAH groups.  
F: Bar graph demonstrating RVMI (right ventricular mass index) measurements in 
IPAH and CTDPAH groups.  
G: Bar graph demonstrating SVIPA (stroke volume index measured from 
pulmonary artery) measurements in IPAH and CTDPAH groups.  
H: Bar graph demonstrating SVIAo (stroke volume index measured from aorta) 
measurements in IPAH and CTDPAH groups.  
I: Bar graph demonstrating LVEF (left ventricular ejection fraction) measurements 
in IPAH and CTDPAH groups. There was a significant difference between these 
patient groups (p = 0.0243)  
J: Bar graph demonstrating RVEF (right ventricular ejection fraction) 
measurements in IPAH and CTDPAH groups.  
K: Bar graph demonstrating VMI (ventricular mass index) measurements in IPAH 
and CTDPAH groups. There was a significant difference between these patient 
groups (p = 0.0137).  
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4.3.3 Correlation between mPAP and CMR measurements 
Please refer to table 4.4 and Figure 4.2. The mPAP correlates significantly with 
CMR measurements of the right heart (RVEDVI, RVESVI, RVMI, RVEF and VMI) in 
both the groups. These results are in agreement with previously published 
literature. The mPAP correlated most strongly with RVMI and VMI, in both the 
IPAH and CTDPAH patient groups. There was a significant correlation between 
mPAP and LVEDVI (p=0.02*) and LVSVI (p=0.02*) in the CTDPAH group. A further 
significant correlation was also identified between mPAP and LVEF (p=0.0058**) 
in the IPAH group only.  
 
Multiple linear regression analysis identified no significant change in right heart 
structure and function (right heart adaptation) for a given mPAP between the 
IPAH and CTDPAH patient groups. 
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Table 4-4: Correlations between mean pulmonary artery pressure 
measurements and cardiac magnetic resonance measurements. 
 
CMR measurement 
versus mPAP 
IPAH CTDPAH 
RVEDVI r = 0.4205 
p = 0.0207 * 
n = 30 
r = 0.4712 
p = 0.0360 * 
n = 20 
RVESVI r = 0.4737 
p = 0.0082 ** 
n = 30 
r = 0.5906 
p = 0.0061 ** 
n = 20 
RVMI r = 0.5097 
p = 0.0040 ** 
n = 30 
r = 0.6796 
p = 0.0010 *** 
n = 20 
LVEDVI r = -0.1408 
p = 0.4581 
n = 30 
r = -0.5131 
p = 0.0207 * 
n = 20 
LVESVI r = -0.01688 
p = 0.9294 
n = 30 
r = -0.1646 
p = 0.4880 
n = 20 
LVMI r = 0.09296 
p = 0.6251 
n = 30 
r = 0.2462 
p = 0.2954 
n = 20 
VMI r = 0.5456 
p = 0.0018 ** 
n = 30 
r = 0.6493 
p = 0.0019 ** 
n = 20 
RVSVI (PA) r = -0.3042 
p = 0.1022 
n = 30 
r = -0.6086 
p = 0.0057 ** 
n = 19 
LVSVI (Aorta) r = -0.3288 
p = 0.0815 
n = 30 
r = -0.5623 
p = 0.0234 * 
n = 16 
RVEF r = -0.6421 
p = 0.0001*** 
n = 30 
r = -0.5750 
p = 0.0100 * 
n = 19 
LVEF r = -0.4915 
p = 0.0058 ** 
n = 30 
r = -0.1647 
p = 0.5421 
n = 16 
 
CMR; cardiac magnetic resonance. mPAP; mean pulmonary artery pressure. 
IPAH; idiopathic pulmonary arterial hypertension. CTDPAH; pulmonary arterial 
hypertension associated with connective tissue disease. r = correlation coefficient. 
n = number of patients. p = value of significance.  
137 
 
Figure 4-2: Correlation plots between mean pulmonary artery pressure 
measurements and cardiac magnetic resonance measurements in IPAH and 
CTDPAH patients. 
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Legend for Figure 4.2 
 
A: The relationship between invasive mPAP and VMI in IPAH and CTDPAH 
patient groups. IPAH (p = 0.0018). CTDPAH (p = 0.0010).  
B: The relationship between invasive mPAP and RVMI in IPAH and CTDPAH 
patient groups. IPAH (p = 0.004). CTDPAH (p = 0.001).  
C: The relationship between invasive mPAP and RVEDVI in IPAH and CTDPAH 
patient groups. IPAH (p = 0.0207). CTDPAH (p = 0.036).  
D: The relationship between invasive mPAP and RVESVI in IPAH and CTDPAH 
patient groups. IPAH (p = 0.0082). CTDPAH (p = 0.0661).  
E: The relationship between invasive mPAP and RVEF in IPAH and CTDPAH 
patient groups. IPAH (p = 0.0001). CTDPAH (p = 0.01).  
IPAH; idiopathic pulmonary arterial hypertension. CTDPAH; pulmonary arterial 
hypertension associated with connective tissue disease. mPAP; mean pulmonary 
arterial pressure. VMI; ventricular mass index. RVMI; right ventricular mass index. 
RVEDVI; right ventricular end diastolic volume index. RVESVI; right ventricular 
end systolic volume index. RVEF; right ventricular ejection fraction. 
  
140 
 
 
4.3.4 Survival analysis 
Using the Kaplan-Meier method (Figure 4.3), significantly poorer survival is 
evident in patients with CTDPAH compared with IPAH. 19 patients died (8 IPAH, 
11 CTDPAH) during the course of this study.  
 
Figure 4-3: Kaplain-Meier survival curves for IPAH and CTDPAH patient 
groups. 
 
Kaplain-Meier survival curves according to diagnosis. p = 0.0461. Patients with a 
diagnosis of CTDPAH had a significantly poorer prognosis than IPAH patients. 
IPAH; idiopathic pulmonary arterial hypertension. CTDPAH; pulmonary arterial 
hypertension associated with connective tissue disease. 
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failure (3-6). Haemodynamic studies have demonstrated the predictive value of 
RAP and CI. Echocardiographic studies have highlighted the predictive value of 
tricuspid annular plane systolic excursion (TAPSE) measurements, RV myocardial 
performance index, atrial size, and pericardial effusion. MRI studies have 
emphasized the predictive value of SVI, RVEF, and indexed RVESV and RVEDV.  
 
Pulmonary arterial hypertension associated with connective tissue disease 
(CTDPAH) is associated with a high morbidity and mortality, and worse outcomes 
compared to the idiopathic form of the disease. Although responses to current 
PAH therapy have been reported to be effective in SSc-PAH (235, 236), some 
have reported less favourable responses as compared with IPAH (223, 237, 238). 
Survival analysis from our study confirmed a significantly poorer outlook in the 
CTDPAH cohort compared to the IPAH group. These data agree with published 
literature. The PAH Quality Enhancement Research Initiative (PAH-QuERI) 
enrolled 791 patients and the 3 year survival probability was significantly lower 
in patients with SSc-PAH than in patients with IPAH (60% vs 77%, p<0.0001). 
Further studies have confirmed patients with SSc-PAH have worse outcomes than 
other subgroups with PAH (11, 239) (240, 241).  
 
The reasons for the striking difference in survival between IPAH and CTDPAH 
remain unclear. Compared with IPAH, patients with CTDPAH are mainly women 
(women/men ratio 4:1), are older (mean age at diagnosis 66 years) and may 
present with concomitant disorders (interstitial lung disease, left heart disease 
etc.). Fisher and colleagues (222) tested the hypothesis that an increased 
prevalence of left heart disease might explain the higher mortality in patients 
with SSc-PAH compared to patients with IPAH. Echocardiography revealed similar 
degrees of right ventricular dysfunction in the 2 groups, whereas a 
predominance of left heart dysfunction was observed in patients with PAH-SSc. It 
was concluded, however, that the presence of left heart disease, although more 
common in PAH-SSc, was not predictive of the higher mortality in these patients. 
Cardiac involvement in SSc has been reported since the 1960s on the basis of 
autopsy observations, which showed in 70-80% of cases a myocardial fibrosis 
pathway characterised by contraction band necrosis of both ventricles and 
replacement fibrosis, in the absence of concomitant coronary artery disease 
(242). The poorer prognosis in SSc-PAH has been confirmed, in the absence of 
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ILD, in the recent prospective study by Launay and colleagues (221). Overbeek 
et al explored patterns of vasculopathy in SSc-PAH patients and compared to 
IPAH patients (243). Lung tissue was obtained at autopsy, open lung biopsy or 
lung transplant. They concluded SSc-PAH is characterized by a small vessel 
intimal fibrosis, which is associated with a PVOD-like pattern in some cases and 
proposed that this may explain its different clinical behavior from IPAH (243).   
 
The right ventricle (RV) is the main prognostic determinant in PAH. Recent 
studies have suggested intrinsic RV dysfunction may account for the differences 
in survival identified between these distinct patient groups. Overbeek et al 
investigated the differences in RV pump function (232) and concluded that RV 
contractility was lower in SSc-PAH than in IPAH. More recently, Tedford and 
colleagues, using pulmonary resistance compliance relations and invasive PV 
loop analysis (233) proposed patients with SSc-PAH have relatively depressed RV 
function, despite similarly augmented pulmonary afterload compared with IPAH. 
  
A diagnosis of PAH was confirmed by right heart catheterisation in all our 
enrolled patients. We found no significant difference in the mPAP, PVRI or CI 
between the IPAH and CTDPAH patient groups in this study. These data are not 
in agreement with previously published literature. Fisher and colleagues 
demonstrated patients with SSc-PAH had a lower mPAP (46.6mmHg versus 
54.4mmHg p=0.002) and PVRI (22.8 versus 17.5 p=0.026) than IPAH patients, 
despite similar levels of cardiac dysfunction (no significant difference between 
CI). Similar patterns were also found in a UK registry investigating the survival 
and characteristics of patients diagnosed with CTDPAH (11) and prospective US 
registry (PAH-QuERI) (244). The higher proportion of patients in WHO FC III/IV 
(IPAH 87%/CTDPAH 90%) in our study could explain this finding. Patients with a 
diagnosis of connective tissue disease (CTD) are often screened for development 
of pulmonary hypertension and, as such, identified at an early stage of disease. 
Our CTDPAH group had severe pulmonary hypertension confirmed at RHC and 
may reflect a late presenting group. In a recent prospective study, Launay and 
colleagues (221) identified that the SSc-PAH patients studied were mostly in 
NYHA FC III/IV and had severe PH at diagnosis. i.e. a late presentation in routine 
practice as opposed to studies who may have picked up patients during a 
screening process. 
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Recent studies have highlighted the lack of correlation between baseline 
haemodynamic data and clinical evolution in patients with SSc-PAH. Baseline 
haemodynamic abnormalities have been milder in the CTDPAH population i.e. 
significantly lower mPAP and PVR, and equally depressed CI compared to 
patients with IPAH; However, follow up indicated they were 4 times more likely 
to die compared with patients with IPAH despite comparable therapy (222). 
These seemingly paradoxical findings suggest that the RV may have a reduced 
ability to adapt to increased PVR in SSc-PAH, perhaps related in part to 
myocardial inflammation and scarring as supported by endomyocardial biopsies 
samples from patients with SSc (245).     
  
CMR measurements obtained from both patient groups reflected the underlying 
diagnosis of pulmonary hypertension. Baseline CMR variables related to the right 
heart correlate with mPAP in both the IPAH and the CTDPAH patient groups. This 
is in agreement with previously published literature. There was a significant 
difference identified in the calculated ventricular mass index (VMI) for the IPAH 
and the CTDPAH groups. The VMI was significantly less in the CTDPAH group 
(0.849 ± 0.2278 versus 1.124 ± 0.4418). The VMI is calculated by dividing the 
right ventricular mass by the left ventricular mass [VMI = RVM/LVM]. Saba et al 
showed that a VMI > 0.6 had a sensitivity of 84% and specificity of 71% for 
detecting PAH of various aetiologies (75). VMI was more accurate than 
echocardiography in diagnosing PH and demonstrated excellent correlation 
(r=0.81) with the mPAP. (75). A larger study by Roeleveld et al, however, 
showed a much weaker correlation between the VMI and mPAP (r=0.56) although 
the VMI was found to be the best among five different CMR-based methods for 
the estimation of mPAP (76). The increased VMI in the IPAH patient group may 
reflect an improved cardiac adaptive process in the IPAH group to the increased 
pulmonary vascular afterload, despite no significant difference in indexed RVM 
being identified. It is well recognized that the left heart is involved in systemic 
sclerosis (246). LVEF was significantly higher in the CTDPAH group (62.08 ± 11.57 
versus 50.91 ± 17.15, p=0.0243) compared to the IPAH group. These results are 
difficult to explain. Multiple linear regression analysis was applied to account for 
mPAP measurements. We were unable to identify any significant differences in 
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right heart adaptation (structure and function) for a given mPAP, which could 
account for the poorer prognosis in the CTDPAH group. 
 
The prognosis of CTDPAH is confirmed to be significantly worse than IPAH. 
Previous studies have suggested intrinsic RV dysfunction may account for the 
differences in survival identified. We did not identify any significant differences 
in RV structure and function AT REST, for a given mPAP, between the 2 distinct 
patient groups. Perhaps exercise testing during CMR (e.g. MR-compatible 
ergometer, dobutamine administration) may be an avenue for further 
investigation. This may tease out subtle differences in RV/LV function between 
the groups. However, it should be noted that the majority of patients presented 
in WHO FC III and therefore exercise may be difficult to perform.       
 
This study compared baseline CMR measurements between IPAH and CTDPAH 
patients. CTDPAH has a poorer prognosis than IPAH. RV function is the main 
prognostic determinant in PAH. We investigated whether there were detectable 
differences in baseline CMR, for a given mPAP, between IPAH and CTDPAH 
patient groups. Contrary to our hypothesis, we did not find any evidence of 
difference in right heart adaptation between the groups. It is likely that the 
survival difference observed is due to a combination of factors including RV 
function, impact of comorbidities, age, myocardial involvement, musculoskeletal 
involvement, presence of ILD and potential contributing element of PVOD. 
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Chapter 5 
Changes in right ventricular function 
measured by CMR imaging in pulmonary 
hypertension patients receiving disease-
targeted therapy: A longitudinal study.   
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5 Changes in right ventricular function measured 
by CMR imaging in pulmonary hypertension 
patients receiving disease-targeted therapy: A 
longitudinal study. 
 
5.1 Introduction 
Pulmonary hypertension (PH) is a progressive disorder affecting the pulmonary 
arteries. It is characterised by vascular proliferation and remodelling which 
results in a progressive increase in pulmonary vascular resistance (PVR) and 
subsequent right ventricular failure (RVF). The RV adapts to the increased 
afterload by increasing its wall thickness and contractility. In most patients, 
these compensatory mechanisms are insufficient and RV dysfunction occurs. 
Recent developments in imaging techniques, such as CMR and echocardiography, 
have improved our understanding of the structure and function of the RV. The 
initial insult involves the pulmonary vasculature yet survival of patients with 
pulmonary hypertension is closely related to right ventricular function (4, 247). 
 
Over the last 20 years, several treatments targeting the pathological 
mechanisms of PH have been introduced. These agents have been approved 
largely based on improved haemodynamic variables on right heart 
catheterisation (RHC) or improved exercise capacity (increase in 6 minute walk 
distance [6MWD]) in randomised controlled trials (RCT). The current aim is for an 
early diagnosis of PH followed by treatment with first line monotherapy (26, 
158). The importance of escalating therapy if a patient does not respond to 
initial treatment has been emphasized in recently published guidelines (7). 
Patients are closely followed up in the outpatient clinic every three to six 
months. Treatments for PH are always expensive, sometimes invasive and carry 
significant side effects. It is extremely important to be able to assess patients 
response to therapy with investigations of appropriate quality in order to 
convince patients, treating physicians, funding agencies, and regulatory bodies 
of the value of treatment. Physicians currently rely on the WHO functional class, 
exercise testing (6MWT and CPET), biomarkers (BNP levels), echocardiography 
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and RHC to assess disease progression and treatment efficacy in the clinic. These 
investigations have acknowledged limitations as discussed in the introduction.  
 
The imperative role of the RV performance in the clinical status and long-term 
outcome of patients with PH is evident. This has raised the question that direct 
assessment of RV function may be a more appropriate way of determining 
response to therapy and monitoring disease progression in pulmonary 
hypertension. CMR provides a comprehensive overall picture of RV structure and 
function as it has unparalleled resolution, is reproducible and can provide three-
dimensional images. CMR is well suited to longitudinal follow up as it is non-
invasive and non-ionising. This imaging technique has gained a dominant role as 
the reference method for clinical trials assessing longitudinal changes in LV 
function after therapeutic interventions (57, 68). It provides a direct evaluation 
of right ventricular size, mass, morphology and function (151). The accuracy and 
reproducibility of CMR in assessing cardiac morphological and functional 
parameters leads to low interstudy variability, which translates into a significant 
reduction in sample size required to test the efficacy of therapeutic 
interventions (57, 248). Despite these clear advantages, the uptake of CMR in 
clinical practice has been limited. This may be partly attributable to cost but 
the lack of published data showing its use in PH patients, especially in those 
receiving treatment, may also be a contributing factor. This study aimed to 
evaluate the use of CMR in the longitudinal assessment of effects of treatment in 
patients with pulmonary hypertension.       
 
This chapter presents the results obtained from my contribution to the EURO-MR 
study. EURO-MR was a prospective, longitudinal study conducted in four 
European centers: Scottish Pulmonary Vascular Unit, Glasgow, UK; Medical 
University Graz, Graz, Austria: Sapienza University of Rome, Rome, Italy and 
Department of Pulmonary Medicine, VU University Medical Center, Amsterdam, 
The Netherlands as part of the EU Framework 6 Pulmotension Initiative (249). 
Please refer to appendix 1 and 2 for the introductory letter and follow up 
newsletter. EURO-MR was designed to evaluate the performance of CMR imaging 
in the longitudinal assessment of pulmonary hypertension patients. I have 
presented the data for 34 patients who completed the baseline and 4 month 
assessment at the SPVU.  
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Table 5-1: EURO-MR: Outline and study timetable. 
 
Timescale CMR Protocol Comparators 
0 months / Baseline CMR 1 • Haemodynamics 
• 6MWT 
• NTproBNP 
• WHO functional 
class 
• Genomics  
4 months CMR 2 • 6MWT 
• NTproBNP 
• WHO functional 
class 
12 months CMR 3 • 6MWT 
• NTproBNP 
• WHO functional 
class 
 
This table outlines the EURO-MR study outline and timetable. 6MWT: six minute 
walk test. NT-proBNP: N-terminal pro–brain natriuretic peptide. WHO: World 
Health Organisation. 
 
5.2 Materials and Methods 
This was a prospective, longitudinal study of 34 patients attending for 
assessment at the Scottish Pulmonary Vascular Unit. This was the starting point 
of the multinational EURO-MR study, which was conducted in four European 
centers as part of the EU Framework 6 Pulmotension Initiative.  
 
The study subjects were incident patients attending the SPVU for initial 
diagnostic assessment and subsequent follow up. The diagnosis of pulmonary 
hypertension was based on RHC in accordance with contemporary guidelines. 
The inclusion criteria were patients with a diagnosis of pulmonary hypertension: 
WHO group 1 (PAH including idiopathic PAH, heritable PAH, PAH associated with 
connective tissue disease and congenital heart disease), WHO Group 3 (PH due 
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to lung disease and/or hypoxia) and WHO Group 4 (Chronic thromboembolic 
pulmonary hypertension) if ineligible for pulmonary thromboendarterectomy. 
This study was approved by the West Glasgow Research Ethics Committee and 
written informed consent was obtained from all study participants.  
 
5.2.1 Study design 
Figure 5-1: Study protocol. 
 
 
 
PH: pulmonary hypertension. WHO FC: World Health Organisation functional 
class. 6MWT: six minute walk test. CMR: cardiac magnetic resonance. 
 
Baseline (0 month) assessment 
This was performed during the subject’s initial in-patient admission: 
i. Full clinical history 
ii. Full physical examination 
iii. WHO functional class 
iv. 6MWT 
v. CMR imaging 
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• 	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• 	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4 month assessment 
This visit comprised a morning or afternoon visit to the Western Infirmary.  
i. Full clinical history 
ii. Full physical examination 
iii. WHO functional class 
iv. 6MWT 
v. CMR imaging    
 
5.2.2 Cardiac magnetic resonance (CMR) image acquisition and 
analysis 
CMR imaging was performed on a 1.5 Tesla MRI scanner (Sonata Magnetom, 
Siemens, Germany). CMR was performed using a protocol described in detail in 
the materials and methods chapter of this thesis. All CMR images were analysed 
by a single operator (L.M.) using the Argus analysis software (Siemans, Erlangen, 
Germany). Individual scans were coded by number and analysed in batches by 
L.M. who was blinded to the haemodynamic and six minute walk distance results 
of any given subject at the time of analysis.  
 
Volumetric analysis: RV and LV volumes [RV end-diastolic volume (RVEDV), RV 
end-systolic volume (RVESV), LV end-diastolic volume (LVEDV) and LV end-
systolic volume (LVESV)] were determined by manual planimetry as described 
previously (materials and methods section). RV and LV stroke volumes (RVSV and 
LVSV), ejection fractions (RVEF and LVEF) and mass (RVM and LVM) were 
determined as previously described. Ventricular mass index (VMI) was 
determined as RVM/LVM (75). RV and LV volumes and mass were then indexed to 
body surface area. 
 
Flow analysis: Right ventricular SV was measured using MR phase-contrast flow 
quantification in an image plane positioned perpendicular to the main pulmonary 
artery, at least 1cm distal to the pulmonary valve. Left ventricular SV (aortic 
flow) was also measured, approximately 2 - 4cm above the aortic valve and 
distal to the coronary arterial ostia. A velocity encoded k-space segmented 
gradient-echo sequence was used to generate 45 matched pairs of anatomical 
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and velocity images. Retrospective ECG-gating was used to ensure coverage of 
the complete cardiac cycle. Patients were instructed to breath freely throughout 
this section of the protocol and the average time of acquisition was 2-3 minutes 
depending on the patient’s heart rate. Please refer to the materials and 
methods section for further information.  
 
Table 5-2: Measurements made from cardiac magnetic resonance imaging in 
this study. 
 
Measurements from CMR imaging 
• RV/LV end diastolic volume index (RV/LVEDVI) 
• RV/LV end systolic volume index (RV/LVESVI) 
• RV/LV ejection fraction (RV/LVEF) 
• RV/LV mass index (RV/LVMI)  
• Ventricular mass index (VMI) 
• Pulmonary artery flow analysis (PASVI) 
• Aortic flow analysis (AoSVI) 
 
 
5.2.3 Right heart catheterisation  
RHC was performed according to international recommendations (26) by SPVU 
physicians, in the catheterisation laboratory. A 7F gauge, balloon tipped, flow 
directed, triple channel thermodilution Swan-Ganz catheter (Baxter Healthcare, 
Irvine, California, USA) was advanced through an 8F introducer sheath inserted 
into the right internal jugular vein or the right femoral vein. All measurements 
were recorded with the patient in a supine position, at rest, breathing room air 
or supplemental oxygen if required. Please refer to materials and methods 
section of this thesis for further information on RHC methodology.  
 
5.2.4 6-minute walk test 
The 6MWT was performed by a respiratory physiologist or by a member of SPVU 
medical staff. The 6MWT was performed on a 20-metre corridor, but otherwise 
according to the American Thoracic Society guideline (139). 
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5.2.5 WHO functional class 
Each patient was assigned to a WHO functional class, which is a four point scale 
to rate the impact of breathlessness and fatigue according to daily activity. 
Please refer to table 5.3 for WHO functional classification. 
 
Table 5-3: World Health Organisation functional classification of pulmonary 
hypertension. 
 
WHO FC Description 
Class I Patients with PH but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue 
dyspnoea or fatigue, chest pain, or near syncope. 
Class II Patients with PH resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity 
causes undue dyspnoea or fatigue, chest pain, or near syncope. 
Class III Patients with PH resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary 
activity causes undue dyspnoea or fatigue, chest pain, or near 
syncope. 
Class IV Patients with PH with inability to carry out any physical activity 
without symptoms. These patients manifest signs of right heart 
failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
 
5.2.6 Statistical analysis 
For demographic, haemodynamic and CMR measurements, mean values ± one 
standard deviation (± SD) were calculated. Comparison between baseline and 4 
month follow up was performed using the paired t test. The correlation between 
the change in CMR measurements and 6MWD was determined by Pearson 
correlation. A significance level of 5% was used in all tests. Statistical analysis 
was performed using Graphpad Prism Version 6 (Graphpad Software, California, 
USA). Data are given as mean ± SD unless otherwise stated.  
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5.3 Results 
5.3.1 Participants 
In total, 34 patients underwent assessment at baseline and after 4 months of 
disease targeted therapy. Baseline characteristics for all patients are 
summarized in table 5.4. There were more female than male patients. Idiopathic 
pulmonary arterial hypertension (IPAH) was the most common aetiology. The 
majority of patients were in WHO functional class III. The patients had 
significant pulmonary hypertension confirmed by right heart catheterisation. 
Mean 6MWD at baseline was 319.7m ± 106.8m. Disease targeted therapy for 
pulmonary hypertension was commenced at baseline in all patients. Only 5 
patients who were scanned at baseline did not attend for their interval CMR scan 
at 4 months and therefore could not be included in this longitudinal project. This 
highlighted that the vast majority of patients in this study tolerated the 
investigation well. 
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Table 5-4: Baseline characteristics for patients enrolled in this study. 
 
Characteristic Cohort (n = 34) 
Age, mean ± SD, years 53.02 ± 21.60 
Female:Male 21:13 
Body surface area, mean ± SD, m2 1.81 ± 0.22 
Aetiology of PH, n (%) 
WHO Group 1 
IPAH 
CTDPAH 
CHDPAH 
Other (FPAH) 
WHO Group 3 
PH due to hypoxic lung disease 
WHO Group 4 
CTEPH 
 
 
13 (38.2) 
6 (17.6) 
2 (5.9) 
1 (2.9) 
 
5 (14.7) 
 
7 (20.6) 
WHO Functional Class, n (%)  
I 
II 
III 
IV 
0 
5 (14.7) 
26 (76.5) 
3 (8.8) 
Baseline 6MWD, mean ± SD, m 319.7 ± 106.8 
 
Data are expressed as mean ± standard deviation. 
IPAH: idiopathic pulmonary arterial hypertension; CTDPAH: pulmonary arterial 
hypertension associated with connective tissue disease; CHDPAH; pulmonary 
arterial hypertension associated with congenital heart disease; FPAH: familial 
pulmonary arterial hypertension; PH associated with hypoxic lung disease: 
pulmonary hypertension associated with hypoxic lung disease; CTEPH: chronic 
thromboembolic pulmonary hypertension; WHO: World Health Organisation; 
mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; 
6MWD 6 minute walk distance. 
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5.3.2 Response to disease-targeted therapy 
There was a significant increase in 6MWD after 4 months of disease targeted 
therapy (319.7 ± 106.8m at baseline, 361 ± 90m at 4 months, p = 0.0005). One 
patient was unable to complete the 6 minute walk test at the 4 month 
assessment. 6 patients walked a shorter distance during the 6MWT at their 4 
month review. All other patients improved their walk distance. Repeat WHO 
assessment at 4 months confirmed one patient had improved from WHO 
functional class III to II and one patient had deteriorated from WHO II to III. 32 
patients remained in the same functional class at both assessments. 
 
Figure 5-2: Change in 6 minute walk distance from baseline (0 months) to 4 
months. 
 
 
6MWT; six minute walk test. n; number of patients. 
 
5.3.3 CMR assessments 
CMR measurements at baseline and after 4 months of disease-targeted therapy 
are summarised in table 5.5. Following 4 months of disease targeted therapy, 
there were significant increases in RVEF (p < 0.0001), RVCI (p = 0.0219), RVSVI (p 
= 0.0102), LVEF (p = 0.0158), LVCI (p = 0.0071), LVSVI (p = 0.0025) and a 
significant decrease in the RVESVI (p = 0.0278). 
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Table 5-5: Baseline and four month cardiac magnetic resonance variables in 
the cohort group. 
 
CMRI Variable Baseline (n=34) 4 months (n=34) P value 
Right ventricle    
RVEDVI (ml/m2) 83.92 ± 22.67 81.67 ± 24.70 p = 0.2916 
RVESVI (ml/m2) 52.50 ± 25.65 48.54 ± 23.60 p = 0.0278 * 
SVI (ml/m2) n=33 35.64 ± 13.54 39.91 ± 9.80 P = 0.0102 * 
CI (L/min/m2) n=33 2.58 ± 0.82 2.823 ± 0.70 P = 0.0219 * 
EF (%) n=33 45.92 ± 20.93 52.57 ± 19.65 p = < 0.0001 **** 
Mass (g/m2) 51.59 ± 22.70 50.66 ± 21.72 p = 0.4350 
Left ventricle    
LVEDVI (ml/m2) 48.86 ± 11.53 52.71 ± 16.79 p = 0.0938 
LVESVI (ml/m2) 18.05 ± 6.22 17.93 ± 8.29 p = 0.9131 
SVI (ml/m2) n=33 27.88 ± 9.43 33.05 ± 9.81 p = 0.0025 ** 
CI (L/min/m2) n=33 2.02 ± 0.59 2.324 ± 0.66 p = 0.0071 ** 
EF (%)n=33 57.40 ± 14.86 63.30 ± 9.19 P = 0.0158 * 
Mass (g/m2) 54.69 ± 9.93 54.08 ± 9.05 p = 0.5858 
VMI 0.96 ± 0.39 0.95 ± 0.39 p = 0.7720 
 
RVEDVI; right ventricular end diastolic volume index. RVESVI; right ventricular 
end systolic volume index. SVI; stroke volume index. CI; cardiac index. EF; 
ejection fraction. LVEDVI; left ventricular end diastolic volume index. LVESVI; left 
ventricular end systolic volume index. VMI; ventricular mass index.  
All data are expressed as mean ±	 standard deviation. 
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Figure 5-3: Changes in cardiac magnetic resonance measurements from the 
left heart: Between baseline and 4 months of disease targeted therapy. 
 
 
 
LVEDVI; left ventricular end diastolic volume index. LVESVI; left ventricular end 
systolic volume index. LVMI; left ventricular mass index. LVCI; left ventricular 
cardiac index. SVI; stroke volume index. LVEF; left ventricular ejection fraction.  
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Figure 5-4: Changes in cardiac magnetic resonance measurements from the 
right heart: Between baseline and 4 months of disease targeted therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RVEDVI; right ventricular end diastolic volume index. RVESVI; right ventricular 
end systolic volume index. RVMI; right ventricular mass index. RVCI; right 
ventricular cardiac index. SVI; stroke volume index. RVEF; right ventricular 
ejection fraction.  
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Association of CMR measurements with 6MWD 
6MWD increased from 319.7 ± 106.8m at baseline to 361 ± 90m at 4 months. 
CMRI variables that changed significantly during the 4 month treatment period 
were compared with the change in 6MWD during treatment. No significant 
correlations were identified between change in 6MWD and change in RVEF, 
RVSVI, RVCI, LVEF, LVSVI or LVCI. Please refer to Figure 5.5.    
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Figure 5-5: Pearson correlations between change in right ventricular 
function and change in six minute walk distance. 
 
 
RVEF; right ventricular ejection fraction. 6MWD; six minute walk distance. 6MWT; 
six minute walk test. SVI; stroke volume index. PA; pulmonary artery. RVCI; right 
ventricular cardiac index.  
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Figure 5-6: Pearson correlations between change in left ventricular function 
and change in six minute walk distance. 
 
 
LVEF; left ventricular ejection fraction. 6MWD; six minute walk distance. 6MWT; 
six minute walk test. SVI; stroke volume index. Ao; aortic. LVCI: left ventricular 
cardiac index. 
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5.4 Discussion 
The aim of this study was to evaluate the performance of CMR imaging in the 
longitudinal assessment of pulmonary hypertension patients. With the advent of 
multiple new disease-targeted therapies for PH it is increasingly important that 
we can assess the progress of patients in a non-invasive manner. This study was 
the starting point for the first multicenter study (EURO-MR) to prospectively 
assess the use of CMR imaging before and during disease-specific therapy (249).  
 
In this longitudinal study, we investigated the effects of treatment on right and 
left ventricular function as assessed by CMR. A significant increase in 6MWD after 
4 months of therapy was demonstrated in our cohort of patients. The CMR 
analysis confirmed there was a significant increase in stroke volume index, 
cardiac index and ejection fraction, when measured in either the left or right 
heart. There was also a significant reduction in right ventricular end-systolic 
volume index associated with treatment. These findings confirm that both left 
and right-sided measurements should be included in the analysis when assessing 
cardiac function in patients with pulmonary hypertension. In our study group, 
there was no change in left sided ventricular volumes with disease-targeted 
therapy. In addition, there was no significant change demonstrated in CMR-
derived ventricular mass for either the left or right heart.   
 
This current study complements data from several smaller trials studying 
changes in CMR derived variables during treatment of pulmonary hypertension. 
We did not, however, demonstrate any treatment related change in ventricular 
mass. In 2003, Michelakis and colleagues (189) performed a small non-
randomised, pilot study of 5 patients with PH to investigate the effect of 
sildenafil 50mg tid. Sildenafil significantly reduced RVM and increased RVSV. In a 
prospective study (2004) of PH patients with prostacyclin (epoprostenol) 
therapy, the significant increase in RVSV (PA flow analysis) corresponded well 
with functional improvement (WHO functional class, 6MWT) (70). It was also 
demonstrated that epoprostenol therapy lowered PVR but did not affect RV 
dilatation or hypertrophy (70). The SERAPH study in 2006 (a comparison study 
between sildenafil and bosentan) demonstrated that RVM decreased significantly 
from baseline after 16 weeks of sildenafil therapy (n=13, p = 0.015) (191) 
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although this was not observed in the 12 patients receiving bosentan. There was 
no significant difference between treatments (p = 0.142). Similarly, Van 
Wolferen et al (2006) demonstrated by CMR that the addition of sildenafil 
reversed RV dilatation and hypertrophy in patients receiving endothelin receptor 
antagonist therapy (190). More recently, a single centre study assessed 16 
patients with PAH by CMR at baseline and after 12 months treatment with 
bosentan (197). Cardiac index, PVR and 6MWT distance improved with 
treatment. There was a trend towards improvement in RV SV (p=0.08) although 
there was no change in RV ejection fraction or RVEDV. This study highlighted the 
need for further investigation of CMR variables associated with RV function and 
how they relate to variables such as 6MWD.  
In PAH, vasoconstriction and vascular remodelling contribute to a progressive 
increase in PVR and PAP which have critical effects on the heart, and in 
particular, the right ventricle. The ability of the RV to adapt to the increased 
afterload resulting from the increased PVR is the main determinant of a patients 
functional capacity and survival. Changes to the RV due to pressure overload in 
PAH are complex, with an increased RV wall stress leading to RV dilatation and 
hypertrophy, which affects the structure and function of the RV as it adapts to 
increased PAP (250). Measurements of RV function have been shown to be 
important in determining patients prognosis and also, in some cases, response to 
treatment (4, 73, 147, 156, 199). The remodelling and RV myocardial 
hypertrophy, which occur in patients with PH, lead to a need for increased 
myocardial perfusion. However, increased wall tension leads to a reduction in 
oxygen supply, increased oxygen extraction and reduced perfusion secondary to 
compression of the coronary circulation and impairment of coronary flow (101, 
251). This study confirmed that there was no significant change in RV or LV mass 
with disease-targeted therapy. It is unknown whether hypertrophy of the RV is 
protective or not. To date, two trials (36, 198) have used CMR-derived RVM as an 
end-point. This particular measurement remains unvalidated and may not be an 
ideal end point since it is unknown whether a hypertrophy of the RV is protective 
or not. There may be a maximal benefit obtained after which continued 
remodelling of the RV is deleterious to the patients condition.       
Approval for disease-targeted therapy for pulmonary hypertension has been 
largely based on improved haemodynamic variables on RHC or improved exercise 
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capacity (increase in 6MWD) in RCTs. Consequently disease progression and 
treatment efficacy in the clinic are frequently assessed using 6MWT or RHC. 
These methods of assessment have acknowledged limitations as described in the 
introduction. With reference to this study, 6MWD provides limited information in 
patients with PAH associated with CTD, a patient group that made up 17.6% of 
the current study population. A baseline 6MWD is prognostic of survival (219) yet 
changes in 6MWD with treatment do not relate to outcomes in patients with PAH 
(252). In the SUPER trial, the significant improvement in 6MWD at week 12 did 
not translate into an increase in survival (253). Patients treated with the highest 
dose of sildenafil achieved the greatest improvements in 6MWD, but had the 
lowest long-term survival rates. A recent pooled analysis of data from 10 
randomised controlled trials of PAH specific therapies showed that although the 
change in 6MWD from baseline to week 12 was a mediator of the relationship 
between treatment and the development of a clinical event, it accounted for 
under 25% of the total relationship (254). The findings of our analysis confirmed 
that the correlations between 6MWD and CMR variables were weak. This 
highlights the importance of monitoring right ventricular function directly to 
assess response to therapy.  
 
The impact of a treatment on disease progression associated with PH can be 
measured by time to clinical worsening (TTCW). This endpoint is viewed as 
clinically relevant by clinicians and regulatory agencies and has been used in 
several clinical trials as a secondary, or more recently a primary end point. The 
composition of this end point varies from study to study. It has been confirmed 
that a uniform definition of TTCW should be used in future (phase III) RCTs in 
PAH. In the definition of TTCW, hard events should include all cause mortality, 
nonelective hospital stay due to PAH (with predefined criteria e.g. institution of 
iv prostatnoids, lung transplantation, or atrial septostomy) and disease 
progression defined as a reduction from baseline of 6MWD by 15% plus worsening 
functional class. Current therapies for PAH have been adopted on the basis of 
short term trials with exercise capacity as the primary end point. New studies in 
pulmonary hypertension medications are now using TTCW as a primary end 
point. The efficacy of macitentan (a dual endothelin receptor antagonist) was 
assessed using the primary end point of morbidity and mortality in a long term 
trial. The primary end point was the time from the initiation of treatment to the 
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first occurrence of a composite end point of death, atrial septostomy, lung 
transplantation, initiation of treatment with intravenous or subcutaneous 
prostanoids, or worsening of PAH (255). The AMBITION (A Study of First-Line 
Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary 
Arterial Hypertension) trial examined the effect of first-line combination 
therapy with ambrisentan and tadalafil versus first-line monotherapy with either 
ambrisentan or tadalafil in patients with PAH using a composite end-point which 
included an inadequate clinical response.     
 
A wide range of CMR measurements have been identified in patients with PH and 
many have been shown to be strongly predictive of mortality and survival. These 
measurements offer the potential for monitoring and assessing response to 
treatment (256). Factors relating to the dynamic function of the right heart 
appear to be the most linked to outcome. Stroke volume (SV) is a key CMR 
prognostic measure in PAH patients. Maintenance of normal SV at rest and during 
exercise in pulmonary hypertension indicates right ventricular adaptation to the 
increase in afterload caused by an increasing PVR and PAP. A low SV is strongly 
linked to mortality in IPAH both at baseline and with treatment (73, 199), and in 
PAH related to systemic sclerosis (257). In PAH and CTEPH patients, 1 year of 
treatment with PAH-specific therapy resulted in significant improvements in 
stroke volume which was related to an increase in 6MWD (199). A recent CMR 
based study confirmed that a 10ml change in SV during follow up should be 
considered as clinically relevant. This value can be used to interpret changes in 
SV during clinical follow up in PH, although validation in a wider range of PAH 
aetiologies is required (199). RVEF is also as an important CMR-measured 
prognostic factor in PAH (73, 200).  Prognosis of patients with PAH remains poor 
(219) despite the improvements in PVR or 6MWD seen during therapy. It has been 
suggested that RV function may be continuing to deteriorate despite the 
encouraging haemodynamic or functional signs e.g. Van de Veerdonk and 
colleagues demonstrated that 25% of patients with reduced PVR following 12 
months of therapy had deteriorating RV function (assessed by RVEF) during this 
period, indicating that RV function does not necessarily adapt to treatment-
induced changes in PVR.  Deterioration in RVEF was associated with poor 
outcome, irrespective of improvements in PVR, emphasising the importance of 
monitoring RV function during the course of the disease (200). LV and RVEDV are 
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also independent predictors of prognosis in IPAH, and changes in following 
treatment are independent predictors of mortality (73, 258). A decline in both 
LV and RVEDV was seen in PAH patients who failed to survive in a recent study 
by Mauritz and colleagues (92). This study also compared changes in RV 
geometric shortening using RV longitudinal and transverse shortening and RV 
fractional area change, and found that longitudinal shortening, transverse 
shortening and RV fractional area change, measured at the beginning of the 
study and 1 year later, were significantly higher in subsequent 5-year survivors 
than in nonsurvivors. As transverse shortening incorporates both free-wall and 
septum movements, the authors suggest that this parameter could be used to 
monitor the decline in RV function in end-stage PAH (92). 
 
The increasing importance of direct assessment of right ventricular function is 
highlighted by the incorporation of CMR measurements into the endpoints of 
upcoming trials. A prospective, multicenter trial (REPAIR – Right vEntricular 
remodeling in Pulmonary ArterIal hypeRtension) is planned to evaluate the 
effects of macitentan on right ventricular and haemodynamic properties in 
patients with symptomatic PAH. Patients will be treated with macitentan for 1 
year. CMR will be performed at baseline, week 26 and week 52. Change in RV 
stroke volume is a primary end point and change in arterial elastance  
(ventriculo-arterial coupling) is a secondary end point.  
 
This study has limitations. The inclusion criteria allowed a heterogeneous 
population of PH patients to be enrolled and, unlike previous studies, it was not 
restricted to patients with pulmonary arterial hypertension (PAH). Although 
disease specific therapy is only recommended in management guidelines for 
PAH, in clinical practice these treatments are also used in WHO groups 3,4 and 
5. Other CMR measurements that may be important prognostically and 
therapeutically were not included in the current analysis. These include 
pulmonary artery stiffness, pulmonary perfusion, right ventricular arterial 
coupling, transverse shortening etc. Clearly, these are important measurements 
and, as imaging techniques improve, will become part of the range of CMR 
derived measurements used to study patients with PH.  
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In conclusion, this study demonstrates that detailed CMR assessments at baseline 
and follow up in this patient cohort provide valuable information about response 
to disease-targeted therapy. There were treatment changes in CMR derived 
variables in both the left and right sided of the heart. These changes were not 
related to the changes in 6MWD and therefore, direct measurement of RV 
function is required in order for the potential benefits of PAH treatment to be 
fully appreciated. CMR imaging enables a unique combination of morphological 
and functional assessment of the right ventricle and pulmonary circulation. CMR 
has emerged as the gold standard for a detailed study of the RV and has become 
an established modality for the physiological assessment of PH patients in cross-
sectional studies, longitudinal follow up studies and clinical trials of therapy. We 
anticipate that MR imaging will increasingly be utilised as the primary modality 
for combined anatomic and functional assessments that enable more complete 
and efficient evaluation of patients with PH.  
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6 General discussion and summary 
Pulmonary vascular medicine is a rapidly evolving clinical speciality in which 
huge progression in treatment options have been made over recent years. 
Pulmonary hypertension is characterised by increased pulmonary vascular 
resistance leading to chronic right ventricular pressure overload. The adaptation 
of the right ventricle is the major prognostic influence in pulmonary 
hypertension. Changes to the RV due to pressure overload in PAH are complex, 
with increased RV wall stress leading to RV dilatation and hypertrophy, which 
affect the structure and function of the RV as it adapts to increased PAP. 
Current methods of assessment of pulmonary hypertension patients are 
suboptimal. The aim of this thesis was to evaluate the role of CMR imaging in the 
assessment of right ventricular function in pulmonary hypertension patients and 
to provide clarity in its role as a non-invasive monitoring technique. 
The results from this thesis have demonstrated that CMR imaging can be 
performed safely and can yield high-quality images in pulmonary hypertension 
patients. The vast majority of patients in our studies tolerated this investigation 
well. Despite frequent verbal reports of claustrophobia, this was rarely an 
insurmountable problem and patients managed with reassurance, distraction 
(music) and prism glasses.  The CMR protocol used involved frequent breath 
holds, which could be arduous. The patients were mostly able to breath-hold 
adequately during the MR pulse sequences despite significant gas exchange 
abnormalities. All CMR scans performed in this study provided satisfactory 
images for analysis. 3 patients on a continuous epoprostenol infusion were 
scanned during my studies. These scans were performed with the assistance of a 
Clinical Nurse Specialist who managed the infusion pump located in the CMR 
control room. All patients enrolled in the longitudinal study returned (if 
physically fit enough) for their interval CMR scans highlighting that this 
investigation was tolerated well in our study. 
A low baseline stroke volume index is predictive of a poor outcome in pulmonary 
hypertension. In addition, a further reduction in SV at 1 year follow up, 
predicted treatment failure and a poor long-term outcome. A non-invasive, 
accurate measure of SV would be beneficial to monitor disease progression in 
patients with PH. The widely accepted reference standard measurement of SV is 
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by thermodilution measured during right heart catheterisation. In chapter 3, we 
evaluated the accuracy of CMR imaging and inert gas rebreathing (using 
photoacoustic analysis) in the measurement of SV compared to the gold standard 
of thermodilution. We confirmed that CMR imaging and IGR provided non-
invasive measurements of SV that were as accurate as those obtained by 
thermodilution. With the advent of multiple new disease targeted therapy, it is 
imperative that we can assess patients noninvasively. This study suggests that 
accurate assessment of a resting SV could be achieved by either of these non-
invasive techniques. 
The ability of the RV to adapt to the increased afterload resulting from rising 
PVR is the main determinant of a patient’s functional capacity and survival. It is 
evident that CTDPAH patients have a much poorer prognosis than IPAH patients. 
We sought to evaluate whether there was any detectable difference in cardiac 
adaptation as assessed by CMR at baseline between these two patient groups, 
which could account for the poorer prognosis. We did not find any difference 
between these two distinct groups, which could be detected by resting CMR 
imaging, for a given mean pulmonary artery pressure.  
The Task Force on Treatment Goals for PH confirms the need to analyse multiple 
goals for defining success of therapy including symptoms, exercise capacity and 
the right ventricular function (259). The importance of morbidity and mortality 
primary endpoints in future clinical trials (260) has been highlighted recently. 
The imperative role of RV performance in the clinical status and long-term 
outcome of patients with PH is evident. Direct assessment of RV function may be 
the most appropriate method of determining response to therapy and monitoring 
disease progression than the currently used assessment tools. The primary 
requirements for a monitoring tool for PH patients are that it should be 
reproducible and observer independent, non-invasive, cost-effective, 
standardised, prognostic and sensitive to treatment. Current guidelines 
recommend a number of techniques to assess disease severity, response to 
treatment and prognosis. Each technique has benefits and limitations as 
previously discussed. The longitudinal study (chapter 5) in this thesis aimed to 
clarify the role of CMR in monitoring PH patients. This study confirmed 
significant changes in CMR measurements with the introduction of disease-
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targeted therapy. These changes were not related, however, to the change in 
6MWD. The correlation between CMR measurements and 6MWD was weak in our 
patient group. Change in 6MWD has been used widely as a key endpoint in many 
PAH trials to date. The use of 6MWD, however, as a surrogate marker of 
outcome (in particular, mortality and morbidity) has been questioned in several 
recent studies.  
CMR imaging is a non-invasive tool that provides high-resolution, three-
dimensional images of the heart. The right ventricle is difficult to assess due to 
its geometry. CMR provides information about right heart structure, volumes and 
function that is not readily obtained via other methods, such as 
echocardiography and RHC. Given the important implications of RV structure and 
function in morbidity and mortality in PH, regular assessment is critical. 
CMR imaging is associated with a range of limitations: higher cost, more limited 
availability relative to other methods, the need for more intensive and time 
consuming analysis, and the requirement for significant technical support and 
expertise. CMR is incompatible with pacemakers and certain infusion pumps, and 
the need for breath holding may be difficult for patients (256, 261). However, 
given the relevance of the right heart in PH, the advantages of this method may 
outweigh these disadvantages in the monitoring of patients with established PAH 
and in the assessment of treatment response in clinical trials.  
 
Future research 
Standardisation of CMR protocols and multicenter trials are needed to assess the 
optimal role of CMR imaging in patients with pulmonary hypertension. 
Longitudinal assessment of novel CMR measurements were not included in the 
current analysis e.g. pulmonary artery stiffness, right ventricular arterial 
coupling or transverse shortening. Further research should be directed towards 
identifying whether these are important prognostically or therapeutically. 
Further investigation into CMR assessment of PH patients during exercise should 
be explored e.g. MR compatible ergometer, dobutamine administration as 
exercise cardiac output is an important outcome measure in PH. 
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CMR imaging provides a unique combination of morphological and functional 
assessment of the right ventricle and pulmonary circulation. It has emerged as 
the gold standard for detailed study of the right ventricle. CMR imaging is a 
relatively new imaging technique in pulmonary hypertension. It is likely to 
provide a useful assessment and monitoring tool for physicians in clinical 
practice as techniques develop. An increasing number of measurements have 
been shown to be prognostic in PAH patients, and studies have shown that CMR 
imaging can be used to detect improvements in cardiac function in response to 
disease targeted therapy. As such, CMR imaging has great potential as a non-
invasive monitoring tool.  
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7 Appendices 
7.1 Appendix 1: Euro-MR introductory letter 
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Euro-MR 
EU Framework 6 Pulmotension 
SPVU STAFF 
Director 
Prof A Peacock 
 
Senior Scientist 
Dr D Welsh 
 
MR Research Fellows 
Dr L McLure 
Dr K Blyth 
 
 
 
 
 
 
 
 
 
 
Longitudinal Assessment of Patients with Pulmonary Arterial Hypertension using Cardiac 
Magnetic Resonance Imaging: Relation to Genomics 
 
 
 
Dear Colleague. 
 
Welcome to the kick-off of  Euro-MR. 
 
As you may know, the University of Bologna and ourselves were awarded EU Framework 6 
funding to evaluate the use of cardiac MR in the assessment of changes in RV function in 
response to targeted therapy in patients with PAH. This will be a longitudinal study relating 
change in MR-derived variables to standard end points such as 6-MWD, NT pro-BNP, WHO 
class etc. In addition, we are interested in the influence of genomics upon the adaptation of 
the right ventricle and pulmonary circulation to treatment of PAH. Specifically we plan to 
assess the mutations of BMPR2 gene and polymorphisms of 5-HTT, endothelial NOS and 
ACE genes. 
 
This is a golden opportunity to generate a Pan-European project in MR for PAH and we have 
received enthusiastic responses from most units we have contacted. We have undertaken to 
read all the scans using the attached protocol but each centre can also use the results for their 
own purposes. 
 
We propose that patients are studied both within and without the context of clinical trials. 
Centres can decide whether or not they wish to be involved in the genetic side of the study. 
 
Whilst some of you have already agreed to take part we are still awaiting news from others. 
Please take this opportunity to reply using the email address below to state whether you wish 
to participate. We have obtained funding to reduce the costs of CMR scans at each centre. 
 
We would be grateful if you could forward contact details of relevant staff in your 
departments. When this information is collated a pack will be forwarded to every participant 
giving detailed information for your physicist and radiologists. We would welcome 
comments. It is our intention to send out a newsletter every 2 months informing centres of 
progress and recruitment numbers from each centre.  
 
 
Best wishes, 
 
 
Professor Andrew Peacock 
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